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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
is one of the European Union’s decentralised agencies. Established in 1993 
and based in Lisbon, it is the central source of comprehensive information 
on drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates factual, objective, 
reliable and comparable information on drugs and drug addiction.  
In doing so, it provides its audiences with an evidence-based picture  
of the drug phenomenon at European level.
The Centre’s publications are a prime source of information for a wide 
range of audiences including policymakers and their advisers; professionals 
and researchers working in the field of drugs; and, more broadly,  
the media and general public.
The annual report presents the EMCDDA’s yearly overview of the drug 
phenomenon in the EU and is an essential reference book for those seeking 
the latest findings on drugs in Europe.
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5This report provides a timely and detailed assessment 
of Europe’s drug situation, and we are grateful to our 
staff who have worked so hard to produce it. However, 
we must acknowledge that the strength of this document 
comes not just from our work here in Lisbon but, more 
fundamentally, from the efforts within the Member States 
to develop a sound and comprehensive information 
system. As well as making an important contribution to 
a mature and informed debate on the drug problem, the 
existence of this monitoring system, we believe, results in 
better and more effective policies.
Such policies are increasingly necessary, as the 
challenges in this area grow ever more complex. A 
common theme running through this report is the dynamic 
nature of the drug problem, and we need to ensure that 
our vision keeps pace with the changing conditions with 
which we are confronted.
This year, the EMCDDA celebrated 15 years of collecting 
information and reporting on the European drug 
problem. To mark this event we held a conference entitled 
‘Identifying Europe’s information needs for effective 
drug policy’. This provided an opportunity for scientists, 
professionals and policymakers from across Europe, and 
beyond, to come to Lisbon to help us map and evaluate 
the existing knowledge base in the drug field and to 
identify current and future information needs.
The conference demonstrated that Europe has developed 
as a formidable laboratory to study and understand drug 
use and drug-related responses, and this now provides 
us with considerable opportunities for collective learning 
and knowledge sharing. Nowhere else exists such a large 
group of culturally different countries who demonstrate a 
common determination in improving their understanding 
and responses to this complex social problem. This can be 
seen in the development of a transversal drug monitoring 
system that encompasses 30 countries with a combined 
population of more than half a billion people. It can 
also be seen in the EU drugs strategy and action plan, 
tools that are designed to take stock of the information 
available and elaborate it into practical and collective 
action. This is particularly important now, as our Member 
States face hard choices about funding priorities, and 
are ever more focused on the need to gain maximum 
benefit from the investments that have been made. We are 
confident that our current report contributes to this process. 
Furthermore, we make a commitment that the identification 
of what constitutes effective practice in the drugs field 
will form an increasingly important part of the EMCDDA’s 
future activities.
The conference also identified a number of important 
issues that are echoed in the analysis presented here. Our 
information systems need to perform better in identifying, 
tracking and reporting on new trends. In achieving 
this, however, it is essential that our reporting remains 
accurate, grounded and non-alarmist. Also highlighted 
was the need to unite in our analysis both supply-side and 
demand-side issues. In this year’s report, we give greater 
prominence to an analysis of supply-side indicators and 
the drug market. We do this cautiously, as insufficient 
efforts have yet been made to improve the quality, 
reliability and comparability of the European data set 
in this area. This is now widely recognised, and we are 
committed to working with our national and European 
partners to address this issue.
One of the findings of this year’s report is that 
assessing Europe’s drug situation needs a simultaneous 
understanding of national features, of subregional 
specificities and, increasingly, of common European, or 
even global, trends. For the future, we need to better 
describe this complex relationship, as this will help us 
not only to understand those factors that can promote or 
inhibit the growth of drug problems, but will also guide us 
in the development of appropriate interventions.
Finally, it should be noted that the European Union and the 
United Nations have renewed their drug policy documents 
almost in parallel in late 2008 and early 2009. The 
new EU action plan on drugs and the new UN political 
declaration and action plan both reflect the international 
commitment to reduce drug use and the harms it can 
cause. To achieve these objectives constitutes a major 
challenge and will only be achieved if the planned actions 
are widely implemented. Monitoring and evaluation are 
key elements in this process, as they allow us to keep our 
policies on course and chart the progress made.
Marcel Reimen
Chairman, EMCDDA Management Board
Wolfgang Götz 
Director, EMCDDA
Foreword
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made on the basis of those countries from which data are available for the period of interest.
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Introductory note
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Policy consensus permits a more targeted drug action plan
This report covers an important period for drug policy, 
both in Europe and beyond. In the European Union, we 
have seen the evaluation of the 2005–08 drug action 
plan — the fifth since 1990 — and the drafting and 
launch of its successor, operative for the years 2009–12. 
Although attention is often given to the differences that 
exist between Member States in their drug policies, from 
a historical perspective the considerable agreement 
that is now evident in discussions at European level is 
striking. Member States may still have distinct policy 
perspectives, to some extent reflecting distinct national 
realities; nonetheless, in many areas, the debate appears 
increasingly mature and consensus driven. This has 
permitted a new EU action plan that can be described 
as pragmatic, focused and targeted. This approach is 
concretely illustrated in the attention given to specific 
areas of practice such as the prevention of drug-related 
deaths, working in prison settings and improving the 
quality of treatment and other interventions.
Internationally, considerable public and professional 
interest has been stimulated by the discussions leading 
up to the adoption of a new United Nations political 
declaration and plan of action to fight the global drug 
problem, which followed the review of the goals set 
at the 1998 Special Session of the General Assembly 
(UNGASS). In this debate, Europe has provided a strong 
voice for drug policies that are balanced, scientifically 
grounded and humane. This has helped to ensure that, 
in the final agreement, the key progressive elements of 
the original 1998 UNGASS documents were preserved. 
Although the UN discussions at times were heated and 
sometimes reflected entrenched political and ideological 
positions, there were also signs that a more pragmatic 
and reasoned approach to identifying what constitutes 
effective action may be gaining ground. The USA, for 
example, softened its approach to the provision of sterile 
injecting equipment to reduce the risk of blood-borne 
infections, reflecting the substantial evidence base for 
effectiveness that now exists in this area. And, more 
generally, in recent policy statements, the USA appears 
to be moving closer to the European model. A strong 
consensus also emerged from the UNGASS meeting 
on the need for effective global monitoring of the drug 
phenomenon, especially given the continued growth 
of problems in developing and transitional countries. 
The reporting mechanism developed to assess the 
implementation of the UNGASS action plans has been 
criticised. But with its demise, important areas of work, 
particularly those concerning demand reduction measures 
remain outside of the existing global reporting framework. 
This issue is likely to be an important topic for the 
forthcoming session of the Commission on Narcotic Drugs.
Law enforcement practice confronted by competing policy 
objectives
Drug law enforcement receives a high profile in this 
year’s annual report, and a ‘Selected issue’ addresses the 
sentencing and other outcomes of those charged with drug 
offences. The number of violations of drug laws reported 
in Europe continues to grow. And although the data are 
difficult to interpret, this observation raises questions about 
the extent to which law enforcement practice is in step 
with policy objectives in this area.
Broadly speaking, the European policy debate has 
moved towards the view that priority should be given to 
interdiction activities targeting the supply rather than the 
use of drugs. Reflecting this, in some countries the legal 
penalties applicable to supply-related offences have 
been raised or minimum tariffs have been introduced. The 
extent to which this shift in emphasis away from users and 
towards drug suppliers is being translated into policing 
practice is difficult to gauge. Only in a few countries do 
offences related to drug supply outnumber those for drug 
possession. Overall, the number of supply-related offences 
has increased; but the number of offences related to 
possession or use of drugs has also increased, and to an 
even greater degree. As well, across Europe the picture 
for supply-related offences is more mixed, with half of 
the reporting countries noting a decline in numbers in the 
medium-term data.
Commentary
Hitting a moving target — the challenge of developing a pragmatic policy 
response to a changing drug problem
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The in-depth review on sentencing for drug law offences 
in Europe that accompanies this report explores what 
happens to those who violate drug laws. Custodial 
sentences are common for supply-related offences, but 
they tend to be given at the lower end of the available 
tariffs, averaging 3 years or less. This may simply reflect 
the reality that many of those charged are at the lower 
end of the supply chain, for example street dealers or 
addicts who also sell drugs to support their habit. This 
finding has implications for the development of minimum 
sentencing guidelines, if they are intended to deter high-
level career criminals from becoming involved in drug 
supply.
In most countries, custodial sentences are rarely 
handed out for drug use or possession. That said, a 
small percentage of those appearing in court will get 
an immediate prison sentence, possibly because of 
aggravating circumstances. This means that increasing 
numbers of drug users come into contact with the criminal 
justice system only to receive an administrative or minor 
sanction. Leaving aside the possible deterrent effect of this 
kind of action, it does raise the question as to what extent 
this contact with certain groups of drug users represents a 
missed opportunity for other demand reduction activities. 
Some countries have developed innovative approaches in 
this area, but overall these are still rare.
As those charged with drug offences are likely to be 
a diverse group, needs assessment is a particularly 
important issue for service development in this area. For 
health-related interventions, these span a continuum from 
prevention, education and harm-reduction approaches, 
to brief interventions and, when warranted, referral to 
specialised drug treatment and social support services. 
Developing a workable model to ensure appropriate 
referral trajectories is likely to pose an organisational 
challenge. Portugal has addressed this problem somewhat 
differently. The use of drugs is no longer subject to 
criminal sanctions, and those found in possession of drugs 
are directly referred for needs assessment to a special 
tribunal, known as a ‘commission for dissuasion of drug 
abuse’. The tribunal can issue fines, but sanctioning is not 
its main objective. This scheme has now been operating 
for 8 years. Initial fears that this approach would lead to 
an increase in drug tourism or increased levels of use do 
not appear to be supported by the data available.
Treatment and health interventions: from ‘one fits all’ 
towards a toolbox of targeted measures
Services for drug users in Europe are becoming 
increasingly diversified and offered as part of an 
integrated package of care. This can be seen, both 
conceptually and in practice. For example, harm-reduction 
and treatment interventions are increasingly linked and 
offered by the same providers. Despite widespread 
recognition of the importance of social reintegration, this 
remains a poorly developed area, and drug users still 
experience considerable difficulties finding jobs, adequate 
housing and developing non-drug-related pursuits.
Although progress has been made in treating drug 
users in Europe, it is uneven, both in terms of the 
substances addressed and geographical coverage. 
The greatest advances have been seen in the area of 
opioid substitution treatment, with the treated population 
now in the region of 650 000 and growing. However, 
eastern Europe as a whole only contributes to a small 
proportion of this total, suggesting that there is a need 
for an expansion of services in some countries. A lesson 
that has emerged from a number of countries is that 
the involvement of general practitioners can contribute 
to an expansion of treatment provision. Shared care 
arrangements with specialised centres not only provide 
support to general practitioners, but also assure treatment 
quality.
Despite the fact that in most countries it is theoretically 
possible to continue or start substitution treatment within 
the prison setting, in practice this is often difficult. Given 
the number of drug users within prisons in Europe, there 
is a pressing need to expand treatment opportunities of 
all types within this setting. This fact is recognised in the 
EU action plan, but currently remains a neglected area in 
most countries.
For drugs other than opioids, the availability of services 
and our understanding of what constitutes effective care 
are less well developed in Europe. However, this problem 
has begun to be recognised, with a growing number of 
European research projects and pilot programmes now 
addressing the treatment needs of stimulant and cannabis 
users. In addition, developments in neuroscience have 
not only improved our understanding of the biological 
mechanisms of addiction, but are now beginning to 
facilitate some innovative approaches. Examples here 
include a cocaine vaccine, now undergoing a large-scale 
trial in Europe. Developments in information technology 
have also facilitated innovation, such as Internet-based 
treatment programmes and the use of text messaging.
New evidence that Europe is moving into a period of 
declining levels of cannabis use
The popularity of cannabis use increased dramatically 
during the 1990s, to the extent that now nearly a quarter 
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of all European adults report having used the drug at least 
once. Subsequently, the situation began to stabilise, and 
the most recent data strongly support the analysis presented 
in last year’s report, of an overall decline in the use of 
this drug. Of particular interest are the latest results from 
the ‘European school survey project on alcohol and other 
drugs’, which provide a window on time trends in drug use 
among schoolchildren. Patterns found here are likely later 
to feed through into older age cohorts. Interestingly, just 
as different temporal patterns could be seen in the upward 
trend in cannabis use in the past, this pattern now appears 
to be repeating itself in reverse. The United Kingdom, for 
example, one of the first countries to record high prevalence 
levels was also one of the earliest to report a decline in 
use. This pattern is now seen in most other west European 
countries. In eastern Europe, levels of use were still 
increasing in most countries until recently. However, even in 
these countries, there are signs of stabilisation in the youth 
population and, if the pattern seen elsewhere is repeated, a 
subsequent decline could be expected.
Understanding the factors that influence the popularity of 
a drug such as cannabis is clearly important. However, 
caution should be used in inferring any simple causal 
explanations. National and EU policy may have played a 
part in influencing these trends; but declining levels of use 
are also seen in the USA and Australia, suggesting that 
broader sociocultural factors are likely to be important. 
Standing out in the European picture is a small group of 
countries, mainly in the north or south of Europe, where 
levels of cannabis use have remained low and stable for 
some time. Understanding the protective factors operating 
in those countries would also be of great interest; but 
again analysis will need to take full account of cultural, 
social and historical factors, as well as considering the 
influence of drug and social policies.
In contrast to the data on overall levels of use, the most 
recent analysis of patterns of problematic cannabis use 
in Europe is more mixed and less encouraging. A caveat 
here is that we currently lack good measures of dependent 
or problem use and, though some progress is being made 
in this direction, we must rely on more indirect measures. 
The number of new cannabis treatment demands may 
now be stabilising, after rising steadily for several years. 
Although to what extent this reflects patterns of use or the 
capacity of services remains unclear. Currently, the best 
behavioural indicator of problem cannabis use is provided 
by extrapolation from estimates of the number of daily 
users of the drug. Trends in daily use are difficult to assess, 
but the data available do not point to any overall decline. 
The EMCDDA estimates that somewhere between 2 % 
and 2.5 % of young adults are using cannabis on a daily 
or near-daily basis, with much higher levels found among 
young males. This represents a large population at risk, 
and highlights the need for better understanding of the 
service needs of this group.
Commentary: responding to Europe’s changing drug problem
At a glance — estimates of drug use in Europe
The estimates presented here relate to the adult population 
(15–64 years old) and are based on the most recent data 
available. For the complete set of data and information on 
the methodology see the accompanying statistical bulletin.
Cannabis
Lifetime prevalence: at least 74 million 
(22 % of European adults)
Last year use: about 22.5 million European adults or  
a third of lifetime users
Last month use: about 12 million Europeans
Country variation in last year use: 
overall range 0.4 % to 14.6 %
Cocaine
Lifetime prevalence: about 13 million  
(3.9 % of European adults)
Last year use: 4 million European adults or  
a third of lifetime users
Last month use: around 1.5 million
Country variation in last year use: 
overall range 0.0 % to 3.1 %
Ecstasy
Lifetime prevalence: about 10 million  
(3.1 % of European adults)
Last year use: about 2.5 million or  
a quarter of lifetime users
Last month use: less than 1 million
Country variation in last year use: 
overall range 0.1 % to 3.5 %
Amphetamines
Lifetime prevalence: about 12 million  
(3.5 % of European adults)
Last year use: around 2 million or a sixth of lifetime users
Last month use: less than 1 million
Country variation in last year use: 
overall range 0.0 % to 1.3 %
Opioids
Problem opioid users: estimated at between 1.2 and  
1.5 million Europeans
Drug-induced deaths accounted for 4 % of all deaths 
of Europeans aged 15–39, with opioids being found in 
around three quarters
Principal drug in more than 50 % of all drug treatment 
requests
About 650 000 opioid users received substitution 
treatment in 2007
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Heroin and cocaine: no strong signs of a diminishing 
problem
There is little to suggest an improving situation in the use 
of heroin and cocaine, the two substances that remain at 
the heart of Europe’s drug problem. That said, drawing 
any clear picture in this area is complicated by difficulties 
in reconciling the information coming from different 
indicators. This problem is particularly apparent for 
cocaine, where as well as a fall in estimated production, 
the volume of the drug seized in the European Union has 
fallen in the most recent data, as has the purity of the drug 
at street level in most countries. In the United Kingdom, 
a country with a large cocaine market, recent falls in 
purity have been considerable. These data could suggest 
declining cocaine availability, but other information puts 
this conclusion into question. The number of seizures of 
the drug is still increasing, prices are falling, and there are 
suggestions of a switch to new trafficking routes through 
eastern Europe, which may have impeded interdiction 
efforts. Cocaine use in Europe remains concentrated in 
western countries, where the trend is generally stable or 
still increasing. However, there is evidence of the further 
diffusion of the drug into other countries. Treatment 
demands related to cocaine are also growing. From the 
evidence available, it is possible to conclude that current 
consumption levels remain high and not diminishing 
in established areas and are continuing to grow 
elsewhere; but there are indications that suppliers may 
be experiencing difficulties in meeting consumer demand 
in some major markets. It will be interesting to see if the 
future brings more concrete evidence of a decrease in the 
availability of this drug after recent reports of a decline in 
global cocaine production.
Heroin still accounts for the greatest share of morbidity 
and mortality related to drug use in Europe. Use of the 
drug had generally been declining since the mid-to-late 
1990s, but today the picture is less clear, and in some 
areas raises concerns. Following marked decreases, the 
number of new treatment demands has been growing 
since 2002, with a significant number of countries now 
reporting increases in both the number and proportion 
of treatment demands related to opioid drugs. Data on 
drug-related deaths, which are largely associated with 
heroin use, also provide no indication of a return to the 
decreasing trend observed prior to 2004. Data on the 
numbers of drug law offences and seizures also show 
increases. Worryingly, a small number of countries note 
that heroin problems have been observed among some 
young people, suggesting that the drug could be diffusing 
into new populations. Altogether, it must be viewed as 
disappointing that the positive analysis of the declining 
trend in heroin-related problems is no longer sustained. 
And, while there is currently no evidence of a return to 
the epidemic spread of heroin use seen in the past, the 
health and social problems arising from the use of this 
drug are considerable. Any indications that the situation 
may be worsening, especially as Europe enters a period 
of economic difficulties, are grounds for considerable 
concern.
Polydrug use and concomitant alcohol problems are now 
the defining elements of the European drug problem
In drug prevention, it has long been understood that 
substance use problems are best addressed holistically 
and in the context of healthy lifestyles and informed 
choices. In contrast, the discourse on drug use is more 
often substance specific. It is hard not to be drawn to 
the conclusion that this one-dimensional perspective 
is becoming increasingly unhelpful in understanding 
the developing nature of patterns of substance use in 
Europe. Individuals who use drugs almost never restrict 
their consumption to a single substance. In Europe today, 
polydrug patterns are the norm, and the combined use 
of different substances is responsible for, or complicates, 
most of the problems we face. This raises the need to 
develop a more comprehensive, integrated and multi-
substance perspective, in order to better understand the 
situation and design and evaluate appropriate responses. 
And it applies equally to the drug market. Actions to 
reduce the supply of one drug are clearly devalued if they 
simply open the door for the use of a substitute, which 
may be even more damaging.
This year’s annual report is accompanied by a ‘Selected 
issue’ on polydrug use, which explores how the use 
of multiple substances impacts across different groups 
of drug users. The findings are disturbing. Among the 
young, multiple substance consumption can increase the 
risks of acute problems and is predictive of developing a 
chronic drug habit in later life. Among older, regular drug 
users, polydrug use is a major issue in drug overdose, 
it complicates drug treatment and is associated with 
violence and offending. The choice of drugs available to 
consumers in Europe is also growing. Noted in the current 
report are: the increasing range of largely uncontrolled 
substances targeting the cannabis market; innovation in 
the production of synthetic drugs; and increasing worries 
about the misuse of prescription medicines. Additionally, it 
has become recognised that a defining factor in Europe’s 
substance use problem is the concomitant consumption 
of alcohol. This too can be seen across every age group. 
Among schoolchildren, the latest data show a strong 
association between binge drinking and drug use. Binge 
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drinking also often goes hand in hand with recreational 
drug use, increasing the risks of negative outcomes among 
young adults. Within the chronic drug-using population, 
alcohol abuse is so common it often goes without mention, 
and the need to address coexisting alcohol dependence 
has become an increasingly important issue for drug 
treatment centres. Alcohol problems can be particularly 
deleterious for those addicted to opioid drugs, as they 
may already have compromised liver function through 
hepatitis infection and the risk of overdose is elevated.
Innovation and precursor availability: interacting factors 
that are having a growing impact on the market for 
synthetic drugs
The EMCDDA is observing an increasingly complex and 
volatile situation in the availability and use of synthetic 
drugs in Europe. The illicit market and its suppliers show 
high levels of innovation in terms of production processes, 
new products and marketing opportunities, as well as 
demonstrating the ability to adapt quickly to control 
measures. In addition, the growing sophistication of the 
marketing of ‘legal alternatives’ to illicit drugs represents a 
worrying development.
An example of market volatility can be seen in recent 
developments in the availability of ecstasy. Until 2007, 
most ecstasy tablets analysed in Europe contained 
3,4-methylenedioxy-methamphetamine (MDMA) or 
another ecstasy-like substance. However, initial data from 
the early-warning system from the beginning of 2009 
suggest that this may be changing in some Member 
States, such as Denmark and the Netherlands. In up to 
half of all tablets analysed in these countries, no MDMA 
or any of its analogues were found. Rather, the pills 
contained 1-(3-chlorophenyl)piperazine (mCPP) either 
alone or in combination with another psychoactive 
substance. Though mCPP is not listed in the UN 
conventions, it has been subject to control measures in 
some EU Member States. The reasons for the current 
market change are not completely clear, but a shortage 
of 3,4-methylenedioxyphenyl-2-propanone (PMK), a 
main precursor for the synthesis of MDMA, is a possible 
explanation. It cannot yet be said if this development is a 
temporary digression or marks a more significant transition 
in the ecstasy market. The EU early-warning system has 
been monitoring mCPP since 2005, and the EMCDDA and 
Europol follow developments in this area closely and will 
produce a report on the market in 2010.
Changes in the ecstasy market may point to increasingly 
successful efforts to prevent the diversion of precursor 
chemicals, and these efforts may also have important 
effects on the availability and use of other substances. 
For example, there are some signs that methamphetamine 
may be displacing amphetamine in parts of northern 
Europe. Again, market factors and precursor chemicals 
appear important here, with methamphetamine production 
sites appearing now to be located in Lithuania, whose 
geographical position facilitates the import of precursors, 
in this case 1-phenyl-2-propanone (BMK), from outside 
of the European Union. The situation in Nordic countries 
adds to concerns about the possible outward diffusion 
of methamphetamine use beyond the Czech Republic. 
In this country, methamphetamine problems are long 
established, but with production usually on a small 
scale for personal or local consumption. A number 
of central European countries now also report some 
methamphetamine use, and Europol reports that a 
few larger production sites have been detected and 
dismantled in other parts of Europe. There is also some 
evidence that methamphetamine use is growing quickly 
in some of the countries bordering the European Union. 
To date, the drug has failed to make inroads into the 
large market for stimulant drugs in western Europe, where 
cocaine or amphetamine use still dominates. Nonetheless, 
given the relative ease with which methamphetamine can 
be produced and the considerable negative impact that 
this drug can have on public health, there is no room for 
complacency. The speed at which problems can develop 
is illustrated by Slovakia, which provides a recent case 
study of a country where methamphetamine use has 
grown significantly.
The Internet and marketing: is ‘spice’ a taste of things to 
come?
Few areas of contemporary life have not been transformed 
by advances in information technology, with the 
Internet now providing not only an unfettered source of 
information, but also a major virtual marketplace for 
the exchange of goods and services. It is, therefore, 
unsurprising that this medium is now having an impact 
on the drugs field. This year, the EMCDDA launched 
a first review of Internet treatment approaches, and it 
appears that, for some forms of prevention, treatment and 
harm-reduction interventions, the web-based approaches 
have considerable potential. Less positively, there are 
difficulties apparent in regulating this virtual and global 
phenomenon, and the Internet can be used to promote the 
use of psychoactive substances. Added to the concerns 
raised by the online marketing of alcohol and medicines 
are those about the appearance of a range of supposedly 
‘legal’ alternatives to controlled psychoactive substances.
Commentary: responding to Europe’s changing drug problem
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The EMCDDA is now regularly monitoring the 
psychoactive substances offered by online retailers. 
This market has grown over the last few years, and 
now includes a wide range of plant-based products, 
in particular herbal mixtures, as well as merchandise 
containing synthetic compounds. New substances 
appearing on the Internet market can range from 
drugs used traditionally in some parts of the world, 
to experimental chemicals synthesised in laboratories 
and untested in humans. Other innovations include the 
development of distinct brands and the use of attractive 
packaging. A notable example of this is the herbal 
mixtures that have been marketed under the ‘spice’ label.
Numerous brands of ‘spice’ have been found with different 
packaging and different ingredient lists. Forensic analysis, 
however, has largely failed to detect the plant-based 
substances declared on the labels, but did identify in some 
samples synthetic cannabinoids that had been added to 
the mixtures. These substances were not among the listed 
ingredients, and would therefore have been consumed 
unknowingly. The cannabinoids found are relatively 
obscure research compounds, some are extremely potent, 
and little is known about their effects on humans.
Attempts to circumvent drug control by marketing 
unregulated substitutes are not new. What is new is 
the wide range of substances now being explored, 
the aggressive marketing of products that have been 
intentionally mislabelled, the growing use of the Internet, 
and the speed at which the market reacts to control 
measures. ‘Spice’ may also provide us with a warning of 
problems to come. The ability of sophisticated chemists, 
often located outside of European jurisdictions, to 
cheaply conduct organic synthesis, potentially provides 
access to a considerable number of psychoactive 
substances. This can bring into the picture whole 
new chemical groups, comprising many analogues, 
which can be difficult to detect and pose considerable 
difficulties for control policies based on individual 
compounds. Moreover, as some of these substances may 
have legitimate uses or be sold supposedly for legitimate 
purposes, they can fall between drug control and trade 
regulation.
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(1) Political declaration and plan of action on international cooperation towards an integrated and balanced strategy to counter the world drug problem.
Introduction
Two new European and international drug policy 
documents have been developed in the past year. In 
December 2008, the European Union unveiled its new 
action plan on drugs (2009–12), and this was followed, 
some months later, by the United Nations’ new political 
declaration and plan of action to counter the world drug 
problem. The content of the new drug policy documents 
and the role of organisations representing civil society in 
their formation are discussed in this chapter. 
The international policy debates included discussions 
about drug trafficking, and reviewed here are recent legal 
developments in minimum penalties for drug trafficking in 
Europe. Harm reduction was also a key issue for policy 
debate, and the legal status of two important interventions 
in this area, needle and syringe exchange and substitution 
treatment, are also covered in this chapter. 
Other topics addressed are the recent adoption and 
evaluation of national drug strategies and action plans, new 
data and trends on drug-related public expenditure and 
developments regarding drug-related research in Europe.
International and EU policy developments
New UN political declaration and plan of action
A new UN political declaration and plan of action (1) was 
adopted at a high-level political meeting during this year’s 
session of the United Nations’ Commission on Narcotic 
Drugs (CND). This was the outcome of a year-long 
reflection, undertaken as part of the 10-year review of the 
progress made in reaching the goals and targets set in 
1998 during the twentieth UN General Assembly Special 
Session (UNGASS) on the world drug problem.
The European Union and its Member States played a 
leading role in the UNGASS review. Europe’s position on 
the UN drug policy to emerge from the review process 
was expressed in a common position paper drafted by 
the Council of the European Union. The paper stressed 
the importance of public health as the first principle of 
the international drug control system and the need for 
a system-wide coherence in the drugs field among UN 
bodies (including INCB, UNODC, UNAIDS, WHO). It 
also called for the inclusion of a set of key elements and 
priorities in the new UN Political Declaration. Among 
these were the need for a comprehensive, integrated and 
balanced drug policy, with drug demand reduction being 
given more weight and harm reduction being included. 
The EU urged that respect of the international human rights 
conventions, including the right to health, should be a key 
element of the new drug policy, and that the development 
of drug policies should be based on scientific evidence. 
Furthermore, the EU argued that, to combat drug 
production, support for alternative development should not 
be conditional on reductions in illicit crop cultivation.
Chapter 1
Policies and laws
Global illicit drug market 
The results of a new study funded by the European 
Commission on the global illicit drug market were 
presented at the 2009 session of the Commission on 
Narcotic Drugs in Vienna (1). The study found no evidence 
that the global drug problem had been reduced between 
1998 and 2007. For some nations, the problem declined 
but for others it worsened, in some cases substantially. 
According to the study, illicit drug markets are not vertically 
integrated or dominated by major dealers or cartels. While 
sales of illicit drugs are estimated to generate more than 
EUR 100 billion, the vast majority of those involved in the 
drug trade make modest incomes. A few individuals make 
great fortunes, but these account for only a small portion of 
the total revenue.
A convergence of national drug policies is reported by 
the study, with demand reduction receiving increasing 
emphasis and harm reduction finding wider acceptance. 
Policies towards sellers and traffickers have toughened. 
The enforcement of drug prohibition is judged by the 
study to have caused substantial unintended harm; much 
of which could have been predicted (e.g. geographical 
displacement of production and trafficking).
(1) European Commission, ‘Report on global illicit drug markets, 
2009’ (available at: http://ec.europa.eu/justice_home/doc_
centre/drugs/studies/doc_drugs_studies_en.htm).
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(2) 13407/08 ADD 3 Cordrogue 69 (http://register.consilium.europa.eu/pdf/en/08/st13/st13407-ad03.en08.pdf).
(3) OJ C 326, 20.12.2008, p. 7.
The new UN document is similar in content to the 
original UNGASS declarations and action plans agreed 
in 1998. It includes many of the elements put forward 
by the European Union, as can be seen in the plan of 
action, which reviews current drug policy problems and 
lists the actions that UN Member States have committed 
themselves to implementing during the next decade. 
Among the key actions and objectives under the heading 
of drug demand reduction are: better respect of human 
rights, increased accessibility of services and improved 
targeting of vulnerable groups. A better balance in drug 
policies, in favour of drug demand reduction, and the 
implementation of evidence-based interventions, as well 
as monitoring and quality assurance mechanisms, are also 
called for. However, the UN document does not explicitly 
acknowledge the contribution of harm reduction, an 
approach that has been pursued in Europe under scientific 
scrutiny. 
EU action plans on drugs
In September 2008, the European Commission published 
its final evaluation of the 2005–08 EU drugs action 
plan (2). The evaluation reviewed the implementation of 
the actions and the attainment of the objectives set out in 
the action plan. It also examined the action plan’s impact 
on the national drug policies of EU Member States and 
looked at recent trends in Europe’s drug situation.
The evaluation found that while not all actions had 
been fully implemented and not all objectives attained, 
progress had been made in almost all areas of the 
action plan. Moreover, the fact that most national drug 
policy documents contain objectives that echo those of 
the EU action plan was noted as evidence of increasing 
convergence among European countries in the field of 
drug policy. A relative stabilisation of Europe’s drug 
situation in recent years was also observed, but the 
contribution of the EU action plan to this trend could not 
be determined. 
Overall, despite some operational shortcomings, the EU 
drugs action plan was judged to have added value in 
three distinct areas: in committing Member States and EU 
institutions to achieving common objectives; in providing a 
framework for coordination and for developing a coherent 
approach in the drug field; and as a policy model at 
international level. 
The final evaluation of the drug action plan informed 
the drafting of its successor, the EU drugs action plan 
(2009–12), which was endorsed by the European Council 
in December 2008 (3). This drug action plan, the fifth 
since 1990, is the second under the current EU strategy on 
drugs (2005–12). Its overall aim is to reduce significantly 
the prevalence of drug use among the population and to 
reduce the social and health damage caused by the use of 
and trade in illicit drugs. 
The new EU action plan identifies five key priorities 
that reflect its areas of action: improving coordination, 
cooperation and raising public awareness; reducing 
the demand for drugs; reducing the supply of drugs; 
improving international cooperation; and, improving 
the understanding of the problem. The new plan is more 
EU drugs action plan (2009–12): new features 
The participation of civil society in drug policy receives 
additional attention in the new EU drugs action plan. 
Through setting up a ‘European Action on Drugs’, the 
action plan aims to stimulate European civil society’s 
commitment about and action on drug problems. The 
action plan also calls on Member States to involve civil 
society at all appropriate levels of drug policy. 
The focus on the quality of interventions in the areas of 
prevention, treatment, harm reduction and rehabilitation 
has been reinforced through actions calling for the drafting 
and exchange of guidelines, good practices and quality 
standards, and for the development of EU minimum 
quality standards or benchmarks in these fields. The 
prison setting also receives additional attention under the 
heading of drug demand reduction, with actions calling on 
Member States to provide services for drug users in prison 
equivalent to those existing outside prison, to implement 
follow-up care after release from prison and, overall, to 
improve the monitoring of drug problems and drug services 
in this setting.
Most of the actions related to supply reduction are aimed 
at improving law enforcement and judicial cooperation 
between Member States, often through increased use of 
EU bodies, projects and tools. Reducing the diversion and 
trafficking of drug precursors within and through Europe 
is the subject of seven different actions, with a broadly 
operational focus. 
In the area of international cooperation, a stronger 
emphasis is placed on alternative development, with three 
actions calling for intensified financial and political support 
for such programmes. A better reflection of the balanced 
approach between demand and supply reduction is also 
pursued in external agreements and programmes.
Under the heading of information, research and evaluation, 
a new action calls for the development of key indicators 
and strategies for the collection of data on drug-related 
crime, illegal cultivation, drug markets and supply reduction 
interventions. Increased emphasis is also placed on 
strengthening research in the drugs field and on developing 
drug policy evaluation both at national and at EU level.
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(4) See ‘EU drugs action plan (2009–12): new features’ p. 19. 
(5) http://www.vngoc.org/details.php?id_cat=8&id_cnt=56
(6) The term ‘national drug-policy document’ means any official document approved by a government that defines general principles and specific 
interventions or objectives in the field of drugs, where officially represented as a drug strategy, action plan, programme or other policy document.
focused than its predecessor, with only about half the 
number of objectives (24) and fewer actions (72). It also 
contains objectives and actions that were not present in 
the earlier action plan (4). An external and independent 
evaluator will conduct a final assessment of the current 
drug action plan and strategy in 2012, and this will be 
followed by a period of reflection in order to prepare the 
next EU drug policy documents. 
Civil society and drug policymaking
The involvement of non-governmental organisations 
(NGOs) in the preparatory discussions for the new EU and 
UN drug policy documents represents an important step 
in the engagement of civil society in this field of policy. 
In May 2008, the European Commission’s Civil Society 
Forum on Drugs debated the first results of the evaluation 
of the EU drug action plan (2005–08) and discussed 
the needs and possible contents of the following action 
plan (European Commission, 2008a). The forum’s 26 
NGOs suggested that the principles of public health and 
human rights should be at the heart of EU drug policy, 
and non-stigmatisation and non-discrimination should 
be emphasised. They also called for more attention to 
be given to vulnerable groups, polydrug use, mental 
health issues, the situation in prisons and the prevention 
of drug-related deaths. Among the priorities for action 
identified by the forum are enhanced coordination 
between governments and civil society, development of 
quality standards in drug demand reduction, improved 
data collection mechanisms and support for alternative 
development in third countries.
The contribution of NGOs to the progress made in 
achieving the goals set at the 1998 UNGASS was 
reviewed by the Vienna NGO Committee on Narcotic 
Drugs, with financial support from the European 
Commission and several EU Member States. The ‘Beyond 
2008’ process was based on nine regional consultations 
culminating in a forum held in July 2008 in Vienna. The 
final declaration and three resolutions adopted by the 
forum highlighted the many activities of NGOs and their 
increasing role in drug policy (5). The NGOs called on 
governments and international organisations to consult 
them regularly and give them increased support. Among 
the many and varied calls made upon Member States 
and international organisations, several themes can be 
identified, including: a comprehensive and balanced 
drug policy based on human rights, public health and 
scientific evidence; increased monitoring and evaluation 
capacities; development and diffusion of best practices 
and, in particular, of UN guiding principles for effective 
treatment; accessibility and adequate provision of narcotic 
drugs as pain relief medicines; alternative sanctions and 
dispositions for drug-related crimes; and respect for the 
human rights of prisoners who are drug-dependent or in 
custody for drug-related crimes. 
National drug strategies and action plans
New developments
Drug strategies and action plans are now essential 
instruments of national drug policies in Europe. All but 
one of the 30 countries monitored by the EMCDDA have 
adopted such documents, which they renew periodically. 
In 2008, new drug policy documents (6) were adopted 
by Greece, France and the United Kingdom. Greece has 
adopted an action plan (2008–12) to complement its 
already existing drug strategy. Among the aims of the new 
plan is the better provision of drug treatment. The new 
French action plan (2008–11) covers illicit drugs, alcohol 
and tobacco. A key priority of the plan is to dissuade 
young people from beginning to use drugs by reaffirming 
the prohibition of drug use and informing young people 
and their parents about the risks related to drug use. 
The new drug strategy (2008–18) and its action plan 
(2008–11) adopted by the United Kingdom aim to restrict 
the supply of illicit drugs and reduce the demand for them, 
while giving particular attention to protecting families and 
strengthening communities.
Ten other EU Member States had national drug policy 
documents expiring in 2008. Spain adopted a new drug 
strategy in February 2009, and eight other countries 
(Bulgaria, Ireland, Italy, Lithuania, Cyprus, Portugal, 
Romania, Slovakia) were in the process of finalising and 
adopting new drug strategies and action plans during 
the first half of 2009; Latvia extended its 2005–08 
programme with a 1-year action plan. The Netherlands 
also plan to replace their 1995 white paper on drug 
policy in 2009, while several countries will see at least 
one of their policy documents coming to the end of its term 
during this year (Czech Republic, Luxembourg, Hungary, 
Slovenia, Croatia, Turkey).
Evaluation
Around two thirds of European countries report that 
they produce an ongoing or annual review of the 
implementation of the actions set out in their national drug 
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(7) The COFOG classification has three hierarchical levels. At the first level, government expenditure is broken down into 10 functions. 
policy documents. In most cases, a progress report based 
on data collected from service providers and ministries 
involved in drug policy is submitted to the government or 
parliament. Most countries have thereby already started to 
implement Action 70 of the EU drugs action plan (2009–
12), which calls upon EU Member States to evaluate 
and fine-tune their national drug policies on a regular or 
ongoing basis. 
A similar assessment can be made regarding the final 
evaluation of national drug strategies and action 
plans, with more than 20 countries reporting that they 
are currently preparing or have recently carried out 
such an evaluation. In some cases, the final report is a 
summary of annual implementation reviews; in others, 
there is an attempt to get a deeper understanding of the 
implementation process, of the effectiveness or of the 
impact of the policy. Of the countries taking the more 
in-depth approach to evaluation, two (Luxembourg, 
Cyprus) have decided to work with external evaluators 
from outside the country. 
Drug policy evaluations face considerable difficulties 
in their attempts to link the outputs of drug strategies or 
action plans with changes in the drug situation. Among 
these are problems in assessing the effects of large sets 
of actions and the limited understanding of the influence 
of key contextual elements, such as drug markets or 
trends in drug use and lifestyles among young people. 
Nevertheless, attempts to establish links between drug 
strategies or action plans and indicators of the drug 
situation have been made by some European countries. 
And this should become more common in the future, with 
the new EU drugs action plan (2009–12) calling for the 
development of instruments to measure the effectiveness 
and impact of drug policies. The EMCDDA is also 
developing guidelines to help Member States assess and 
interpret the results of their drug policy documents. 
Public expenditure
Detailed, reliable information on drug-related public 
expenditure is needed by policymakers in order to 
assess the actual allocation of resources in this area 
and, ultimately, the cost–benefit relations of drug policy. 
Estimating in economic terms the resources deployed by 
the state in response to the use of illicit drugs is therefore 
an essential step towards understanding the wider impact 
of drug use. 
Estimates of public expenditure are based on government 
budgets and accountancy documents. However, estimating 
the total expenditure incurred in implementing national 
drug policy is difficult, as it involves bringing together 
figures for activities carried out at different levels of 
government (e.g. local, regional, national), which may be 
funded under various budget headings, and are often not 
specifically identified as related to drugs. 
The total drug-related public expenditure in Europe has 
been estimated at EUR 34 billion for 2005 (EMCDDA, 
2008a). Due to high levels of under-reporting it is 
not possible to update this estimate. The difficulties in 
information collection in this area are illustrated by the 
fact that among the 23 countries reporting data for 2007, 
only the Czech Republic was able to give a breakdown of 
expenditure across all levels of government. Most countries 
could provide data on central government expenditure, 
and seven also reported expenditure by regional or local 
government (Belgium, Denmark, Estonia, Austria, Finland, 
Croatia) or from social security funds (Germany). 
Labelled and unlabelled expenditure
Labelled expenditure is the planned drug-related public 
expenditure made by the general government of the state. 
It reflects the voluntary commitment of the state in the field 
of drugs and can be traced back by a detailed review of 
public budgets. Of the 23 countries providing data for 
2007, 16 reported only labelled expenditure. In many 
cases (e.g. Estonia, France, Poland, Romania), the greater 
part of the labelled expenditure identified was incurred 
in connection with the implementation of national drug 
policy documents. 
Not all drug-related expenditure is identified as such 
in national budgets. In most countries, the amount 
expended in some drug-related activities is embedded in 
other programmes and interventions (e.g. overall police 
operations budget, or interventions targeting both licit 
and illicit substances). In these cases, such ‘unlabelled 
expenditure’ must be estimated by a cost-modelling 
approach. The results of earlier studies show that, in most 
cases, unlabelled expenditure represents the greater part 
of the national expenditure on the drugs problem.
Public expenditure related to drugs can be categorised 
according to the classification of the functions of 
government (COFOG) system (EMCDDA, 2008e). Three 
countries submitted labelled expenditure classified to 
the first level of COFOG (Luxembourg, Finland, United 
Kingdom for England only), with only the United Kingdom 
including figures for ‘general public services’, ‘education’ 
and ‘social protection’ (7). In these three countries, ‘health’ 
received the highest proportion of the total disbursement, 
followed by ‘public order and safety’ (Table 1). In contrast, 
for those countries providing COFOG data for unlabelled 
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(8) Council recommendation of 18 June 2003 (OJ L 165, 3.7.2003, p. 31). 
(9) See Figure 11, p. 77.
expenditure, the greater part was allocated to ‘public 
order and safety’, followed by ‘health’. This is in line with 
the findings of earlier reports (see EMCDDA, 2008e), 
which suggest that, while the greater portion of labelled 
expenditure may be allocated to ‘health’ interventions, 
‘public order and safety’ activities receive the lion’s share 
of drug-related public expenditure. 
Trends 
For most of the countries for which consistent information 
is available, labelled expenditure, at constant prices, 
increased in 2007 compared with 2005. Increments 
varied from 14 % to 23 % (Czech Republic, Ireland, 
Lithuania, Luxembourg, Croatia) to 72 % (Cyprus, Finland). 
In the United Kingdom, labelled expenditure remained 
stable over this period.
National legislation 
The European Union’s balanced approach to drug policy 
gives equal weight to reducing the demand for and the 
supply of drugs. An examination of national legislation 
passed during the last 10 years shows that EU Member 
States have been actively legislating in a manner 
consistent with this political commitment. Countries have 
been setting up regulatory frameworks for certain harm 
reduction activities, while increasing the punishments for 
drug trafficking. Halfway through the period, two EU 
instruments gave added impetus to these processes. In 
2003, the European Council issued a recommendation 
on the prevention and reduction of drug-related harm, 
which called for actions including provision of appropriate 
substitution treatment and access to distribution and 
exchange of injection materials (8). And, the Council 
Framework Decision 2004/757/JHA of 25 October 2004 
called for stronger penalties for trafficking illicit drugs. This 
section will describe the trends over the last 10 years in 
the regulation of harm-reduction activities and penalties 
against traffickers. It will show that the activity in these 
areas at national level has been reflected in agreements at 
EU level, though some countries have exercised their rights 
to go further than the minimum standards set by these 
agreements.
Opioid substitution treatment
Since 1998, some 45 legal texts have been reported by 
18 countries regarding establishment of or changes to the 
legal framework of substitution treatment programmes. 
Several of these texts have been dedicated to establishing 
or regulating the programmes in some detail: in Ireland 
(1998), Poland (1999), Germany (2000), Czech Republic 
and Portugal (2001), Greece and Luxembourg (2002), 
Belgium and France (2004), Latvia (2005) and Austria 
and Lithuania (2007). 
While European countries have covered many different 
aspects of opioid substitution treatment in the laws and 
regulations adopted, up to 2004 there was a noticeable 
trend for them to define the substances permitted. During 
this period, about a quarter of the texts authorised or 
regulated the use of substances such as methadone and 
buprenorphine. In contrast, one third of those reported 
since 2002 defined or eased access to programmes. 
Prescription of substances for opioid substitution is 
sometimes limited by law to doctors in treatment centres, 
though prescription by other doctors is often allowed (9). 
Authorised dispensaries are usually also specified in the 
legislation, mostly pharmacies or treatment centres, though 
some countries also allow doctors to dispense.
Table 1: Labelled and unlabelled drug-related public expenditure in 2007 for those EU Member States 
reporting by COFOG (classification of functions of government)
COFOG category Luxembourg  
EUR million (%)
Finland (1) 
EUR million (%)
United Kingdom 
EUR million (%)
Labelled Unlabelled (2) Labelled Unlabelled Labelled
General public services — — — — 50.4 (3.6)
Public order and safety 4.7 (37.6) 15.1 (70.2) — 62.3 (82.2) 358.9 (27.2)
Health 7.8 (62.4) 6.4 (29.8) 14.3 (100) 3.8 (5.0) 958.2 (68.8)
Education — — — 9.7 (12.8) 15.2 (1.1)
Social protection — — — — 10.5 (0.8)
(1) Data from 2006.
(2) Full details of the modelling procedures used to derive estimates of unlabelled expenditure are provided by Luxembourg.
Sources: Reitox national reports (2008).
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Needle and syringe programmes
Needle and syringe programmes may operate at a local, 
regional or national level, sometimes with a specific 
national legal framework to permit them, but usually 
without. Laws reported in Europe in the early part of the 
last 10 years were largely aimed at providing a legal 
basis for such interventions (Slovenia in 1999, Poland in 
2001, Finland in 2003), or to define or facilitate access 
rights to needle and syringe programmes (Belgium and 
France in 1998, Finland in 2003). The focus of legislation 
quickly shifted to regulating these programmes, with 
Belgium, Portugal and Luxembourg passing specific, 
detailed laws or decrees in 2000, 2001 and 2003 
respectively that regulated who may carry out such 
schemes and whether or not dispensing machines 
are permitted. In Portugal, the regulatory framework 
was extended in 2007 to include needle and syringe 
programmes in prisons.
Some countries have adopted legislation to address 
concerns that needle and syringe programmes could 
possibly be in conflict with legal provisions intended to 
criminalise the ‘facilitation’ or ‘incitement’ to use drugs. 
In Belgium and Germany, this issue has been addressed 
with a clause in the law that specifically exempts certain 
programmes from any such charge, although limits may 
be placed on the number of syringes dispensed. In a few 
countries, guidance is issued to the police on appropriate 
law enforcement practice near needle and syringe outlets. 
Overall, police confiscation of sterile syringes or needles 
is reported to be rare across the European Union. 
Penalties for trafficking 
Over the last 10 years, EU Member States have indicated 
both individually and collectively that drug trafficking 
offences should be punished more severely, even if the 
offences themselves are defined differently in the laws of 
almost 30 countries. ‘Trafficking’ offences may include 
production or cultivation, import and export, transporting, 
offering, selling and/or possession, with intent to distribute 
or supply, or the concept of acting ‘for gain’ or ‘on a 
commercial basis’. 
In the period 1999–2004, six countries passed laws 
increasing the penalties for certain drug trafficking 
offences. In 1999, Ireland created the new offence of 
possession of a large amount of drugs (worth more than 
EUR 12 700) with intent to supply, which would carry a 
mandatory minimum sentence of 10 years’ imprisonment. 
In 2000, the United Kingdom introduced a minimum 
sentence of 7 years’ imprisonment for a third conviction 
of trafficking in class A drugs, and in 2001 Greece 
tightened the legislation on sentencing of traffickers, 
limiting their rights to conditional release. Changes to the 
Estonian Criminal Code, in 2002 and 2004, increased 
the maximum penalties for traffickers of small quantities 
from 3 to 5 years, and of large quantities from 5 to 
10 years. In Denmark, the penalties for trafficking were 
raised from 6 to 10 years and, for trafficking large 
amounts or particularly dangerous substances, from 10 to 
16 years. Also in 2004, Lithuania increased penalties 
for basic trafficking offences from a maximum of 2 years 
to between 2 and 8 years, and for a large amount from 
between 2 and 8 years to between 8 and 10 years. 
In October 2004, the Council Framework Decision 
2004/757/JHA set out minimum provisions of criminal 
acts and penalties for trafficking. Since then, four more 
countries have passed laws to bring basic trafficking 
penalties into line with the decision. In 2006, the 
Netherlands raised the maximum penalty for trafficking of 
large quantities of drugs from 4 to 6 years, while Poland 
increased the penalties for possession of large quantities 
and supply to minors from a maximum of 5 years to a 
maximum of 8 years, setting also a minimum period of 
6 months. In Slovakia, the basic penalty for trafficking was 
increased from between 2 and 8 years to between 4 and 
10 years, with the maximum penalty for larger amounts 
increasing from 10 to 15 or even 20 years. Finally, 
in Austria, the maximum penalty for giving narcotic 
substances to others, or cultivation of some narcotic 
plants, was increased in 2007 from 6 to 12 months’ 
imprisonment. Penalties for more serious offences were 
not changed, though the definition of a large quantity was 
reduced from 25 to 15 times the threshold quantity.
Drug-related research
Research on the drugs problem carried out in each 
European country was reported on in a ‘Selected issue’ 
European Legal Database on Drugs 
The European Legal Database on Drugs (ELDD) is the 
EMCDDA’s online database of information on European 
drugs-related legislation for the Member States and 
Norway. The ELDD provides legal texts in their original 
formats, profiles of the drug laws in each country and 
detailed reports on specific topics. In its Topic overviews, it 
also provides summaries of the legal position on selected 
subjects including illegal drug trafficking, substitution 
treatment, and needle and syringe programmes (1). 
(1) ELDD topic overviews: http://eldd.emcdda.europa.eu/html.cfm/
index5036EN.html
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(10) More information on EU and national drug-related research is available at http://www.emcdda.europa.eu/themes/research
(11) See http://ec.europa.eu/justice_home/fsj/drugs/fsj_drugs_intro_en.htm
published by the EMCDDA in 2008 (10). This year, 
references to national research in the latest Reitox reports 
are analysed to provide an insight into the research 
recently conducted in European countries. Also reported 
on in this section is a study on drug-related research in the 
EU released this year by the European Commission. 
Research projects in Member States
European countries referred to more than 350 research 
projects undertaken or published in 2007 and 2008 in 
the latest Reitox national reports. The United Kingdom 
referred to the highest number of research projects, over 
80, followed by Germany and the Netherlands, each with 
over 30, and the Czech Republic, Ireland and Finland, 
with over 20.
Research on responses to the drug situation accounted for 
more than one third of the recent studies, while another 
third focused on prevalence, incidence and patterns of 
drug use, and one fifth on the consequences of drug 
use. Among the subject areas that appeared to attract 
considerably less research attention were: determinants 
and risk and protective factors, mechanisms and effects of 
drugs, supply and markets, and methodological issues.
The results of this analysis, while limited in scope, give 
support to the new EU action plan’s calls for increased 
research efforts in those priority areas that are under-
represented, in particular drug supply.
Analysis of drugs research in the European Union
Drug supply is also among the areas identified as being 
under-represented in current research by a study carried 
out for the European Commission entitled ‘Comparative 
analysis of research into illicit drugs in the European 
Union’. The report noted prevention, legal frameworks 
and interdiction as other fields disproportionately under-
researched, while research on epidemiological topics 
was found to be more common (11). The study found that, 
although comprehensive expertise exists in Member 
States, improved data comparability between countries 
and increased visibility of research should be pursued.
Participation in European research activities was found 
to vary considerably between countries, with much of the 
international cooperation taking place on an informal 
basis. However, the study emphasised that drug-related 
research can be facilitated by European and international 
networks of researchers. Research capacity, overall quality 
and funding availability vary widely in the EU, and there 
is a considerable need for capacity building and for 
funding to cover a broader range of policy areas linked to 
the EU drug action plan.
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Introduction
This chapter presents an overview of the responses to 
drug problems in Europe, where possible highlighting 
trends, developments and quality issues. Prevention 
measures are first reviewed followed by interventions 
in the areas of treatment, harm reduction and social 
reintegration. Taken together, all these measures form a 
comprehensive drug demand reduction system. They can 
be considered as complementary, and are sometimes 
provided in combination and by the same facilities. This is, 
for example, increasingly the case for treatment and harm 
reduction measures.
The responses developed in the framework of drug law 
enforcement are also addressed in a new section which 
includes the most recent data on drug law offences. The 
chapter ends with a review of the available data on the 
needs of drug users in prisons and the existing responses 
in this particular setting. 
Prevention
Drug prevention can be divided into different levels 
or strategies, which range from targeting society as a 
whole (environmental prevention) to focusing on at-risk 
individuals (indicated prevention). Ideally, the different 
strategies do not compete but complement each other. 
The following overview focuses on recent developments 
and on newly reported results of controlled trials in the 
prevention field. 
Universal prevention
Universal prevention addresses entire populations. It aims 
to deter or delay the onset of drug use and drug-related 
problems by providing young people with the information 
and skills necessary to avoid starting to use drugs. 
Prevention measures undertaken in Europe are now, for the 
first time, being systematically monitored by the majority 
of Member States. The most recent reports confirm that 
interventions aimed at delivering information about drugs, 
such as one-off lectures, constitute the main approach in 
school-based and community-located universal prevention 
in all these countries. The effectiveness of this type of 
intervention, however, is not supported by the available 
evidence. However, interventions with better scientific 
foundations, such as prevention programmes following 
standardised protocols, are now reported from additional 
countries (Czech Republic, Cyprus, Austria, Poland, 
Slovenia, Slovakia). 
The limited number of prevention programmes of proven 
effectiveness is being addressed in Europe by the EU-Dap 
study (www.eudap.net). Involving 7 000 students aged 
12–14 in seven European countries, the study is evaluating 
a programme based on the comprehensive social 
influence approach, which combines training in life-skills 
with normative education and knowledge acquisition on 
substances. After 2 years, the programme has been found 
to be effective in reducing frequent drunkenness and 
frequent use of cannabis.
The EU-Dap results are influenced by gender, with the 
overall effectiveness of the programme being accounted 
for by its effect on boys only. It is not clear if this is 
because girls are less at risk or if they did not respond 
to the programme. Gender-dependent effects also came 
up in a Danish controlled trial on a life-skills programme. 
Girls accounted for the largest effect in terms of bullying, 
past-week and past-month alcohol consumption, while 
boys accounted for the largest effect for drinking more 
than five drinks on one occasion and having tried 
cannabis. 
A controlled trial in Prague compared a community-based 
programme, which included an educational component, a 
peer approach, life skills training and parent programmes, 
against the standard ‘minimum preventive programme’ 
in schools (Miovský et al., 2007). The community-based 
programme was more effective in reducing alcohol use 
and affecting attitudes towards substance use among 
pupils aged 13–15, especially in certain vulnerable groups 
of children, including those from single-parent families. It 
was therefore suggested that the programme has potential 
for use in selective prevention. 
Chapter 2
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(12) http://www.emcdda.europa.eu/themes/best-practice/evidence/selective-prevention
(13) http://www.lwl.org/LWL/Jugend/lwl_ks/Projekte_KS1/Fgn-english 
(14) The treatment demand indicator received data from 23 countries for outpatient centres, with a coverage of more than 70 % of units in most countries, 
and from 20 countries for inpatient centres, with a coverage of over 50 % of units in most countries.
Selective and indicated prevention
Both selective and indicated prevention acknowledge that 
problem drug use is concentrated in vulnerable groups or 
individuals with limited social and personal opportunities 
(EMCDDA, 2008c). Selective prevention intervenes with 
specific groups, families or communities, where people, 
due to their scarce social ties and resources, may be more 
likely to develop drug use or progress into dependency. 
The evidence base for this approach is presented in a 
new section of the EMCDDA’s Best practice portal (12). 
Indicated prevention aims to identify individuals with 
behavioural or psychological problems that may be 
predictive for developing problem substance use later 
in life, and to target them individually with special 
interventions. 
New information on selective prevention targeting ethnic 
groups has been reported by Belgium and Luxembourg. 
For young offenders, systematic intervention protocols, 
after contact with the criminal justice system, are reported 
to exist only in Austria, Germany, Catalonia (Spain) and 
Luxembourg, while other countries reported generic or 
punctual interventions. Since 2008, FRED (13), a systematic 
intervention protocol for young offenders, is being 
implemented with EU-support in 10 Member States. A new 
evaluation of FRED in 140 German facilities has shown 
limited levels of re-offending and drug taking among 
participants. 
New indicated prevention projects are reported only from 
Germany, the Netherlands, Slovakia and Sweden, and 
they continue to be very rare in Europe despite information 
about their effectiveness (EMCDDA, 2009b). Current 
examples of indicated prevention projects in Europe 
include the Parent Management Training-Oregon model, 
which is implemented in the Netherlands and Norway for 
parents of children aged 4–12 with disruptive behaviour 
disorder. Similarly, the ‘Komet för föräldrar’ method, which 
is used in nearly 30 % of Sweden’s municipalities, targets 
parents of children showing externalising behaviour 
problems combined with difficulties in establishing positive 
peer relations. A randomised controlled trial involving 
159 families showed significantly improved competences 
in parenting among participating parents and reduced 
behavioural problems among their children.
Treatment
Around 400 000 drug users are reported to have entered 
drug treatment in 2007 (14). Less than half of those entering 
treatment did so for the first time. Overall, the great majority 
of treatment demands (86 %) were made in outpatient 
treatment centres. This proportion has grown in recent years 
for various reasons, including the increased availability and 
diversification of specialised outpatient treatment. 
In Europe, the main modalities used for the treatment of 
drug problems are psychosocial interventions, opioid 
substitution and detoxification. Psychosocial interventions 
offer support to users as they attempt to manage and 
overcome their drug problems. These interventions 
include counselling, motivational enhancement, cognitive-
behavioural therapy, case management, group and family 
therapy and relapse prevention. Psychosocial interventions 
form the foundation of community-based outpatient and 
inpatient treatment, and they also normally complement 
opioid substitution treatment. Drug detoxification is a 
Substance-specific mass media campaigns 
Substance-specific mass media campaigns targeting 
cannabis use (Denmark, Ireland, France, Netherlands, 
United Kingdom) and, more recently, cocaine use (Ireland, 
Spain, United Kingdom) have been developed in Europe. 
Almost all these campaigns warn of the dangers of using 
the drug, and some of them use shock tactics. Only 
two campaigns take a different approach. The United 
Kingdom–Colombian campaign ‘Shared responsibility’ 
addresses the responsibility of users for the environmental 
and social harm associated with cocaine production. The 
Dutch cannabis campaign in 2006 targeted normative 
beliefs with real-life stories of young people as positive 
role models, instead of warnings and depiction of use. 
Its evaluation found that negative social norms against 
cannabis smoking were reinforced and that there were 
no negative effects on intention to use and on normative 
beliefs (Wammes et al., 2007). 
Mass media campaigns highlighting the danger of drug use 
are only rarely evaluated for changes in behaviour, attitudes 
or intention to use drugs. In addition, concerns have been 
expressed about their poor effectiveness and possible harm. 
For example, a thorough evaluation of the outcome of the 
US national cannabis campaign revealed no overall effects. 
There was, however, evidence that the campaign had 
unintended effects in favour of cannabis, and individuals 
who had previously been uninterested in the drug, reported 
an intention to use it (Hornik et al., 2008). Similar problems 
were reported in the evaluation of the Scottish cocaine 
campaign ‘Know the score’ (EMCDDA, 2007a). 
Decision-making by young people is a complex 
process, strongly influenced by peer group interactions 
and perception of social norms. So far, mass media 
communication appears not to have responded effectively 
to this complexity.
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(15) See Tables TDI-10 and TDI-21 in the 2009 statistical bulletin.
(16) See Table TDI-16 (part ii) in the 2009 statistical bulletin.
(17) See ‘Assistance to drug users in prison’, p. 35. 
(18) See Tables HSR-1 and HSR-2 in the 2009 statistical bulletin.
(19) See Table HSR-3 in the 2009 statistical bulletin.
short-term, medically supervised intervention aimed at 
resolving the withdrawal symptoms associated with chronic 
drug use. It is generally provided in inpatient settings. The 
relative size of the different treatment modalities in each 
country is influenced by several factors, including the 
organisation of the national health care system.
Outpatient treatment
Historically, drug treatment was provided largely in 
residential settings and most of the clients were heroin 
users. This situation changed during the 1980s and 1990s 
with the rapid expansion of outpatient treatment and, 
more recently, with the growing numbers of cannabis and 
cocaine users seeking treatment. Additionally, problems 
with licit or prescription drugs became more common. 
In 2007, opioids, chiefly heroin, continued to be the main 
drug reported by users entering treatment in outpatient 
settings, cited as primary drug by 54 % of clients, followed 
by cannabis (21 %) and cocaine (18 %). Several countries 
report an increase in the proportion of clients entering 
treatment for problems with drugs other than opioids, 
especially among new clients (see Chapters 3 and 5). 
Drug users entering treatment in outpatient settings are 
predominantly young men, with an average age of 31 
years and males almost four times as numerous as females 
(3.7:1). The age and sex profile of treatment clients varies 
with primary drug. Cannabis clients are on average 
much younger (25) than opioid (32) and cocaine (33) 
clients. Regardless of primary drug, the average age of 
clients entering treatment for the first time is about 2 years 
lower than that of all clients. Higher than average male 
to female ratios are reported for cocaine (5.1:1) and 
cannabis (5.5:1) clients (15). 
The most common route of referral for clients entering 
outpatient treatment is self-referral, accounting for about 
one third of all clients; about a quarter are referred to 
treatment by the criminal justice system; and the remaining 
are referred through social and health services or informal 
networks, including family and friends. Referral to 
treatment from hospitals and other medical sources is rare, 
except in Finland, where it accounts for 25 % of clients. 
Hungary is also an exception, with over 70 % of clients 
being referred by the criminal justice system (16). It is worth 
noting that the Hungarian criminal code envisages that ‘no 
punishment applies for possession of small amounts in the 
case of a drug addict demonstrating to have undergone 
drug treatment’.
Outpatient psychosocial treatment is mostly provided by 
public institutions (16 countries) or by non-governmental 
organisations (10 countries). According to national 
experts, this type of treatment is available to the majority 
of those who seek it in 10 countries, and available 
to nearly all of them in a further 13 countries. In four 
countries (Bulgaria, Estonia, Romania, Turkey), however, 
outpatient psychosocial treatment is estimated to be 
available to less than half of those who actively seek it 
(see Figure 1A). These ratings may hide considerable 
variation within countries and differences in the 
availability of specialised treatment programmes for 
cannabis or cocaine users.
Opioid substitution treatment
Substitution treatment combined with psychosocial care 
is the predominant treatment option for opioid users 
in Europe. It is generally provided as an outpatient 
treatment, though in some countries it is also available in 
inpatient settings. For example, in Austria, 65 % of clients 
undergoing long-term inpatient treatment are prescribed 
slow-release morphine. Substitution treatment is also 
increasingly provided in prisons (17). 
With the introduction of high-dosage buprenorphine 
treatment in Cyprus in 2007, opioid substitution treatment 
is now available in all EU Member States, as well as 
Croatia and Norway (18). In Turkey, substitution treatment 
has yet to be introduced, though it is permitted under a 
2004 regulation on treatment centres. In 16 countries, 
specialised public outpatient services are the main 
providers of substitution treatment. However, office-based 
general practitioners, often in shared-care arrangements 
with specialised centres, play an increasing role in 
the provision of this type of treatment and are its main 
providers in some countries (Walloon region of Belgium, 
Czech Republic, Germany, France, Luxembourg, Austria, 
Norway) (see Chapter 6). 
In 2007, about 650 000 opioid users are estimated 
to have received substitution treatment in Europe (19). 
According to national experts, this type of treatment is 
available to nearly all opioid users in nine countries and 
to the majority of users in a further seven. Elsewhere, 
substitution treatment is estimated to be available to a 
minority of opioid users in 10 countries (Estonia, Greece, 
Latvia, Lithuania, Hungary, Poland, Romania, Slovakia, 
Finland, Norway). The data on availability of substitution 
treatment suggests the existence of a regional divide, with 
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the lower levels of availability reported for countries in the 
east or north of Europe (Figure 1B).
Inpatient treatment
Inpatient or residential treatment requires clients to stay 
overnight for a duration of several weeks to several 
months. These programmes generally adopt a drug-free 
policy (without substitution treatment), with the aim of 
enabling the client to abstain from drug use. Clients are 
given accommodation, individually structured psychosocial 
treatments, and take part in activities geared towards 
rehabilitating them into society. A therapeutic community 
approach is often used in this context. Inpatient drug 
treatment is also provided by psychiatric hospitals, notably 
for clients with co-morbid psychiatric disorders.
In 2007, around 40 000 people, or one in 10 of all drug 
users entering treatment, are reported to have entered 
treatment in inpatient settings. More than half of them 
mentioned opioids as their principal drug (56 %), with 
most of the other clients identifying their principal drug as 
cannabis (14 %), stimulants other than cocaine (14 %) and 
cocaine (7 %). 
Figure 1: Availability of treatment modalities in relation to need, assessed by national experts: (A) psychosocial outpatient,  
(B) substitution, (C) psychosocial inpatient, (D) detoxification
A B
C D
Full Extensive Limited Rare Not available No information
NB: Availability is defined by the estimated proportion of drug users in need of treatment who can receive it: nearly all (full), the majority, but not 
nearly all (extensive), more than a few, but not the majority (limited), only a few (rare), not available. Information was collected by means of a 
structured questionnaire.
Sources: Reitox national focal points.
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The mean age of drug users entering inpatient treatment 
is 30 years, but opioid and cocaine clients are on 
average older (31) than those in treatment for non-cocaine 
stimulants (28) and cannabis (26). Most inpatient clients 
are men, with an overall male to female ratio of 3.6:1. 
The ratio is lower among primary users of non-cocaine 
stimulants (2.2:1) and higher among users of cocaine 
(5.1:1) and cannabis (8:1). In most countries where 
comparison is possible, the proportion of drug clients with 
no employment and unstable accommodation is higher 
among those entering treatment in inpatient settings than 
among outpatient clients (20).
The main providers of inpatient treatment are non-
governmental organisations (12 countries) and public 
institutions (11 countries). Private institutions play this 
role in Denmark and Luxembourg, while they are the 
second most important providers in 10 countries. National 
experts estimate that inpatient psychosocial treatment is 
available to the majority of those seeking it in 12 countries 
and to almost all who seek it in a further nine countries. 
However, in six countries (Bulgaria, Denmark, Estonia, 
France, Hungary, Romania), this treatment modality was 
considered to be available to less than half of those who 
actively seek it (see Figure 1C).
Detoxification
Detoxification is generally a prerequisite to initiate 
long-term, abstinence-based residential treatment. It is 
commonly, but not exclusively, an inpatient intervention 
provided in hospitals, specialist treatment centres or 
residential facilities with medical or psychiatric wards. 
Public institutions are the main providers of detoxification 
in 21 countries. Non-governmental organisations are 
the largest providers in Belgium (Flanders) and the 
Netherlands, while the private sector is predominant in 
Luxembourg and Bulgaria. National experts estimate that 
detoxification is available to a majority of those who seek 
it in nine countries, and to almost all in a further 10. In 
eight countries (Estonia, Ireland, Greece, France, Latvia, 
Romania, Slovenia, Norway), detoxification is estimated to 
be available to less than half of those who actively seek it 
(see Figure 1D).
Quality assurance
Health planners and policymakers in Europe increasingly 
look for mechanisms to ensure high quality in drug 
treatment. They also tend to give priority to ‘evidence-
based’ interventions when considering the provision of 
treatment and the allocation of funds. 
Guidelines are becoming an important tool in the quality 
assurance of drug treatment. Treatment guidelines include 
recommendations based on scientific evidence, expert 
opinion, service user preferences and national health care 
systems. They are designed to help choose and apply the 
appropriate drug treatment interventions. In 20 out of 27 
reporting countries, national drug treatment guidelines are 
drawn up by an authorised institution.
Existing guidelines cover, in particular, pharmacological 
drug treatment. National guidelines for substitution 
treatment are reported by 18 countries, and 11 countries 
report guidelines for detoxification. However, about 
one third of these countries do not report adherence to 
the guidelines as a condition for operating or receiving 
funding for a treatment facility.
National guidelines for psychosocial treatment and social 
reintegration are less common. Only seven Member 
States (Bulgaria, Czech Republic, Germany, Denmark, 
Netherlands, Slovenia, United Kingdom) report the 
availability of guidelines for psychosocial interventions, 
and five (Czech Republic, Germany, Portugal, Slovenia, 
United Kingdom) for social reintegration. The scarcity of 
national guidelines is probably due to the limited evidence 
available, and this points to the need for more multi-site 
randomised controlled trials in these fields.
Continued staff training is important in ensuring the 
delivery of high quality services. Training courses 
designed specifically for addiction treatment staff and 
some form of continued training related to drug treatment 
for medical doctors are common in the European Union. 
Most countries make similar training opportunities 
available to other professionals including nurses, social 
workers and psychologists.
Regular outcome evaluations for all types of drug 
treatment are reported by few countries. Five Member 
States evaluate substitution and detoxification treatment, 
and only Denmark, Germany and the United Kingdom 
evaluate the outcome of psychosocial treatment 
interventions on a regular basis. Single or irregular 
treatment outcome evaluations are also reported by some 
countries. 
Harm reduction 
The prevention and reduction of drug-related harm is a 
public health objective in all Member States and in the 
EU drugs strategy (European Commission, 2007). Among 
the main interventions in this field are opioid substitution 
treatment and needle and syringe exchange programmes, 
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(21) http://www.hepatitiscfachtag.org/
(22) See Table TDI-15 (part ii) in the 2009 statistical bulletin.
which target overdose deaths and the spread of infectious 
diseases. These measures are reported to be available in 
all countries except Turkey. While considerable differences 
exist in the range and levels of service provision (see 
Chapters 6 and 7), the general European trend is one of 
growth and consolidation of harm-reduction measures. 
Most countries provide a range of health care and 
social services, including individual risk assessment and 
advice, safer use training, infectious diseases testing and 
counselling, vaccination and treatment of viral hepatitis. 
These services are often provided at low-threshold agencies. 
The focus of harm reduction responses has expanded 
beyond the HIV/AIDS epidemic into the broader perspective 
of catering for the health and social needs of problem drug 
users, especially those who are socially excluded. 
A process of professionalisation can also be observed 
in recent years, and more scrutiny is applied to assure 
high quality standards. For example, in 2006/07, harm 
reduction services in England were inspected in order 
to identify areas for improvement. Quality may also 
be assured through stipulating adherence to specific 
standards in funding contracts, as reported by the Czech 
Republic and Estonia.
Responsibility for quality assurance lies with national 
institutions in 14 countries, while in countries with a 
federal system, agencies at sub-national level can be 
in charge. Guidance can be underpinned by research 
findings on cost-effectiveness, as is the case in the United 
Kingdom’s guidance on needle and syringe programmes 
(NICE, 2009). Client involvement and feedback by 
staff is also sought to develop and improve service 
quality. Mechanisms to disseminate best practice and 
new research findings to professionals include national 
knowledge platforms, such as ‘resultaten scoren’ (scoring 
results) in the Netherlands and international awareness 
events, for example on hepatitis C (21). A data collection 
protocol for specialist low-threshold harm reduction 
agencies was also produced by the European Network 
of Social Inclusion and Health in cooperation with the 
EMCDDA (Hedrich et al., 2008a), as part of EU-funded 
projects to develop and implement European health 
indicators. 
Social reintegration
Social reintegration is recognised as an essential 
component of comprehensive drug strategies. It can be 
implemented at any stage of drug use and in different 
settings, and includes capacity building, improvement 
of social skills, measures to facilitate and promote 
employment and to obtain or improve housing. In 
practice, reintegration programmes may offer vocational 
counselling, work placements and housing support. 
Prison-based interventions, which have an impact on 
relapse and re-offending, may link inmates to community-
based housing and social support services in preparation 
for their release (Directorate-General on Health and 
Consumers, 2008a). In general, the outcomes of social 
reintegration measures often rely on efficient collaboration 
between health and social care institutions.
Homelessness, together with living in unstable 
accommodation, is one of the most serious forms of social 
exclusion facing drug users, affecting about 10 % of those 
entering treatment in 2007 (22). This figure is likely to be 
much higher for certain groups of drug users. 
All Member States report the availability of housing 
schemes that can accommodate drug users. Information 
on the extent to which the housing needs of drug users 
are met, however, is scarce. In Slovakia, for example, due 
to limited financial resources, the housing capacity of the 
rehabilitation services often falls short of the demand.
Supported accommodation is reported by several countries 
(e.g. Czech Republic, Germany, Ireland, Netherlands, 
Best practice portal: new module on treatment
Following the introduction of the modules on universal and 
selective prevention in 2008, the EMCDDA has launched 
a new module dedicated to drug treatment on its ‘Best 
practice portal’. It includes a synthesis of findings about the 
efficacy of pharmacological and psychosocial treatment 
for opioid, stimulant and cannabis disorders, based on the 
latest reviews. Work on the portal has been facilitated by a 
European Commission-funded study on quality of treatment 
and exchange of best practice (Directorate-General for 
Health and Consumers, 2008b).
The treatment module presents the findings of studies that 
compare the efficacy of different interventions. Efficacy 
is ideally determined by carrying out controlled trials 
or randomised controlled trials where interventions are 
compared against specific outcome measures. Most of the 
evidence base in this area comes from studies conducted 
in the United States. Studies in Europe are now becoming 
more common, and include some ground-breaking work on 
new agents for opioid substitution treatment.
The new module also includes: links to other information 
sources, evaluated interventions, a glossary and a brief 
synopsis of the gaps in the current evidence base. The 
portal will be expanded to include additional topics in the 
future. 
EMCDDA Best practice portal: http://www.emcdda.
europa.eu/best-practice
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(23) See Tables TDI-12 and TDI-13 in the 2009 statistical bulletin.
(24) For a definition of drug supply reduction, see the box on p. 28 of the EMCDDA 2008 Annual report.
(25) For a discussion of the relationships between drugs and crime see EMCDDA (2007b).
Finland, Sweden, United Kingdom). These temporary 
housing schemes usually consist of bed and breakfast 
accommodation or small furnished flats with short-
term tenancies, and are often provided at discharge 
from residential treatment to enable individuals to 
live independently. In Ireland, for example, users are 
responsible for paying the rent and some domestic services, 
while support workers help them with their tenancy and to 
gain access to education, training or employment. 
As 45 % of users entering treatment have at best completed 
primary school, and about 40 % of users entering treatment 
are unemployed (23), helping drug users to find employment 
and vocational training are key elements of social 
reintegration. Programmes in this area are reported by most 
Member States. In Hungary, the Czech Republic, Lithuania, 
Slovenia and Slovakia, the reintegration of drug users 
into the labour market has benefited from projects funded 
under the EU initiative against discrimination in the labour 
market (EQUAL). Most of these projects help stabilised drug 
treatment clients to find work placements in line with their 
abilities. The value of this approach is supported by the 
results of a Scottish study, which found that recovering drug 
users who received employment-related support were three 
times more likely to have found paid employment (McIntosh 
et al., 2008).
Drug law enforcement and drug law 
offences
The enforcement of the legislation on drugs involves 
various authorities located in different departments of 
government (e.g. police, justice, health). In practice, the 
term ‘drug law enforcement’ is commonly associated with 
the set of activities implemented by police and police-like 
institutions (e.g. customs) to enforce the laws relating to 
drug use and the drug market. Among the areas covered 
are drug use and possession, trafficking and production, 
as well as diversion of chemicals and money laundering. 
Drug law enforcement is a central component of Europe’s 
response to drugs, and it receives a large, possibly the 
largest, share of the resources devoted to the drug problem. 
A recent attempt to compare the allocation of drug-related 
public expenditure in Europe suggested that, on average, 
government spending on drug-related ‘public order and 
safety’ (police forces, courts and prisons) could be nearly 
three times the amount spent to deal with the health 
problems associated with drug use. A significant proportion 
of the money allocated to ‘public order and safety’ is likely 
to be received by police forces (EMCDDA, 2008e). 
The nature and intensity of drug law enforcement efforts 
may vary, depending on national legislation and its 
application, as well as on the resources and priorities 
of the institutions involved, which include general law 
enforcement agencies and specialised units (‘drug 
squads’).
Unlike some other areas of law enforcement, where police 
officers typically respond to breaches of the law, often 
reported by members of the public, the bulk of drug law 
enforcement work may be defined as proactive, as it is 
performed mostly on the initiative of drug law enforcement 
institutions. This is because many drug offences can 
be viewed as a ‘consensual crime’, where consenting 
individuals secretly participate in an unlawful activity of 
which the police will remain unaware unless discovered by 
chance (e.g. during a foot patrol) or by active detection.
As a consequence, drug law enforcement includes a 
large set of activities which often rely on the gathering, 
processing and sharing of information by human and 
electronic means, including computerised databases and 
dedicated communication networks. This is particularly 
the case for activities geared to reducing the supply 
of drugs (24), where law enforcement plays a key role, 
and includes dealing with informants, conducting covert 
operations (‘undercover work’) and electronic surveillance, 
including intercepting communications.
Controlled deliveries of drugs and targeted operations 
aimed at disrupting or eliminating drug selling points are 
some of the operational tactics used by law enforcement 
agencies in Europe. Performing checks and searches on 
people and vehicles at and around strategic locations, 
such as ports, airports and land borders, is a more 
generic tactic, which also includes other aims, such as 
immigration control. 
Law enforcement institutions, especially customs, are 
also tasked in many countries with enforcing laws on 
controlled chemicals. This involves processing importation 
and exportation requests as well as identifying and 
investigating suspicious transactions. Dismantling 
clandestine illicit drug laboratories may be another task of 
law enforcement forces in countries where synthetic drugs 
are manufactured. 
Drug law offences
Initial reports on drug law offences, mainly from the 
police, are the only data on drug-related crime routinely 
available in Europe (25). The reports usually refer to 
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(26) See Figure DLO-1 and Table DLO-1 in the 2009 statistical bulletin.
(27) See Table DLO-2 in the 2009 statistical bulletin.
(28) See the ‘Country overviews’ for the Czech Republic and the Netherlands on the EMCDDA website (http://www.emcdda.europa.eu/publications/
country-overviews). 
(29 ) See Figure DLO-1 and Table DLO-4 in the 2009 statistical bulletin.
(30) See Figure DLO-1 and Table DLO-5 in the 2009 statistical bulletin.
(31) See Table DLO-3 in the 2009 statistical bulletin.
(32) See Figure DLO-3 and Table DLO-6 in the 2009 statistical bulletin. 
(33) See Figure DLO-3 and Table DLO-8 in the 2009 statistical bulletin.
offences such as drug production, trafficking and dealing, 
as well as drug use and possession for use.
Data on drug law offences may be viewed as indirect 
indicators of drug use and drug trafficking, or as more 
direct indicators of law enforcement activity. However, 
they include only those drug-related activities that have 
come to the attention of law enforcement institutions, and 
they may also reflect national differences in legislation, 
priorities and resources. Furthermore, national information 
systems may differ, especially in relation to recording 
and reporting practices. For these reasons, it is difficult 
to make valid comparisons between countries, and it is 
more appropriate to compare trends rather than absolute 
numbers.
On the basis of data provided by 21 Member States, 
representing 85 % of the population aged 15–64 in 
the European Union, the number of reported drug law 
offences increased by an estimated 29 % between 2002 
and 2007. The data reveal upward trends in all reporting 
countries except Bulgaria, the Czech Republic, Greece, 
Luxembourg, Hungary and Slovenia, all of which were 
stable or observed an overall decline over the period (26). 
Use- and supply-related offences
There has been no major shift in the balance between 
drug law offences related to use and those related to 
supply (dealing, trafficking, production) compared to 
previous years. In most European countries, offences 
related to drug use or possession for use continue to 
comprise the majority of drug law offences, accounting 
for as much as 91 % (Spain) of the total in 2007 (27). 
Offences related to supply are, however, predominant in 
the Czech Republic (87 %) and the Netherlands (69 %) 
(Figure 2). In the Czech Republic, possession of small 
quantities of drugs without intent to supply is punishable 
by a warning or a fine, while in the Netherlands drug-use 
related offences are generally not prosecuted (28). 
Between 2002 and 2007, the number of drug law 
offences related to use increased in most reporting 
countries, with only Bulgaria, Greece, the Netherlands 
and Slovenia reporting a decline across the period (29). 
Overall, the number of drug law offences related to use 
in the European Union increased by an estimated 32 % 
between 2002 and 2007. 
Offences related to the supply of drugs also increased 
during the period 2002–07, but at a much lower pace, 
with an increase of about 14 % in the European Union. 
Over this period, eight countries report an overall 
decline in supply-related offences, and eight report an 
increase (30).
Trends by drug
Cannabis continues to be the illicit drug most often 
mentioned in reported drug law offences in Europe (31). 
In the majority of European countries, offences involving 
cannabis accounted for between 55 % and 85 % of 
reported drug law offences in 2007. Offences related to 
other drugs exceeded those related to cannabis in only 
two countries: Lithuania, heroin (26 %); and the Czech 
Republic, methamphetamine (59 %). In Latvia, drug law 
offences are evenly distributed between cannabis, heroin 
and ecstasy.
In the 5-year period 2002–07, the number of drug law 
offences involving cannabis increased or remained stable 
in most reporting countries, resulting in an estimated 
increase of 23 % in the European Union. Downward 
trends are reported by Bulgaria, the Czech Republic and 
Slovenia (32). 
Cocaine-related offences increased over the period 
2002–07 in all reporting countries except Bulgaria and 
Germany. In the European Union, overall, offences related 
to cocaine increased by about 59 % over the same 
period (33).
EMCDDA 2009 ‘Selected issue’ on sentencing 
statistics
The EMCDDA published in 2009 a new ‘Selected issue’ 
on sentencing statistics, which examines the outcomes of 
drug-law offences in European countries. The report looks 
at available national statistics from police, prosecutors and 
courts, and examines them according to the type of offence 
(possession, trafficking) and the type of outcome (fine, 
custody, treatment). The key question being addressed is: 
What is the most likely outcome in each country for being 
stopped for a drug possession or supply offence?
This ‘Selected issue’ is available in print and on the 
Internet in English only (http://www.emcdda.europa.eu/
publications/selected-issues/sentencing).
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(34) See Figure DLO-3 and Table DLO-7 in the 2009 statistical bulletin.
(35) See Figure DLO-3 in the 2009 statistical bulletin.
(36) Data on prisons in Europe are available from the Council of Europe at: http://www.coe.int/t/e/legal_affairs/legal_co-operation/prisons_and_
alternatives/Statistics_SPACE_I/List_Space_I.asp
(37) Source: http://www.kcl.ac.uk/depsta/law/research/icps/worldbrief for figures for Russia and the United States of America.
The downward trend in heroin-related offences in the 
European Union noted in previous reports now appears 
to have ceased, and an increase of about 7 % has been 
observed for the period 2002–07. However, national 
trends have been diverging, and the upward trend is 
mainly due to increases during the last 2 years in Belgium, 
Greece, Spain, France, Poland and Portugal, and a 
stabilisation in Germany and Austria (34).
The number of offences related to amphetamines reported 
in the European Union continues to show an upward trend, 
with an estimated increase of 59 % between 2002 and 
2007. Ecstasy-related offences, in contrast, have decreased 
by an estimated 22 % over the same period (35).
Health and social responses in prison 
On a given day, there are over 600 000 people in 
prison in the European Union (36), giving an average 
imprisonment rate of about 120 prisoners per 100 000 
population. National prison population rates range from 
65 to 320 prisoners per 100 000 population with most 
Member States from central and eastern Europe reporting 
higher than average rates. Nevertheless, the national 
figures, and the EU-average, remain considerably below 
the rates reported from Russia (629) and the  
USA (756) (37). 
Prisoners convicted of drug law offences make up 
somewhere between 10 % and 30 % of the prison 
Figure 2: Offence type in reports for drug law offences in Europe
% 0 25 50 75 100
Norway
Turkey
Croatia
United Kingdom
Sweden
Finland
Slovakia
Slovenia
Romania
Portugal
Poland
Austria
Netherlands
Malta
Luxembourg
Lithuania
Latvia
Cyprus
Italy
France
Spain
Greece
Ireland
Estonia
Germany
Denmark
Czech Republic
Bulgaria
Belgium
Use-related offences Supply-related offences Use and supply-related offences Other types of offences
NB: For further information, see Figure DLO-2 in the 2009 statistical bulletin.
Sources: Reitox national focal points.
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(38) See Tables DUP-105 and DUP-2 in the 2009 statistical bulletin.
(39) See Table DUP-3 in the 2009 statistical bulletin.
(40) See Table DUP-4 in the 2009 statistical bulletin.
(41) OJ L 165, 3.7.2003, p. 31. 
population in most EU countries. An unknown proportion 
of others are sentenced for property crimes to support 
a drug addiction, or other drug-related crime. Although 
the total numbers are low, the rate of drug law offenders 
among sentenced prisoners has increased over the past 
years in several central and east European Member 
States. 
Drug use in prison populations
There is still a lack of standardisation of definitions, 
research questions and methodologies used in studies on 
prison drug use (Vandam, 2009; Directorate-General for 
Health and Consumers, 2008a), though existing studies 
show that drug use continues to be more prevalent among 
prisoners than among the general population. Data from 
several studies carried out from 2002 onwards, mostly 
in western Europe, show that between a third and half 
of those surveyed reported regular use of an illicit drug 
prior to imprisonment. Studies also indicate that the most 
harmful forms of drug-use may be concentrated among 
prisoners, with between a fifth and a third of those 
surveyed reporting to have ever injected drugs (38).
On admission to prison, most users reduce or stop 
consuming drugs, mainly due to problems in acquiring the 
substances. However, the fact that illicit drugs find their 
way into most prisons, despite all the measures being 
taken to reduce their supply, is recognised by both prison 
experts and policymakers in Europe. Studies carried out 
since 2002 show that between 1 % and 50 % of inmates 
report having used drugs within prison, and that up to 
27 % report regular use while incarcerated (39). A study 
of 1 457 prisoners, from six German prisons, found 
that 22 % had injected drugs in prison, while studies in 
four other countries reported rates of 10 % or more (40). 
Injecting drug users in custody appear to share their 
equipment more often compared to users not in prison. 
This raises issues around the potential spread of infectious 
diseases among the prison population.
Prison health in Europe
Prisoners are entitled to the same level of medical care 
as persons living in the community, and prison health 
services should be able to provide treatment for problems 
related to drug use in conditions comparable to those 
offered outside prison (CPT, 2006; WHO, 2007). This 
general principle of equivalence is recognised in the 
European Union through the Council Recommendation of 
18 June 2003 on the prevention and reduction of health-
related harm associated with drug dependence (41), 
and the new EU drug action plan (2009–12) calls for its 
implementation. 
The provision of health care services to prisoners is now 
receiving more attention from national policymakers, and 
there are signs that EU Member States are improving 
the services they offer to prisoners. For example, several 
countries now report the existence of national prison 
health policies and programmes. Nevertheless, much 
remains to be done to ensure that prisoners have access 
to health care at a level and quality comparable to that 
offered outside prison. In addition, prisons must face the 
challenges posed by the specific health care needs of 
drug users, such as blood-borne infectious diseases and 
co-morbid psychiatric problems.
Assistance to drug users in prison
Services offered to prisoners in European countries 
include: information on drugs and health; screening 
for infectious diseases and vaccination; treatment for 
drug dependence, including detoxification, substitution 
treatment and drug-free approaches; preparation for 
release. Examples of the continued expansion of services 
to prisoners include the introduction of substitution 
treatment in prisons in the Czech Republic, Poland and 
Sweden, a drug-free treatment programme in Cyprus 
and the extension of the Danish ‘treatment guarantee’ 
(to provide access to drug treatment within two weeks of 
request) to prisons. 
The continuation of substitution treatment when imprisoned 
is approved in official regulations of 26 countries, but 
not used in five of them, while initiation of this type 
of treatment in prison  is approved in 21 countries. 
According to expert ratings, however, there are differences 
in the provision of this intervention. Substitution treatment 
is available in almost all prisons in nine countries, and in 
more than half of the prisons in a further four. In the Czech 
Republic, France, Germany and the United Kingdom, 
it is estimated that substitution treatment is provided in 
less than half of the prisons, and in Hungary, Poland, 
Finland and Sweden only in a few prisons. Finally, in nine 
countries (Bulgaria, Estonia, Greece, Cyprus, Lithuania, 
Latvia, Slovakia, Romania, Turkey) this type of treatment is 
not available in prison, though preparations to introduce 
it are under way in Bulgaria and Romania, and legal 
changes are under discussion in Latvia. 
Limited provision of substitution treatment in the community 
is generally mirrored by the absence or the very limited 
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(42) See Figure HSR-2 in the 2009 statistical bulletin.
(43) See Table HSR-7 in the 2009 statistical bulletin.
provision of this type of treatment in prison (42). Other 
obstacles to receiving substitution treatment in prison 
reported by Member States include: the lack of a 
regulatory framework for its initiation (Finland), and the 
requirement to pay for the treatment (French-speaking 
community in Belgium). The provision of substitution 
treatment is also often dependent on local conditions, and 
sometimes relies on the initiative of the individual prison 
doctor.
Expert ratings of the availability and level of provision 
of other prevention and harm reduction measures in 
prison are available for 26 EU countries, Norway and 
Turkey. Individual counselling on infectious diseases and 
assessment of drug-related risk behaviour is reported 
to exist in prisons in 26 countries. Hepatitis C testing 
upon prison entry is available in 22 countries, but not in 
Hungary, Poland and Turkey; however, in Hungary, more 
than 14 % of all prisoners were screened for HCV in the 
first 9 months of an ongoing campaign that began in 2007. 
Other interventions include targeted prison hepatitis B 
vaccination programmes, drug-specific health promotion 
training for prison staff, and advice and training on safer 
use, which are each reported to be provided in thirteen 
countries, though with varying levels of coverage. 
The level of provision of measures to prevent overdoses 
is similar. While pre-release counselling on overdose 
risk is available in 18 countries, it is estimated that it has 
been provided to more than a few prisoners over the past 
12 months only in eight countries. Information materials 
on drug-related deaths and emergencies, elaborated 
specifically for the prison environment, are available in 
only seven countries (43). 
The provision of needle and syringe exchange in prison 
settings is reported by Germany, Spain, Luxembourg, 
Portugal and Romania, and it is planned in the United 
Kingdom (Scotland). Resistance from prison staff and lack 
of confidentiality have been reported as obstacles to the 
successful implementation of some needle and syringe 
exchange programmes in prison.
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Introduction
The use of cannabis in Europe has evolved considerably 
over the last decade, as has the debate on how to 
respond appropriately to the widespread use of this drug. 
In the early and mid-1990s, a few countries stood out as 
having a high prevalence, whereas the European norm 
was levels of use which, by today’s standards, were low. 
In most countries, cannabis use increased during the 
1990s and early 2000s, and this has resulted today in a 
less varied European picture, even if important differences 
between countries still exist. Moreover, the last few years 
have seen a growing understanding of the public health 
implications of the long-term and widespread use of this 
drug, and rising reported levels of treatment demand for 
cannabis related problems. Europe may now be moving 
into a new phase, as data from general population and 
school surveys point to a stabilising or even decreasing 
situation. Levels of use remain high by historical standards, 
however; and what constitutes an effective response to 
cannabis use remains a key question in the European 
debate on drugs.
Supply and availability
Production and trafficking
Cannabis can be cultivated in a wide range of environments 
and grows wild in many parts of the world. It is currently 
estimated that cannabis is cultivated in 172 countries and 
territories (UNODC, 2009) (44). These facts taken together 
mean that it is difficult to produce accurate estimates of the 
worldwide production of cannabis. The UNODC (2009) 
estimates global production of herbal cannabis in 2008 at 
between 13 300 tonnes and 66 100 tonnes. 
Cannabis cultivation in Europe is widespread and possibly 
increasing (Korf, 2008). In 2007, 19 European countries 
mentioned domestic cannabis cultivation, though the 
scale of the phenomenon seems to vary considerably. 
A significant proportion of cannabis used in Europe 
is, nevertheless, likely to be the result of intra-regional 
trafficking.
Herbal cannabis in Europe is also imported, mostly from 
Africa (e.g. Nigeria, Morocco, Ghana, South Africa) 
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Table 2: Production, seizures, price and potency of herbal cannabis and resin
Cannabis resin Herbal cannabis
Global production estimate (tonnes) 2 200–9 900 13 300–66 100
Global quantities seized (tonnes) 1 300 5 600
Quantity seized (tonnes) 
EU and Norway 
(Including Croatia and Turkey)
 
853 
(859)
 
70 
(96)
Number of seizures 
EU and Norway 
(Including Croatia and Turkey)
 
324 000 
(325 000)
 
227 000 
(241 000)
Mean retail price (EUR per gram) 
Range 
(Interquartile range) (1)
 
3–11 
(5–9) 
 
1–12 
(4–9)
Range of mean potency (THC content) 2–13 % 1–10 %
(1) Range of the middle half of the reported mean prices.
NB: All data for 2007, except global production estimates which are for 2008.
Sources: UNODC World drug report (2009) for global values, Reitox national focal points for European data.
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(45) The data on European drug seizures mentioned in this chapter can be found in Tables SZR-1 to SZR-6 in the 2009 statistical bulletin. 
(46) Due to differences in shipment size and distances travelled, as well as the need to cross international borders, cannabis resin could be more at risk 
of being seized than domestically produced herbal cannabis.
and less often from south-west Asia (Pakistan) and the 
Americas (Jamaica) (INCB, 2009a). 
Global production of cannabis resin in 2008 is estimated 
at between 2 200 tonnes and 9 900 tonnes (UNODC, 
2009), with Morocco continuing to be the main producer. 
The area under cannabis resin production is reported to 
have declined from 134 000 hectares to 76 400 hectares 
between 2003 and 2005 (UNODC and Government 
of Morocco, 2007). Resin production is also reported 
in other countries, including Afghanistan and Pakistan 
(UNODC, 2009). Cannabis resin produced in Morocco is 
typically smuggled into Europe via the Iberian Peninsula 
and the Netherlands, being then further distributed to 
other European countries.
Seizures
In 2007, an estimated 5 600 tonnes of herbal cannabis 
and 1 300 tonnes of cannabis resin were seized 
worldwide, an overall increase of about 10 % over the 
previous year. North America continued to account for the 
bulk of herbal cannabis seized (66 %), while quantities of 
resin seized remained concentrated in western and central 
Europe (66 %) (UNODC, 2009). 
In Europe, an estimated 241 000 seizures of herbal 
cannabis, amounting to 96 tonnes, were made in 
2007 (45). The number of seizures has more than doubled 
between 2002 and 2007. The amount of herbal cannabis 
seized halved during the first 2 years of this period 
thereafter increasing, though remaining well below 
the 130 tonnes seized in 2002. The highest number of 
seizures of herbal cannabis was reported by the United 
Kingdom, accounting for approximately half of the total in 
2005 and 2006. Turkey (25.5 tonnes) and Belgium (12.8 
tonnes) reported record seizures in 2007.
Seizures of cannabis resin in Europe exceed herbal 
cannabis seizures, both in number and amount seized (46). 
In 2007, about 325 000 seizures of cannabis resin were 
made, resulting in the interception of 859 tonnes of the 
drug, almost nine times the quantity of herbal cannabis 
seized. Between 2002 and 2007, the number of cannabis 
resin seizures increased, though the amount seized 
fluctuated over the same period. Just over half of the 
total number of cannabis resin seizures and around three 
quarters of the quantity seized in 2007 were reported 
by Spain, while record quantities of cannabis resin were 
seized by Belgium (59 tonnes), Portugal (43 tonnes) and 
Turkey (6 tonnes).  
Seizures of cannabis plants have increased steadily 
since 2002, reaching an estimated 15 000 cases in 
2007. Countries report the quantity seized either as the 
number of plants or as an estimate of the weight. The 
number of plants seized was 2.4 million, a figure that 
has been relatively stable over the past 2 years, up from 
about 1.5 million in 2002. The weight of plants seized 
has increased markedly over the period and reached 
27 tonnes in 2007, of which 25 tonnes were reported 
by Spain.  
Potency and price
The potency of cannabis products is determined by their 
content of delta-9-tetrahydrocannabinol (THC), the primary 
active constituent. Cannabis potency varies widely 
between and within countries, and between different 
cannabis products. Information on cannabis potency is 
Drug supply and availability: data and sources 
Systematic and routine information to describe illicit drug 
markets and trafficking is still limited. Production estimates 
of heroin, cocaine and cannabis are obtained from 
cultivation estimates based on fieldwork (sampling on the 
ground) and aerial or satellite surveys. These estimates 
have some important limitations, linked for instance with 
variations in yield figures or with the difficulty of monitoring 
crops such as cannabis, which may be grown indoors or 
are not restricted to certain geographical areas. 
Drug seizures are often considered as an indirect indicator 
of the supply, trafficking routes and availability of drugs. 
They are a more direct indicator of drug law enforcement 
activities (e.g. priorities, resources, strategies), while also 
reflecting both reporting practices and the vulnerability of 
traffickers. Data on purity or potency and retail prices of 
illicit drugs may also be analysed in order to understand 
retail drug markets. However, the availability of this type 
of data may be limited and there may be questions of 
reliability and comparability. Intelligence information from 
law enforcement agencies may help complete the picture. 
The EMCDDA collects national data on drug seizures, 
purity and retail prices in Europe. Other data on drug 
supply comes from UNODC’s information systems and 
analyses, complemented by additional information from 
Europol. Information on drug precursors is obtained from 
the European Commission, which collects data on seizures 
of these substances in the EU, and the INCB, which is 
involved in international initiatives to prevent the diversion of 
precursor chemicals used in the manufacture of illicit drugs.
The data and estimates presented in this report are the best 
approximations available, but must be interpreted with 
caution, as many parts of the world still lack sophisticated 
information systems related to drug supply.
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(47) See Tables PPP-1 and PPP-5 in the 2009 statistical bulletin for potency and price data.
mostly based on forensic analysis of cannabis seized, 
selected on a sample basis. The extent to which the 
samples analysed reflect the overall market is unclear and, 
for this reason, data on potency should be interpreted with 
caution. In 2007, the reported national mean THC content 
of cannabis resin ranged from 2.9 % to 13.3 %. The 
mean potency of herbal cannabis, excluding home-grown 
sinsemilla (‘nederwiet’) in the Netherlands, ranged from 
1.2 % to 10.2 %. Over the period 2002–07, the reported 
mean potency of resin and herbal cannabis remained 
stable or decreased in most of the 16 European countries 
for which this analysis could be made. However, upward 
trends in the mean THC content of cannabis resin were 
registered in Portugal and Luxembourg. Increases in the 
potency of herbal cannabis were observed in five other 
countries. Information on the potency of locally produced 
herbal cannabis over a number of years is available 
only for the Netherlands, where a recent decline in the 
mean potency of nederwiet was observed, from a peak 
of 20.3 % in 2004 to 16.0 % in 2006, remaining at that 
level in 2007 (47).
The mean retail price of cannabis resin, in 2007, ranged 
from EUR 3 to EUR 11 per gram in the 18 countries 
providing information, with half of them reporting values 
between EUR 5 and EUR 9. The mean retail price of 
herbal cannabis ranged between EUR 1 and EUR 12 
per gram in the 17 countries supplying information, with 
about half of them reporting prices of between EUR 4 
and EUR 9. For the 11 countries with data covering the 
period 2002–07, the mean retail price of cannabis resin, 
corrected for inflation, declined. Over the same period, 
the data available for herbal cannabis point to a more 
stable situation.
Prevalence and patterns of use
Cannabis use among the general population
It is conservatively estimated that cannabis has been 
used at least once (lifetime prevalence) by around 
74 million Europeans, that is over one in five of all 15- to 
64-year-olds (see Table 3 for a summary of the data). 
Considerable differences exist between countries, with 
national prevalence figures varying from 1.5 % to 38.6 %. 
For most of the countries, the prevalence estimates are in 
the range 10–30 %. 
Many countries report comparatively high prevalence 
levels of last year and last month use of cannabis. It is 
estimated that around 22.5 million Europeans have used 
cannabis in the last year, or on average 6.8 % of all 15- 
to 64-year-olds. Estimates of last month prevalence will 
include those using the drug more regularly, though not 
necessarily in an intensive way. It is estimated that about 
12 million Europeans used the drug in the last month, on 
average about 3.6 % of all 15- to 64-year-olds. 
Population surveys: an important tool for 
understanding drug use patterns and trends in 
Europe
Drug use in the general or school population can be 
measured through representative surveys, which provide 
estimates of the proportion of individuals that report having 
used specific drugs over defined periods of time. Surveys 
also provide useful contextual information on patterns 
of use, sociodemographic characteristics of users and 
perceptions of risks and availability.
The EMCDDA, in close collaboration with national experts, 
has developed a set of core items for use in adult surveys 
(the ‘European Model Questionnaire’, EMQ). This protocol 
has now been implemented in most EU Member States. 
However, there are still differences in the methodology 
used and year of data collection, and this means that small 
differences, in particular between countries, should be 
interpreted with caution. 
Surveys are expensive to conduct and few European 
countries collect information each year, although many 
collect it at intervals of two to four years. In this report, 
data is presented based on the most recent survey 
available in each country, which in most cases is between 
2004 and 2007. 
Of the three standard time frames used for reporting survey 
data, lifetime prevalence (use of a drug at any point in 
one’s life) is the broadest. This measure does not reflect the 
current drug use situation among adults, but can be helpful 
to understand patterns of use and incidence. For adults, 
the EMCDDA’s standard age ranges are 15–64 years (all 
adults) and 15–34 years (young adults), and the focus is 
on the last year and last month time frames (use during 
the last 12 months or last 30 days before the survey) (1). 
For school students, lifetime and last year prevalence are 
similar, as illicit drug use before age 15 is rare.
The European school survey project on alcohol and other 
drugs (ESPAD) uses standardised methods and instruments 
to measure drug and alcohol use among representative 
samples of 15- to 16-year-old school students. Surveys 
have been conducted in 1995, 1999, 2003 and 2007.  
In 2007, data were collected in 35 countries, including  
25 EU Member States, Norway and Croatia (2). 
(1) For more information, see http://www.emcdda.europa.eu/
publications/methods/gps-overview
(2) A summary of the main findings of the 2007 ESPAD survey is 
available in 23 languages (http://www.emcdda.europa.eu/
html.cfm/index77163EN.html). The full report can be found 
online at the ESPAD website (http://www.espad.org).
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(48) See Figure GPS-1 in the 2009 statistical bulletin.
Cannabis use among young adults 
Cannabis use is largely concentrated among young 
people (15–34 years), with the highest levels of last year 
use generally being reported among the 15- to 24-year-
olds. This is the case in almost all European countries, with 
the exception of Portugal (48). 
Population survey data suggest that, on average, 31.1 % 
of young European adults (15–34 years) have ever used 
Table 3: Prevalence of cannabis use in the general population — summary of the data
Age group Time frame of use
Lifetime Last year Last month
15–64 years
Estimated number of users in Europe 74 million 22.5 million 12 million
European average 22.1 % 6.8 % 3.6 %
Range 1.5–38.6 % 0.4–14.6 % 0.1–7.2 %
Lowest-prevalence countries Romania (1.5 %)
Malta (3.5 %)
Bulgaria (5.6 %)
Cyprus (6.6 %)
Romania (0.4 %)
Malta (0.8 %)
Greece (1.7 %)
Bulgaria (1.9 %)
Romania (0.1 %)
Malta (0.5 %)
Sweden (0.6 %)
Lithuania (0.7 %)
Highest-prevalence countries Denmark (38.6 %)
Italy (31.2 %)
France (30.6 %)
United Kingdom (30.0 %)
Italy (14.6 %)
Spain (10.1 %)
Czech Republic (9.3 %)
France (8.6 %)
Italy (7.2 %)
Spain (7.1 %)
France, Czech Republic (4.8 %) 
15–34 years
Estimated number of users in Europe 41.5 million 17 million 9 million
European average 31.1 % 12.5 % 6.8 %
Range 2.9–48.0 % 0.9–20.9 % 0.3–13.4 %
Lowest-prevalence countries Romania (2.9 %)
Malta (4.8 %)
Cyprus (9.9 %)
Greece (10.8 %)
Romania (0.9 %)
Malta (1.9 %)
Greece (3.2 %)
Cyprus (3.4 %)
Romania (0.3 %)
Sweden (1.3 %)
Greece, Lithuania (1.5 %)
Highest-prevalence countries Denmark (48.0 %)
France (43.6 %)
United Kingdom (40.1 %)
Czech Republic (38.3 %)
Italy (20.9 %)
Czech Republic (19.3 %)
Spain (18.8 %)
France (16.7 %)
Spain (13.4 %)
Italy (10.4 %)
Czech Republic, France (9.8 %)
15–24 years
Estimated number of users in Europe 19 million 10 million 5 million
European average 30.5 % 15.8 % 8.3 %
Range 3.7–43.9 % 1.5–28.2 % 0.5–16.9 %
Lowest-prevalence countries Romania (3.7 %)
Malta (4.9 %)
Cyprus (6.9 %)
Greece (9.0 %)
Romania (1.5 %)
Greece, Cyprus (3.6 %)
Sweden (6.0 %)
Portugal (6.6 %)
Romania (0.5 %)
Greece (1.2 %)
Sweden (1.6 %)
Cyprus, Lithuania (2.0 %)
Highest-prevalence countries Czech Republic (43.9 %)
France (42.0 %)
Denmark (41.1 %)
Germany (39.0 %)
Czech Republic (28.2 %)
Spain (24.1 %)
Italy (22.6 %)
France (21.7 %)
Spain (16.9 %)
Czech Republic (15.4 %)
France (12.7 %)
Italy (11.5 %)
European prevalence estimates are based on weighted averages from the most recent national surveys conducted from 2001 to 2008 (mainly 2004–08), therefore they cannot 
be attached to a single year. The average prevalence for Europe was computed by a weighted average according to the population of the relevant age group in each country. 
In countries for which no information was available, the average EU prevalence was imputed. Populations used as basis: 15–64 (334 million), 15–34 (133 million) and 15–24 
(63 million). The data summarised here are available under ‘General population surveys’ in the 2009 statistical bulletin.
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(49) See the box on population surveys, p. 40. 
(50) See Figure EYE-1 (part ii) in the 2009 statistical bulletin.
(51) See Figure EYE-1 (part i) in the 2009 statistical bulletin. 
(52) See Figure GPS-10 in the 2009 statistical bulletin.
(53) Where information on the exact years was not available, information from the previous or following year was used. 
cannabis, while 12.5 % have used the drug in the last 
year and 6.8 % have used it in the last month. Still higher 
proportions of Europeans in the 15–24 age group are 
estimated to have used cannabis in the last year (15.9 %) 
or last month (8.3 %). National prevalence estimates 
of cannabis use vary widely between countries in all 
measures of prevalence, with countries at the upper end 
of the scale reporting values up to 10 times those of the 
lowest-prevalence countries.
Cannabis use is generally higher among males than 
among females (see EMCDDA, 2006a), though marked 
differences between countries are observed. For example, 
the ratio of males to females among those reporting use of 
cannabis in the last year ranged from 6.4:1 in Portugal to 
1.4:1 in Austria. 
Cannabis use among school students 
The ESPAD survey (49) provides comparable data on 
alcohol and drug use among 15- to 16-year-old school 
students in Europe (Hibell et al., 2009). In 2007, the 
survey was conducted in 25 EU Member States as well 
as Norway and Croatia. Some countries (e.g. Spain, 
Sweden, United Kingdom) conduct their own national 
school surveys which provide data, including on cannabis 
use, that is comparable with the ESPAD and the HBSC 
(Health-Behaviour in School-aged Children) surveys. 
The 2007 ESPAD data revealed that the highest lifetime 
prevalence of cannabis use among 15- to 16-year-old 
school students is in the Czech Republic (45 %) (50), while 
Estonia, France, the Netherlands, Slovakia and the United 
Kingdom report prevalence levels ranging from 26 % 
to 32 %. Lifetime prevalence levels of cannabis use of 
between 13 % and 25 % are reported by 15 countries. 
The lowest levels (less than 10 %) are reported in Greece, 
Cyprus, Romania, Finland, Sweden and Norway. Overall, 
lifetime prevalence of cannabis use among school students 
varies little between the sexes. 
The highest last month prevalence of cannabis use among 
15- to 16-year-olds in Europe is reported by Spain (20 %) 
and the Czech Republic (18 %) (51). 
International comparisons 
European figures can be compared with those from other 
parts of the world. For instance, in the United States, the 
National survey on drug use and health (Samhsa, 2007) 
estimated a lifetime prevalence of cannabis use of 49 % 
among young adults (15–34 years, recalculated by the 
EMCDDA) and a last year prevalence of 21 %. For the 
same age group, lifetime prevalence of cannabis use was 
58 % and last year prevalence 28 % in Canada (2004), 
while in Australia (2007) the figures were 47 % and 16 %. 
All these figures are above the corresponding European 
averages, which are respectively 31.1 % and 12.5 %.
Among school students, only Spain and the Czech 
Republic report levels of lifetime prevalence of cannabis 
use that are comparable to those reported in the United 
States and Australia.
Trends in cannabis use 
National survey data reported to the EMCDDA show 
that in almost all EU countries cannabis use increased 
markedly during the 1990s, in particular among young 
people (Figure 3) and school students. By the turn of the 
century, in most European countries a sizable proportion 
of the young population had used or were using the 
drug, as illustrated by the fact that between 1998 and 
2003, lifetime prevalence of cannabis use among the 
15- to 34-year-olds increased to levels of around 30 % in 
seven countries and exceeded 40 % in an additional two. 
Corresponding levels of last year prevalence among this 
age group were as high as 15–20 % in seven countries 
and last month prevalence reached 8–15 % in six 
countries.
The trend in cannabis use in the United Kingdom is 
particularly interesting. In the early and mid-1990s, this 
country stood out in the European picture as the one 
reporting the highest prevalence estimates. This picture 
has progressively changed, as levels of use rose in 
other countries. Moreover, cannabis use in the United 
Kingdom has been steadily declining since around 2003, 
particularly among the 16–24 age group (52), suggesting 
a generational shift. A downward or stabilising trend can 
now be seen elsewhere, in both school and some general 
population survey data. Of the 11 countries for which it 
is possible to analyse the trend in last year prevalence 
among young adults between 2002 and 2007, four 
report decreases of at least 15 % of the initial value, and 
in a further four the situation appears stable (53). In three 
countries, prevalence levels have increased by at least 
15 %, although other data put this upward trend into 
question.
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(54) ESPAD regards increases or decreases of more than three percentage points as indicative of change. 
(55) See Figure EYE-1 (part xii) in the 2009 statistical bulletin.
(56) See Figure EYE-1 (part xiii) in the 2009 statistical bulletin.
(57) See the ‘Selected issue’ on polydrug use.
(58) See Figure GPS-2 in the 2009 statistical bulletin.
Trends among school students
As with adults, increases in cannabis use among school 
students occurred in a number of European countries between 
1995 and 2003, but in general have come to a halt or 
decreased more recently. Only two of the countries monitored 
by the EMCDDA that participated in ESPAD school surveys in 
2007 (Lithuania, Slovakia) report an increase of more than 
three percentage points in lifetime cannabis use since 2003, 
while nine countries report an equivalent decrease during 
this period (54). School survey data from the United States 
and Australia also report a decreasing trend, which was first 
observed in Australia in 1999 (55).
Different patterns are found across Europe in the time 
trends in cannabis use among school students between 
1995 and 2007 (Figure 4). Seven countries, located 
mainly in northern and southern Europe (Greece, 
Cyprus, Malta, Romania, Finland, Sweden, Norway), 
have reported overall stable and low lifetime prevalence 
of cannabis use during the whole period. Most west 
European countries, as well as Croatia and Slovenia, 
which had high or strongly increasing lifetime cannabis 
prevalence up until 2003, saw a decrease or stabilisation 
in 2007. Among these 11 countries, nine reported a 
decrease of more than three percentage points and two 
were stable. The situation is somewhat different in most 
of central and eastern Europe, where the increasing 
trend observed between 1995 and 2003 appears to be 
levelling out. In this region, six countries report a stable 
situation and two report an increase of more than three 
percentage points (56). 
In some European countries, increases in lifetime cannabis 
use among school students between 1995 and 2003 were 
accompanied by increases in the lifetime prevalence of 
cigarette smoking. Since 2003, both trends have reversed 
in many countries, suggesting a possible link between 
tobacco and cannabis smoking among young people (57).
Patterns of cannabis use 
Available data point to a variety of patterns of cannabis 
use. Of those aged 15–64 who have ever used cannabis, 
only 30 % have done so during the last year (58). However, 
among those who have used the drug in the last year, on 
average 50 % have done so in the last month, and recent 
research shows that repeated use of this substance can 
be stable over long periods of time, even among younger 
users (Perkonigg, 2008).
Figure 3: Trends in last year prevalence of cannabis use among young adults (aged 15 to 34)
%
0
5
10
15
20
25
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Italy
Spain
France 
Slovakia
United Kingdom (1)
Denmark  
Germany
Netherlands
Finland 
Hungary
Sweden
Greece
(1) England and Wales.
NB: See Figure GPS-4 in the 2009 statistical bulletin for further information.
Sources: Reitox national reports (2008), taken from population surveys, reports or scientific articles.
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(59) The European averages are an estimation based on a weighted average (for the population) for countries with information, and imputed for 
countries without information. The figures obtained are 1.2 % for all adults (15–64 years) and 2.3 % for young adults (15–34 years). See Table 
GPS-7 in the 2008 statistical bulletin.
(60) See Table GPS-7 in the 2009 statistical bulletin. 
(61) Analysis of national population survey data for the United States between 2000 and 2006. NSDUH online analysis facility: http://webapp.icpsr.
umich.edu/cocoon/SAMHDA/SERIES/00064.xml, accessed on 25 February, 2008 and analysed using variables MJDAY30A and DEPNDMRJ. 
Estimating the prevalence of intensive and long-term 
patterns of use is an important public health issue due 
to its correlation with negative consequences, such as 
respiratory problems, underachievement or dependence 
(Hall and Solowij, 1998). Daily or almost daily use (use 
on 20 days or more in the last 30 days) is currently the 
best available comparable indicator of intensive use. 
Data on this form of cannabis use in Europe was collected 
in 2007/08 as part of a ‘field trial’ coordinated by the 
EMCDDA in collaboration with national experts and the 
Reitox focal points of 13 countries, accounting for 77 % 
of the EU adult population (15–64). On the basis of these 
data it is estimated that over 1 % of all European adults, 
about 4 million, are using cannabis daily or almost daily. 
Most of these cannabis users, about 3 million, are aged 
between 15 and 34 years, representing approximately 
2–2.5 % of all Europeans in this age group (59). 
Trends in intensive cannabis use are difficult to assess due 
to the scarcity of data. Of the seven countries providing 
data on recent trends, four (Spain, France, Italy, Portugal) 
reported an increase in the prevalence of daily cannabis 
use, one a stable situation (Ireland), while only two 
reported a decline (Greece, Netherlands) (60). These 
results point to a possible overall increase in the number of 
intensive cannabis users in Europe during the past decade.
Cannabis dependence has been increasingly recognised 
as a possible consequence of regular use of the drug, 
even if the severity and consequences may appear less 
serious than those commonly associated with some 
other psychoactive substances (e.g. heroin or cocaine). 
Nevertheless, due to the relatively larger proportion of the 
population using cannabis regularly, the overall impact 
of intensive forms of cannabis use on public health may 
be significant. Users, in particular heavy users, can also 
experience problems without necessarily fulfilling clinical 
criteria for dependence. 
Studies show that the development of cannabis 
dependence is less abrupt than with other drugs (e.g. 
cocaine) and that among those who used the drug at 
least once in their life, the proportion ever developing 
dependence might not exceed 10 % (Wagner and 
Anthony, 2002). In general population survey data from 
the United States, dependence was detected in some 
20–30 % of daily users (61). Other studies suggested that 
cannabis dependence can be relatively stable over time 
(Swift et al., 2000). Nevertheless, probably over half of 
Figure 4: Different patterns in trends in lifetime prevalence of 
cannabis use among 15- to 16-year-old school students
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(62) See Figure EYE-1 (part v) and (part vi) in the 2009 statistical bulletin.
(63) See the ‘Selected issue’ on polydrug use. 
(64) See Figure EYE-1 (part iii) and (part vii) in the 2009 statistical bulletin.
(65) See the ‘Selected issue’ on polydrug use. 
(66) See Figures TDI-1 and TDI-2 and Tables TDI-3 (part iv) and TDI-5 (part ii) in the 2009 statistical bulletin.
dependent cannabis users who stop using the drug are 
able to do so without treatment (Cunningham, 2000; 
Ellingstad et al., 2006). 
Patterns among school students
The 2007 ESPAD surveys also show that lifetime cannabis 
use is correlated with perceptions of lower risk and higher 
availability of the drug (62). Compared with the general 
population of students, cannabis users are more likely to 
use alcohol, tobacco and other illicit drugs (63).
New data from the ESPAD study also sheds some light on 
more intensive patterns of cannabis use. In 10 European 
countries, between 5 % and 12 % of 15- to 16-year-old 
male school students reported having used cannabis on 
40 or more occasions. This proportion was at least double 
that found among the female students, supporting other 
data that show that intensive patterns of use are more 
commonly found among young males. Early onset of use 
has been associated with the later development of more 
intensive and problematic forms of drug consumption. 
In most of the 10 countries with relatively high rates of 
frequent use, between 5 % and 9 % of the school students 
reported that they had initiated cannabis use at age 13 or 
younger (64).
Treatment
Treatment demand 
In 2007, cannabis was the primary drug in about 20 % 
of all treatment entries (73 000 clients), making it the 
second most reported drug after heroin. However, country 
differences are considerable, with Bulgaria, Lithuania 
and Slovenia reporting less than 5 % of their clients as 
primary cannabis users and Denmark, France, Hungary, 
the Netherlands and Turkey reporting more than 30 %. 
These differences may be explained by the prevalence of 
cannabis use, drug treatment needs, treatment provision 
and organisation or referrals practices. In the two 
countries with the largest proportions of cannabis clients, 
counselling centres target young drug users in France, and 
cannabis offenders in Hungary are offered drug treatment 
as an alternative to punishment. The criminal justice system 
plays a substantial role in treatment referral in both of 
these countries but, overall, Member States report that 
most cannabis users entering treatment in Europe do it on 
their own initiative. 
Clients entering outpatient centres because of cannabis 
use often also report the use of other drugs. Based on a 
data collection in 14 countries, 85 % of them take another 
drug, mostly alcohol (65 %) or cocaine (13 %), and some 
report use of both alcohol and cocaine (12 %) (65).
Trends in new demands for drug treatment
In the 19 countries for which data are available, the 
number and proportion of primary cannabis users among 
those entering treatment for the first time increased from 
around 19 000 to 34 000 (from 25 % to 31 %) between 
2002 and 2007 (66). This trend seems, however, to have 
been interrupted between 2006 and 2007, with most 
countries reporting a decreasing or stable proportion of 
Short scales to measure problematic forms of 
cannabis use in general population surveys
There is evidence that cannabis dependence can be 
measured in the general population as reliably as in 
samples of treated users, including the measurement of 
withdrawal symptoms (Mennes et al., 2009). The EMCDDA 
is therefore developing, in collaboration with several 
countries, methods for monitoring the more intensive and 
significant long-term forms of cannabis use. 
Different methodologies to estimate, within the general 
population surveys, the prevalence of intensive and 
problematic forms of drug use, mainly cannabis use, 
have been tested in recent years. German experts have 
reviewed the literature and the work currently done in this 
field, and have identified four short cannabis scales that 
have been tested in samples of the general population in 
Europe. These are the Severity of Dependence Scale (SDS), 
Problematic Use of Marijuana (PUM), the Cannabis Abuse 
Screening Test (CAST) and the Cannabis Use Disorders 
Identification Test (CUDIT) (Piontek et al., 2008). These 
scales include between four and 10 items, and their 
psychometric properties (e.g. their ability to differentiate 
cases from non-cases consistently and in compliance with 
the desired concept of cannabis dependence or problems) 
were generally found to be very good. 
Some difficulties remain, however, in this field because 
of the lack of consensus regarding which construct (e.g. 
dependence, abuse, harmful use, use related problems) or 
set of constructs should be measured to assess problematic 
forms of cannabis use. There are also estimation 
difficulties, as measures of a phenomenon with a low 
prevalence may produce many ‘false positive’ cases and, 
therefore, an overestimation of problematic cannabis use in 
the overall population. Additional validation studies, which 
are currently in progress or planned, might help overcome 
these difficulties.
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(67) See Table TDI-21 (part ii) in the 2009 statistical bulletin.
(68) See Table TDI-10 (part iv) and (part vi) in the 2009 statistical bulletin.
(69) See Tables TDI-18 (part i) and TDI-111 (part viii) in the 2009 statistical bulletin.
new cannabis clients. This might be linked with recent 
trends in cannabis use, but can also reflect changes in 
reporting practices, service capacity saturation or use of 
other services (e.g. primary health care, mental health 
care).
Client profiles 
Cannabis users entering outpatient treatment in Europe 
are mainly young males, with a male to female ratio of 
5.5:1 and a mean age of 25 years (67). Among drug users 
entering outpatient treatment for the first time, primary 
cannabis use is reported by 67 % of those aged 15–19 
years (68) and by 78 % of those younger than 15 years.
Overall, 24 % of primary cannabis users entering 
outpatient treatment are occasional users, probably often 
referred by the criminal justice system; 12 % use cannabis 
weekly or less often; about 18 % use it 2–6 times a 
week; and 47 % are daily users, the most problematic 
group. Considerable differences are observed between 
countries. In Hungary, Romania and Croatia, the majority 
of cannabis clients are occasional users, while in Belgium, 
Denmark, Spain, France, Malta and the Netherlands the 
majority are daily users (69). A French study, among clients 
of specialised counselling centres, found that 63 % of 
daily cannabis users were dependent (Obradovic, 2008).
Many cannabis clients are still students and are living in 
stable accommodation (EMCDDA, 2008a). However, in 
France 34 % of cannabis clients have attended technical 
schools, compared to 6.8 % in the general population 
(Obradovic, 2008), reflecting a lower educational level.
The relationship between cannabis use and co-morbid 
psychiatric disorders remains an unresolved and complex 
question (EMCDDA, 2008a). However, studies have found 
that people with mental health disorders, particularly 
schizophrenia, have a higher risk of developing intensive 
cannabis use (Henquet et al., 2005). And, there is clear 
evidence that cannabis use can adversely affect those 
with pre-existing mental health problems (ACMD, 2008). 
It may also be relatively common for drug services to 
see adolescents referred for cannabis problems who 
have underlying mental health problems (Schroder et al., 
2008). This could be because they may not seek or find 
appropriate treatment for their problems in generic mental 
health care services (Zachrisson at al., 2006). 
Treatment provision 
Specific treatment programmes for cannabis users can 
provide services tailored to the needs of this group and 
may also reduce the risk of young people mixing with 
more problematic and older drug users. In 2008, the 
EMCDDA collected information on the availability of such 
programmes in Europe. National experts reported that 
they existed in 13 out of 25 reporting countries (Figure 5). 
Availability of services varied between countries. It was 
estimated that: nearly all those seeking specific treatment 
would obtain it in France, Greece and Slovenia; more than 
half of them in Germany and the United Kingdom; and 
only a minority in the remaining eight countries. Among 
the 12 countries reporting that specific programmes for 
cannabis users do not exist, Bulgaria, the Czech Republic, 
Estonia, Cyprus, Romania and Turkey are planning to set 
them up during the next 3 years.
Figure 5: Availability of specific treatment programmes for 
cannabis users and last month prevalence of cannabis use (%) 
among 15- to 24-year-olds
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NB: Availability is defined by the estimated proportion of cannabis 
users in need of treatment who can receive it: nearly all (full), the 
majority, but not nearly all (extensive), more than a few, but not 
the majority (limited), only a few (rare), unavailable.
 Data on the availability of specific treatment programmes 
were provided by national experts, judging the degree to 
which treatment capacity matches the demand of cannabis 
users who actively seek treatment. Specific programmes can 
provide structured treatment to problem cannabis users, support 
to relatives, counselling to non-problem cannabis users or 
young offenders. Such programmes are reported to exist in the 
Netherlands but information on their availability is not known. 
Last month prevalence of cannabis use among the 15- to 24-year-
olds gives an indication of the proportion of young people 
who may come into contact with such programmes. It does not 
indicate the treatment needs or level of problem cannabis use in 
a country. 
 For more information on prevalence see Table GPS-16 in the 
2009 statistical bulletin.
Sources: Reitox national focal points.
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(70) See ‘Internet-based treatment’.
Treatment programmes for cannabis users in Europe
In Greece, OKANA’s Units for Adolescents provide 
an early intervention programme for experimental or 
occasional cannabis users, while more structured treatment 
is provided to intensive and problem users. The treatment 
is mostly based on systemic and family therapy.
In France, about 275 dedicated consultation centres, 
located throughout the country, provide prevention 
information, brief interventions and support to young 
drug users (mostly cannabis), young offenders and their 
relatives. When problem drug use (e.g. dependence) or 
severe co-morbidities are diagnosed, clients are referred 
to specialist services. 
In Austria, several counselling centres (e.g. at ChEck 
it!, B.I.T., Clean Bregenz) implement specific concepts 
for young cannabis users which aim to separate them 
from other attendees, mainly opioid users, and integrate 
their relatives and friends in the counselling or treatment 
process. 
In Germany, the Internet-based cannabis cessation 
programme ‘Quit the shit’ (70) has been transferred to 12 
drug counselling facilities in seven federal states. FRED 
(see Chapter 2) offers motivational interviewing-based 
counselling for those referred by the criminal justice 
system. Candis, a treatment programme for patients 
with cannabis-related disorders, based on motivational 
enhancement, cognitive behavioural therapy and 
psychosocial problem solving is currently implemented 
in Dresden. An evaluation of this programme showed 
positive results and findings from an ongoing follow-up 
study in 10 further centres will determine whether it will be 
implemented elsewhere. 
Belgium, Germany, France, the Netherlands and 
Switzerland are also collaborating in an international 
study named Incant, which investigates the effectiveness of 
a comprehensive family-based treatment for problematic 
cannabis use.
The scientific literature suggests that a number of 
psychotherapies, such as motivational and cognitive-
behavioural therapies, are effective for cannabis treatment 
but that none has been found to be more effective than 
the others (Nordstrom and Levin, 2007). Some problem 
cannabis users may also benefit from brief interventions, 
delivered for example by social services for juveniles, 
general practitioners and schools. 
A recent randomised controlled trial involving 326 young 
intensive cannabis users found, at either 3 or 6 months 
follow-up, no differences in cannabis cessation rates 
between those undergoing motivational interviewing and 
those receiving mere advice or information about drug use 
(McCambridge et al., 2008). Individual therapist effects 
and a therapist–intervention interaction, however, were 
detected in relation to cannabis cessation after 3 months. 
These findings illustrate the importance of training care 
providers delivering interventions to young cannabis users, 
especially outside of specialist services.
Internet-based treatment
Internet-based drug treatment has existed in the European 
Union since 2004 and its provision is still limited. A 
recent study provides insights into the current state of 
development of this type of intervention in the European 
Union (EMCDDA, 2009a). Internet-based treatment can be 
defined as ‘specifically elaborated or adapted, structured 
and scheduled drug treatment interventions, offered in and 
communicated over the World Wide Web’. Interventions 
for treating cannabis use disorders have been identified in 
Germany, the Netherlands and the United Kingdom, while 
others designed for cocaine and ‘club drug’ (e.g. ecstasy) 
users were also found in the Netherlands.
Internet-based treatment is developed by organisations in 
the treatment or prevention fields and aims at helping users 
to assess their substance use and to assist them in their 
attempts to change this behaviour. Interventions provide 
information and knowledge tests or games about drugs and 
drug dependence, or drug consumption self-tests. Common 
to all of them is the availability of a structured treatment 
intervention, which is either a pre-tailored self-help 
programme without contact to counsellors, or a structured 
programme with scheduled contacts. The latter can be 
implemented via one-to-one chats or message boards. 
Contact with other users via a forum is also sometimes 
provided, thereby creating virtual self-help groups.
There is still a lack of available evidence on the efficacy 
of these types of interventions, but findings from the first 
randomised controlled trials point towards a potential 
benefit. Preliminary evaluation results of the ‘Quit the shit’ 
intervention for cannabis users in Germany has shown that 
32 % of participants reported abstinence after completing 
the programme and that first-time treatment seekers, in 
particular, were reached. The low access threshold of these 
interventions may allow them to reach individuals who are 
reluctant to use other services. At the same time, they might 
also be confronted with severe problems, such as drug 
dependence or other mental health problems, which lie 
beyond the capacities of Internet-based treatment.
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Introduction
Amphetamines (a generic term that includes both 
amphetamine and methamphetamine) and ecstasy are 
among the most commonly used illicit drugs in Europe. In 
terms of the absolute numbers, cocaine use may be higher, 
but its geographic concentration means that in many 
countries, after cannabis, the second most commonly used 
illicit substance is either ecstasy or amphetamines. Moreover, 
in some countries, use of amphetamines constitutes an 
important part of the drug problem, accounting for a 
substantial proportion of those in need of treatment.
Amphetamine and methamphetamine are central nervous 
system stimulants. Of the two drugs, amphetamine is by 
far the more commonly available in Europe, whereas 
significant methamphetamine use appears to be restricted 
to the Czech Republic and Slovakia. 
Ecstasy refers to synthetic substances that are chemically 
related to amphetamines, but which differ to some extent 
in their effects. The best-known member of the ecstasy 
group of drugs is 3,4-methylenedioxy-methamphetamine 
(MDMA), but other analogues are also sometimes found 
in ecstasy tablets (MDA, MDEA). Ecstasy use was virtually 
unknown in Europe before the late 1980s, but increased 
rapidly during the 1990s. The drug’s popularity has 
historically been linked with the dance-music scene and, 
in general, synthetic drug use is associated with particular 
cultural sub-groups or social settings. 
The most widely known synthetic hallucinogenic drug in 
Europe is lysergic acid diethylamide (LSD), consumption 
of which has been low and somewhat stable for a 
considerable time. In recent years, there appears to 
have been a growing interest among young people in 
naturally occurring hallucinogens such as those found in 
hallucinogenic mushrooms. 
Supply and availability 
Synthetic drug precursors
Law-enforcement efforts target the controlled chemicals 
necessary for illicit drug production, and this area is one 
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Table 4: Production, seizures, price and purity of amphetamine, methamphetamine, ecstasy and LSD
Amphetamine Methamphetamine Ecstasy LSD
Global production estimate 
(tonnes)
230–640 (1) 72–137 n.a.
Global quantities seized (tonnes) 23.6 18.2 7.9 0.9
Quantity seized 
EU and Norway  
(Including Croatia and Turkey)
7.9 tonnes
(8.1 tonnes)
340 kilograms
(340 kilograms)
Tablets
21 million
(22 million)
Units
68 000
(68 000)
Number of seizures 
EU and Norway 
(Including Croatia and Turkey)
39 500
(40 000)
4 500
(4 500)
23 000
(24 000)
950
(960)
Mean retail price (EUR) 
Range 
(Interquartile range) (2)
Gram
5–30
(12–23)
Gram
8–51
Tablet
3–19
(4–8)
Dose
4–30
(7–12)
Range of mean purity 4–40 % 3–66 % 21–90 mg —
(1) Only aggregate estimates of amphetamine and methamphetamine global production are available. 
(2) Range of the middle half of the reported mean prices.
NB: All data are for 2007; n.a., data not available.
Sources: UNODC World drug report (2009) for global values, Reitox national focal points for European data.
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(71) See ‘What is a drug precursor?’
(72) For information on the sources of data for drug supply and availability, see p. 39.
(73) Captagon is one of the registered trade names for fenetylline, a synthetic central nervous system stimulant, although tablets sold with this logo on the 
illicit market are commonly found to contain amphetamine mixed with caffeine. 
(74) This analysis is preliminary, as data for the United Kingdom are not yet available for 2007.
(75) The data on European drug seizures mentioned in this chapter can be found in Tables SZR-11 to SZR-18 in the 2009 statistical bulletin. 
in which international cooperation is particularly valuable. 
‘Project Prism’ is an international initiative set up to prevent 
the diversion of precursor chemicals used in the illicit 
manufacture of synthetic drugs (71), through a system of 
pre-export notifications for licit trade and the reporting of 
shipments stopped and seizures made when suspicious 
transactions occur. Information on activities in this area 
is reported to the International Narcotics Control Board 
(INCB, 2009b).
The INCB reports large increases in 2007 in world 
seizures of two key precursors of methamphetamine, 
ephedrine with 22 tonnes (compared to 10.2 tonnes in 
2006), and pseudo-ephedrine with 25 tonnes (compared 
to 0.7 tonnes in 2006). EU Member States (mainly 
Sweden and Bulgaria) accounted for 0.6 tonnes of 
ephedrine, more than twice the amount seized in 2006, 
and over 7 tonnes of pseudoephedrine, almost all in 
France.
By contrast, global seizures of 1-phenyl-2-propanone 
(P2P, BMK), which can be used for the illicit manufacture 
of both amphetamine and methamphetamine, declined 
sharply in 2007 to 834 litres (compared to 2 600 litres in 
2006). Seizures of P2P in the EU amounted to 582 litres, 
compared to 2 005 litres in 2006.
Global seizures of 3,4-methylenedioxyphenyl-2-propanone 
(3,4-MDP2P, PMK), used to manufacture MDMA, 
continued to decrease in 2007 to 2 300 litres, down from 
8 800 litres in 2006. However, world seizures of safrole, 
which may replace 3,4-MDP2P in the synthesis of MDMA, 
soared in 2007, with 46 000 litres confiscated (62 litres in 
2006), though only 8 litres was confiscated in the EU. 
Amphetamine
Global amphetamine production remains concentrated 
in Europe, which accounted for 81 % of all amphetamine 
laboratories reported in 2007 (UNODC, 2009), but it 
is also found in other parts of the world, notably North 
America (72). Global seizures of amphetamines in 2007 
amounted to almost 24 tonnes, of which about two thirds 
was intercepted in the Near and Middle East, linked to 
‘Captagon’ tablets (73) produced in south-east Europe 
(see Table 4). Western and central Europe accounted for 
36 % of global seizures, reflecting Europe’s role as both a 
major producer and consumer of this drug (CND, 2008; 
UNODC, 2009). 
Most amphetamine seized in Europe is produced, in order 
of importance, in the Netherlands, Poland and Belgium, 
and to a lesser extent in Estonia and Lithuania. In 2007, 
29 sites involved in the production, tableting or storage 
of amphetamines were discovered in the European Union 
and reported to Europol. 
In 2007, an estimated 40 000 seizures amounting to 8.1 
tonnes of amphetamine powder were made in Europe (74). 
Over the period 2002–07, the number of seizures has 
increased steadily while the amount of amphetamine 
intercepted has fluctuated, though on a generally upward 
trend, and reached a new high in 2007 (75).
What is a drug precursor? 
In the drugs field, the term ‘precursor’ is used to refer to 
substances that have licit applications, but which may 
also be used to manufacture drugs illicitly. Other terms, 
such as ‘essential chemicals’, may also be applied to these 
substances. 
The legal basis for international control of ‘precursors’ is 
Article 12 of the 1988 United Nations Convention against 
illicit traffic in narcotic drugs and psychotropic substances. 
The convention establishes two tables listing 23 ‘substances 
frequently used in the illicit manufacture of narcotic drugs 
and psychotropic substances’, whose diversion to illicit 
ends should be prevented. 
Article 12 was transposed into the initial European 
legislation adopted in 1990 to discourage diversion 
of these substances to illicit ends (EEC No 3677/90), 
and regulations adopted later in order to regulate their 
trade within the EU (EC No 273/2004), between the EU 
and non-EU countries (EC No 111/2005), and establish 
licensing procedures and monitoring rules (EC No 
1277/2005). 
Category 1 of the EU regulations includes mostly 
substances that are indispensable for the manufacture of 
synthetic drugs, such as ephedrine and pseudoephedrine 
(for methamphetamine); 3,4-methylenedioxyphenyl-2-
propanone (PMK), isosafrole and safrole (for ecstasy); 
and 1-phenyl-2-propanone (P2P, BMK) (for amphetamine 
and methamphetamine). Category 2 contains important 
reagents such as potassium permanganate and acetic 
anhydride, which are widely used to manufacture cocaine 
and heroin, respectively. Category 3 lists more common 
reagents including hydrochloric acid and sulphuric acid 
(for heroin and cocaine), and solvents such as acetone (for 
cocaine and MDMA) and toluene (for methamphetamine 
and MDMA).
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The purity of amphetamine samples intercepted in Europe 
in 2007 varied widely and to such an extent that any 
comment on average values must be made with caution. 
Nevertheless, mean purity of samples range from less than 
10 % in Denmark, Germany, France and United Kingdom 
to greater than 30 % in the Netherlands, Poland and some 
Baltic and Nordic countries. Over the past 5 years, the 
purity of amphetamine has been stable or falling in most 
of those 20 countries where sufficient data are available 
to allow analysis of trends.
In 2007, the mean retail price of amphetamine ranged 
between EUR 10 and EUR 20 a gram for over half of 
the 17 reporting countries. Of the 11 countries where a 
comparison of data for 2007 and 2006 was possible, 
Spain, France and Austria reported increases in the retail 
price, while the rest reported stable or decreasing prices. 
Methamphetamine
Production of methamphetamine is concentrated in east 
and south-east Asia and North America, with increasing 
reports of related activity in Latin America and Oceania. 
In 2007, 18.2 tonnes of methamphetamine was seized, 
continuing a stable trend since 2004. Most of the drug 
was seized in east and south-east Asia (56 %), followed 
by North America, with Europe contributing with only 2 % 
of seizures (UNODC, 2009). 
Illicit production of methamphetamine does occur in 
Europe, though it is largely limited to the Czech Republic, 
where about 390 small-scale ‘kitchen laboratories’ 
were detected in 2007. The drug is also reported to be 
produced in Slovakia and Lithuania. 
In 2007, almost 4 500 seizures of methamphetamine, 
amounting to approximately 340 kg of the drug, 
were reported in Europe. Norway accounts for the 
highest number of seizures and the largest amount of 
methamphetamine recovered. Between 2005 and 2007, 
both the number and the quantity of methamphetamine 
seized in Europe have been increasing, though both 
remain low in comparison to other drugs. 
Ecstasy
Global ecstasy production in 2007 is estimated by 
UNODC (2009) at between 72 and 137 tonnes. 
Production appears to have become more geographically 
diffuse, with manufacture occurring closer to consumer 
markets in North America, east and south-east Asia, and 
Oceania. Despite this, Europe remains the main location 
for ecstasy production, which is concentrated in the 
Netherlands, Belgium, and to a lesser extent, Germany, 
the United Kingdom and Poland. 
Global ecstasy seizures in 2007 reached 7.9 tonnes, with 
increases reported in most regions. West and central 
Europe accounted for 36 % of the global seizures, and 
south-east Europe for 2 % (UNODC, 2009). Overall, 
more than 24 000 seizures, resulting in the interception 
of an estimated 22  million ecstasy tablets were reported 
in Europe in 2007. The Netherlands reported the largest 
quantity seized, which at 8.4 million tablets represents 
a doubling of the quantity reported in 2006. Only two 
other European countries reported seizures approaching 
this magnitude in 2007, with France and Germany both 
reporting about one million tablets seized. The United 
Kingdom also reported seizing over 6 million tablets in 
2006, but data for 2007 are not yet available. 
Over the period 2002–07, the number of ecstasy seizures 
reported in Europe dropped sharply in 2003, but has 
since shown a slight increase year on year. Over the same 
period, the quantity seized declined to a low in 2005, but 
has increased again, and appears to be approaching the 
2002 level. 
In Europe, most ecstasy tablets analysed in 2007 
contained MDMA or another ecstasy-like substance 
(MDEA, MDA) as the only psychoactive substance present, 
with 17 countries reporting that this was the case in 
over 70 % of all tablets analysed. Countries reporting 
lower proportions of ecstasy tablets with MDMA or its 
analogues included Bulgaria (47 %), Cyprus (44 %) 
and Austria (61 %). In Luxembourg, most tablets (83 %) 
analysed contained no controlled substance, as was the 
case in Cyprus (53 %). In Turkey, only 23 % of the tablets 
analysed were found to contain MDMA-like substances. 
The typical MDMA content of ecstasy tablets tested in 
2007 was between 19 and 75 mg in the 11 countries 
providing data. In addition, high-dose ecstasy tablets 
containing over 130 mg of MDMA were reported by 
Methamphetamine production in Europe: 
EMCDDA–Europol joint publication 
In 2009, the EMCDDA and Europol launched a series of 
joint publications on the supply of drugs in Europe. The 
first report in the series provides a comprehensive overview 
of methamphetamine production and trafficking issues 
in Europe, and reviews the responses at European and 
international levels (1). 
Reports on the supply of other synthetic drugs in Europe, 
including amphetamine and ecstasy, will be added to the 
series at a later stage. 
(1) Available at: http://emcdda.europa.eu/publications
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(76) Survey data on ‘amphetamine use’ often do not distinguish between amphetamine and methamphetamine, though, as use of methamphetamine is 
uncommon in Europe, prevalence should typically reflect the use of amphetamine (sulphate or dexamphetamine).
(77) Data from all ESPAD countries and Spain. See Figure EYE-2 (part vi) in the 2009 statistical bulletin.
some countries (Bulgaria, France, Netherlands, Slovakia, 
Norway). There are no clear trends in the purity of ecstasy 
tablets.
Ecstasy is now considerably cheaper than it was in the 
1990s, when it first became widely available. While 
there are some reports of tablets being sold for less than 
EUR 2, most countries are reporting mean retail prices 
in the range of EUR 4–10 per tablet (Figure 6). The data 
available for 2002–07 suggest that the retail price, 
adjusted for inflation, has continued to fall.
Hallucinogenic substances
LSD use and trafficking in Europe is still considered 
marginal. The data available indicate a decline in 
quantities seized over the period 2002–07, while the 
number of seizures increased slightly between 2003 and 
2007. LSD retail prices (adjusted for inflation) have been 
slightly declining since 2003, and in 2007 the mean 
value ranged between EUR 5 and EUR 12 per unit for the 
majority of reporting countries.
Hallucinogenic mushrooms, which grow wild in many 
European countries and may be purchased on the Internet, 
were mentioned by 11 of the 28 countries reporting drug 
seizures for 2007. In five of the six countries reporting a 
trend in either seizures, prevalence of use or availability of 
hallucinogenic mushrooms, the trend was downward. One 
country (France) reported an increase in prevalence of use 
and seizures, which was attributed to the availability of 
mushrooms and mushroom growing kits from the Internet.
Prevalence and patterns of use
Relatively high levels of amphetamines or ecstasy use 
among the general population are reported by some 
EU Member States (Czech Republic, Estonia, United 
Kingdom). In a few countries, the use, often by injection, 
of amphetamine or methamphetamine accounts for a 
substantial proportion of the overall number of problem 
drug users and those seeking help for drug problems. In 
contrast to these chronic user populations, a more general 
association exists between the use of synthetic drugs, 
ecstasy in particular, and nightclubs and dance events; this 
results in significantly higher levels of use being reported 
among young people, and exceedingly high levels of use 
being found in some settings or specific sub-populations. 
Finally, the overall consumption levels of hallucinogenic 
drugs such as lysergic acid diethylamide (LSD) and 
hallucinogenic mushrooms are generally low and have 
been largely stable in recent years.
Amphetamines
Recent population surveys indicate that lifetime prevalence 
of the use of amphetamines (76) in Europe varies between 
countries, from nearly zero to 11.7 % of all adults (15–64 
years). On average, it is estimated that 3.5 % of all 
European adults have used amphetamines at least once. 
Last year use of the drug is much lower, with a European 
average of 0.5 %. These estimates suggest that around 
12 million Europeans have tried amphetamines, and about 
2 million have used the drug during the last year (see 
Table 5 for a summary of the data).
Among young adults (15–34 years), lifetime prevalence of 
amphetamines use varies considerably between countries, 
from 0.1 % to 15.3 %, with a weighted European average 
of about 5 %. Last year use of amphetamines in this age 
group ranges from 0.1 % to 3.1 %, with the majority of 
countries reporting prevalence estimates of between 0.5 % 
and 2.0 %. It is estimated that, on average, 1.1 % of young 
Europeans have used amphetamines during the last year. 
Among 15- to 16-year-old school students, lifetime 
prevalence of amphetamines use ranges from 1 % to 
8 % in the 26 EU Member States, Norway and Croatia, 
surveyed in 2007, though prevalence levels of more than 
5 % were reported only for Bulgaria, Latvia (both 6 %) 
and Austria (8 %) (77).
Figure 6: Retail price of ecstasy tablets
< 6
6 to 10
> 10
No information 
Mean price (EUR)
NB: Countries which only provided a minimum and maximum value 
have been included if those values fall within one of the ranges. 
See Table PPP-4 in the 2009 statistical bulletin.
Sources: Reitox national focal points.
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(78) Equivalent to 3.4 to 6.3 cases per 1 000 aged 15–64 years; recalculated from the original sample aged 15–54, assuming no cases in the 55–64 
age group. 
(79) See Table TDI-5 (part ii) in the 2009 statistical bulletin.
(80) See Figure TDI-1 and Table TDI-36 in the 2009 statistical bulletin. 
Problem amphetamine use
The EMCDDA indicator on problem drug use can be 
applied to amphetamine use, where it defines as such 
the injecting or long duration and/or regular use of the 
substance. Only Finland has provided a recent national 
estimate of problem amphetamine users, estimated at 
between 12 000 and 22 000 in 2005 (78), which is about 
four times the estimated number of problem opioid users in 
the country.
The number of reported treatment demands relating to the 
use of amphetamine as the primary drug is relatively small 
in most European countries, but accounts for a sizeable 
proportion of reported treatment entries mainly in Sweden 
(34 %), Finland (23 %), Latvia (16 %) and Hungary 
(11 %). Four other countries (Belgium, Denmark, Germany, 
Netherlands) report between 6 % and 10 % of treatment 
entries from clients citing amphetamine as their primary 
drug; elsewhere the proportion is less than 3 % (79).
The overall number and proportion of amphetamine users 
among new clients entering drug treatment have remained 
broadly stable between 2002 and 2007. Only Denmark, 
Latvia and the Netherlands report significant increases, 
while Sweden and Finland report a decrease in the 
proportion of new amphetamines clients (80). However, 
methodological limitations should be considered when 
looking at trend data, due to recent changes in some 
national monitoring systems (e.g. Latvia).
The mean age of amphetamine users entering treatment 
is 29 years. The proportion of women is higher than for 
other drugs, with a male to female ratio of about 2:1. 
Table 5: Prevalence of amphetamines use in the general population — summary of the data
Age group Time frame of use
Lifetime Last year
15–64 years
Estimated number of users in Europe 12 million 2 million
European average 3.5 % 0.5 %
Range 0.0–11.7 % 0.0–1.3 %
Lowest-prevalence countries Romania (0.0 %)
Greece (0.1 %)
Malta (0.4 %)
Cyprus (0.8 %)
Greece, Malta, Romania (0.0 %)
France (0.1 %)
Highest-prevalence countries United Kingdom (11.7 %)
Denmark (6.3 %)
Spain (3.8 %)
Norway (3.6 %)
Estonia (1.3 %)
Denmark (1.2 %)
Norway (1.1 %)
United Kingdom (1.0 %)
15–34 years
Estimated number of users in Europe 7 million 1.5 million
European average 5.0 % 1.1 %
Range 0.1–15.3 % 0.1–3.1 %
Lowest-prevalence countries Romania (0.1 %)
Greece (0.2 %)
Malta (0.7 %)
Cyprus (0.8 %)
Greece, Romania (0.1 %)
France (0.2 %)
Cyprus (0.3 %)
Highest-prevalence countries United Kingdom (15.3 %)
Denmark (10.5 %)
Latvia (6.1 %)
Norway (5.9 %)
Denmark (3.1 %)
Estonia (2.9 %)
Norway (2.0 %)
Latvia (1.9 %)
European prevalence estimates are based on weighted averages from the most recent national surveys conducted from 2001 to 2008 (mainly 2004–08), therefore they cannot 
be attached to a single year. The average prevalence for Europe was computed by a weighted average according to the population of the relevant age group in each country. In 
countries for which no information was available, the average EU prevalence was imputed. Populations used as basis: 15–64 (334 million) and 15–34 (133 million). The data 
summarised here are available under ‘General population surveys’ in the 2009 statistical bulletin.
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(81) See Table TDI-37 in the 2009 statistical bulletin. 
(82) See Table TDI-5 (part ii) in the 2009 statistical bulletin. 
(83) See Figure GPS-9 (part ii) and Tables GPS-17 and GPS-18 in the 2009 statistical bulletin.
(84) See Tables TDI-5 and TDI-37 (part i), (part ii) and (part iii) in the 2009 statistical bulletin. 
(85) See Tables GPS-8 (part i), GPS-9, GPS-11 and GPS-17 in the 2009 statistical bulletin.
Amphetamine users in treatment frequently report the 
use of other drugs, mainly cannabis and alcohol, and 
sometimes opioids (81). In those countries where primary 
amphetamine users make up a high proportion of those 
entering treatment, injection is the most frequently reported 
method of use (63–83 %).
Problem methamphetamine use
In contrast to other parts of the world, where the use 
of methamphetamine has increased in recent years, 
levels of its use in Europe appear limited. Historically, 
use of this drug in Europe has been concentrated in the 
Czech Republic and Slovakia. In 2007, the number of 
problem methamphetamine users in the Czech Republic 
was estimated to be approximately 20 400–21 400 
(2.8 to 2.9 cases per 1 000 aged 15–64 years), twice 
the estimated number of problem opioid users; and in 
Slovakia, approximately 5 800–15 700 (1.5 to 4.0 cases 
per 1 000 aged 15–64 years), around 20 % fewer than 
the estimated number of problem opioid users. 
In both of these countries, methamphetamine is reported 
as the primary drug by a large proportion of clients 
entering treatment: 61 % in the Czech Republic and 26 % 
in Slovakia. Between 2002 and 2007, the demand for 
treatment related to methamphetamine use has been 
increasing in both countries (82).
Injection is the most commonly reported means of 
administration reported by methamphetamine users in 
treatment (82 % in Czech Republic, 41 % in Slovakia). 
Use of other drugs is also often reported, mainly 
cannabis, alcohol and opioids. In Slovakia, a sharp 
increase has been noted in the number of recipients 
of opioid substitution treatment reporting the use of 
methamphetamine. 
Methamphetamine users entering treatment in the Czech 
Republic and Slovakia are relatively young, on average 
24–25 years, and predominantly male. Women, however, 
make up a higher proportion of those in treatment for 
problems related to methamphetamine than for other 
drugs. 
Ecstasy
It is estimated that about 10 million European adults 
have tried ecstasy (3.1 % on average) and that about 
2.5 million (0.8 %) have used it in the last year (see 
Table 6 for a summary of the data). Considerable 
variation exists between countries, with recent surveys 
suggesting that between 0.3 % and 7.5 % of all adults 
(15–64 years) have ever tried the drug, and with most 
countries reporting lifetime prevalence estimates in the 
range 1–5 %. Last year use of the drug varies across 
Europe, from 0.1 % to 3.5 %. On all measures, and as 
with most other illicit drugs, reported use is far higher 
among males than among females. 
Ecstasy consumption is much more common among young 
adults (15–34 years), where lifetime prevalence estimates 
ranged at national level from 0.6 % to 14.6 %, with 
between 0.2 % and 7.7 % of this age group reporting last 
year use of the drug. It is estimated that 7.5 million young 
Europeans (5.6 %) have ever tried ecstasy, with around 
2 million (1.6 %) using it during the last year. Estimates 
of prevalence are higher still if attention is restricted to a 
younger age band: among the 15–24 age group, lifetime 
prevalence ranges from 0.4 % to 18.7 %, though most 
countries report estimates in the 2.1–6.8 % range. Last 
year use of ecstasy among this age group is estimated 
at between 1.0 % and 3.9 % in the majority of countries, 
though there is a considerable difference between the 
lowest national estimate at 0.3 % and the highest at 
12 % (83).
Among 15- to 16-year-old school students, lifetime 
prevalence of ecstasy use ranges from 1 % to 5 % in most 
of the 28 countries surveyed in 2007. Only four countries 
report higher prevalence levels: Bulgaria, Estonia, 
Slovakia (all 6 %) and Latvia (7 %).
The number of primary ecstasy users entering treatment 
in 2007 remained trivial. In two thirds of the countries, 
ecstasy is mentioned by less than 1 % of drug clients; 
elsewhere, the proportion varies between 1 % and 
5 %. With an average age of 24 years, ecstasy 
clients are among the youngest groups entering drug 
treatment and often report the concomitant use of other 
substances, including cannabis, cocaine, alcohol and 
amphetamines (84). 
LSD and hallucinogenic mushrooms
Lifetime prevalence of LSD use among the adult population 
(15–64 years) ranges from almost zero to 5.2 %. Among 
young adults (15–34 years), lifetime prevalence estimates 
are a little higher (zero to 6.6 %), although much lower 
prevalence ranges are reported for last year use and 
among the 15- to 24-year-olds (85). In contrast, in the few 
countries providing comparable data, the use of LSD is 
often exceeded by that of hallucinogenic mushrooms, 
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(86) Data from ESPAD for all countries but Spain. See Figure EYE-2 (part v) in the 2009 statistical bulletin.
where lifetime prevalence estimates for young adults range 
from 0.3 % to 8.3 %, and last year prevalence estimates 
between 0.2 % and 2.8 %. 
Among 15- to 16-year-old school students, prevalence 
estimates for the use of hallucinogenic mushrooms are 
higher than those for LSD and other hallucinogens in 10 of 
the 26 countries reporting data on these substances. Most 
countries report lifetime prevalence estimates for the use of 
hallucinogenic mushrooms of between 1 % and 4 %, with 
Slovakia (5 %) and the Czech Republic (7 %) reporting 
higher levels (86). 
Trends in the use of amphetamines and ecstasy
The stabilising or even downward trends in amphetamine 
and ecstasy consumption in Europe, noted in previous 
Table 6: Prevalence of ecstasy use in the general population — summary of the data
Age group Time frame of use
Lifetime Last year
15–64 years
Estimated number of users in Europe 10 million 2.5 million
European average 3.1 % 0.8 %
Range 0.3–7.5 % 0.1–3.5 %
Lowest-prevalence countries Romania (0.3 %)
Greece (0.4 %)
Malta (0.7 %)
Lithuania (1.0 %) 
Romania (0.1 %)
Greece, Malta (0.2 %)
Poland (0.3 %)
Highest-prevalence countries United Kingdom (7.5 %)
Czech Republic (7.1 %)
Ireland (5.4 %)
Latvia (4.7 %)
Czech Republic (3.5 %)
Estonia (1.7 %)
Slovakia (1.6 %)
United Kingdom, Latvia (1.5 %)
15–34 years
Estimated number of users in Europe 7.5 million 2 million
European average 5.6 % 1.6 %
Range 0.6–14.6 % 0.2–7.7 %
Lowest-prevalence countries Greece, Romania (0.6 %)
Malta (1.4 %)
Lithuania, Poland (2.1 %)
Romania (0.2 %)
Greece (0.4 %)
Poland (0.7 %)
Italy, Lithuania, Portugal (0.9 %)
Highest-prevalence countries Czech Republic (14.6 %)
United Kingdom (12.7 %)
Ireland (9.0 %)
Latvia (8.5 %)
Czech Republic (7.7 %)
Estonia (3.7 %)
United Kingdom (3.1 %)
Latvia, Slovakia, Netherlands (2.7 %)
European prevalence estimates are based on weighted averages from the most recent national surveys conducted from 2001 to 2008 (mainly 2004–08), therefore they cannot 
be attached to a single year. The average prevalence for Europe was computed by a weighted average according to the population of the relevant age group in each country. In 
countries for which no information was available, the average EU prevalence was imputed. Populations used as basis: 15–64 (334 million) and 15–34 (133 million). The data 
summarised here are available under ‘General population surveys’ in the 2009 statistical bulletin.
EMCDDA ‘Selected issue’ on polydrug use
Alongside the 2009 annual report, the EMCDDA is 
publishing a ‘Selected issue’ on polydrug use. The 
document reviews the available definitions of this very 
common pattern of drug use and presents data which 
allow a better understanding of the prevalence and 
characteristics of polydrug use in different populations 
(school-aged children, adults, problem drug users). Existing 
interventions that target this phenomenon in the prevention, 
treatment and harm-reduction fields are also described. 
The report also includes a brief overview of the risks 
associated with some of the most common drug mixtures 
and a discussion on monitoring polydrug use in the future.
This ‘Selected issue’ is available in print and on the 
Internet in English only (http://www.emcdda.europa.eu/
publications/selected-issues/polydrug-use).
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(87) In Denmark in 1994 the information refers to ‘hard drugs’, which was considered mainly amphetamines. 
(88) See Figure GPS-21 in the 2009 statistical bulletin.
reports, are supported by the most recent data. After 
general increases in the 1990s, population surveys 
now point to an overall stabilisation, or even moderate 
decrease, in the popularity of both drugs, although this 
pattern is not seen in all countries. 
Last year use of amphetamine among young adults 
(15–34) in the United Kingdom has declined substantially 
from 6.2 % in 1998 to 1.8 % in 2008. In Denmark, 
amphetamine use increased from 0.5 % in 1994 to 3.1 % 
in 2000, with a similar figure in 2008 (87). Among the 
other countries reporting repeated surveys over a similar 
time span (Germany, Greece, Spain, France, Netherlands, 
Slovakia, Finland), the trends are largely stable 
(Figure 7). During the 5-year period 2002–07, of the 
11 countries with sufficient data on last year prevalence 
of amphetamine use among the 15–34 age group, four 
report a decrease of at least 15 % of the initial value, 
three report stabilisation and four report an increase.
For ecstasy use among young adults (15–34), the picture 
is more mixed. After general increases in use in some 
European countries in the late 1980s and early 1990s, 
leading to similar levels of ecstasy use in Germany, 
Spain and the United Kingdom in the mid-1990s, last 
year prevalence of use has decreased to an estimated 
European average of 1.6 %. Among countries with more 
recent surveys, prevalence remains higher in the United 
Kingdom compared to other countries (88). Over the 5-year 
period 2002–07, last year prevalence of ecstasy use 
among young adults decreased by at least 15 % of the 
initial value in three of the 11 countries providing sufficient 
information, while it remained stable in four countries and 
increased in four. 
Cocaine could be replacing amphetamines and ecstasy in 
some countries and among some sectors of the drug-using 
population. This hypothesis can be illustrated in the United 
Kingdom and, to some extent, in other countries (e.g. 
Denmark, Spain), where concurrent increases in cocaine 
consumption and decreases in the use of amphetamines 
have been observed (EMCDDA, 2008b). 
ESPAD and other school surveys conducted in 
2007 suggest, overall, little change in the levels of 
experimentation with amphetamine and ecstasy among 
students aged 15 to 16 years. Considering differences of 
at least two percentage points between 2003 and 2007, 
lifetime prevalence of amphetamine use increased in nine 
countries. By the same measure, ecstasy use increased 
in seven countries. A decrease in lifetime prevalence of 
amphetamine use was observed only in Estonia, while 
Czech Republic, Portugal, Croatia reported a decrease in 
ecstasy use.
Amphetamines and ecstasy in recreational 
settings: use and interventions
Drug and alcohol use is sometimes associated with certain 
recreational settings where young people congregate (e.g. 
dance events, music festivals). Studies on drug use in these 
settings can provide a window on the behaviour of those 
Figure 7: Trends in last year prevalence of use of amphetamines (left) and ecstasy (right) among young adults (aged 15–34)
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(1) England and Wales.
NB: Only data for countries with at least three surveys in the period 1998 to 2008 are presented. See Figures GPS-8 and GPS-21 in the 2009 
statistical bulletin for further information.
Sources: Reitox national reports, taken from population surveys, reports or scientific articles.
57
Chapter 4: Amphetamines, ecstasy and hallucinogenic substances
using amphetamines and ecstasy or other drugs such as 
ketamine and GHB. Estimates of drug use in these settings 
are typically high, but are not generalisable to the wider 
population, and much of the drug use tends to occur on 
weekends and during holiday periods (EMCDDA, 2006b).
Prevalence data from studies conducted in recreational 
settings in 2007 are available from five countries (Belgium, 
Czech Republic, Latvia, Lithuania, Austria). Lifetime 
prevalence estimates ranged from 15 % to 71 % for 
ecstasy use and from 17 % to 68 % for amphetamines. 
Four of these studies also reported lifetime prevalence 
estimates for hallucinogenic mushrooms, ranging from 4 % 
to 64 %. Frequent use of ecstasy or amphetamines can also 
be found in these settings but it is generally much lower. 
An indication of the extent to which the use of these 
drugs may be concentrated among the young, club-going 
population can be gleaned from the 2007/08 British 
Crime Survey. Among 16- to 24-year-olds, those who 
reported visiting a nightclub four or more times in the last 
month were more than three times as likely to have used 
ecstasy (8 %) in the last year than those not attending 
nightclubs (2.3 %) (Hoare and Flatley, 2008).
The health and safety of people who attend nightclubs 
and use drugs is a growing public health concern. 
Guidelines, such as the ‘Safer dancing’ guidelines 
developed in the United Kingdom, have become an 
important tool in this field. However, while 12 countries 
now report having developed such guidelines for nightlife 
venues, only the Netherlands, Slovenia, Sweden and 
the United Kingdom report that they are monitored and 
enforced. 
Safe-clubbing guidelines aim to reduce opportunities 
for drug-related problems to occur and include the 
accessibility of free cold water, immediate availability of 
first aid, and outreach prevention work. Reports on the 
availability of such measures, in nightclubs with sufficiently 
large target populations for the intervention to be 
implemented, were provided by national experts. Overall, 
it shows the limited availability of simple measures to 
prevent or reduce health risks and drug use in European 
nightlife settings. Outreach prevention work is reported 
to be available in the majority of relevant nightclubs only 
in Lithuania and Slovenia and in a minority of nightclubs 
in 18 countries. It does not exist in six countries. Five 
countries report immediate availability of first aid in the 
majority of relevant nightclubs (Luxembourg, Portugal, 
Slovenia, United Kingdom, Norway); the measure is 
available only in a minority of relevant nightclubs in 15 
countries, and is unavailable in Greece and Sweden. 
Finally, free cold water is available in the majority of 
relevant nightclubs in 11 countries and in a minority of 
them in nine countries. This measure is not available in 
Greece, Cyprus and Romania.
Treatment
Users of amphetamines generally receive treatment in 
outpatient drug services which, in countries with histories 
of significant levels of the use of amphetamines, can 
be specialised in treating this type of drug problem. 
Treatment for the most problematic users of amphetamines 
may be provided in inpatient drug services or in 
psychiatric clinics or hospitals. 
Specific treatment programmes for problem amphetamines 
users are reported in nine countries (Germany, Estonia, 
Spain, Italy, Austria, Portugal, Slovenia, Slovakia, 
United Kingdom). The availability of these programmes 
varies between countries. Only three of these countries 
(Portugal, Slovenia, United Kingdom) report that 
specialised programmes are available to the majority 
of amphetamines users who actively seek treatment. In 
the other six countries, national experts estimate that 
specialised amphetamines treatment is available to less 
than half of the users seeking it. The content of these 
specific programmes for users of these drugs is often not 
well documented.
Therapeutic options with robust evidence of effectiveness 
are generally lacking to guide the treatment of 
dependence on psychostimulants, such as amphetamines. 
Promising results have been reported for recent 
investigations on pharmacological agents to manage 
abstinence or reduce the cravings associated with 
amphetamines dependence, which up to now have been 
lacking. A Finnish study on the use of methylphenidate 
and aripiprazole reported positive initial results, with 
those who received methylphenidate producing fewer 
amphetamine-positive urine samples than those receiving 
aripiprazole or a placebo (Tiihonen et al., 2007). And, 
a recent literature review showed positive results both for 
methylphenidate and dexamphetamine in the treatment of 
methamphetamine dependence (Elkashef et al., 2008). 
Dexamphetamine has long been available for the 
treatment of highly problematic users of amphetamines 
in England and Wales, where it may be prescribed by 
any doctor. However, information on this practice in 
the United Kingdom is limited. A survey of pharmacy 
services conducted over 10 years ago estimated that 
900 to 1 000 clients were receiving this treatment (Strang 
and Sheridan, 1997). Most prescriptions were issued 
by doctors working in hospitals or clinics, and almost 
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all from doctors working in the National Health Service 
(NHS). A survey of 265 NHS specialist services, carried 
out in 2000, revealed that dexamphetamine prescribing 
was available in about one third of the services 
surveyed (Rosenberg et al., 2002). However, the United 
Kingdom guidelines on clinical management of drug 
dependence recommend against substitute prescribing 
of dexamphetamine, due to a lack of demonstrated 
effectiveness (NTA, 2007).
As yet, no one psychosocial intervention has shown strong 
evidence of effectiveness in helping psychostimulant users 
to maintain abstinence. In the literature, the interventions 
that have demonstrated the most efficacy in treating 
users of stimulant drugs are cognitive behavioural 
approaches such as relapse prevention. The effectiveness 
of other types of intervention is not well supported. The 
literature is particularly hindered by the paucity of well-
conducted studies among primary amphetamine users, 
especially treatment outcome studies (Baker et al., 2004). 
Furthermore, a recent Cochrane review on psychosocial 
interventions for psychostimulant dependence concluded 
that consistent, positive behavioural results (retention in 
treatment, reduction in drug consumption) have been 
observed only in interventions that included contingency 
management as a component. However, this approach is 
rarely used in Europe, though there have been some pilot 
projects (see Chapter 5). 
Further research into psychosocial and pharmacological 
treatment for those with problems related to the use of 
amphetamines, especially injectors, is needed. Current 
treatment practices and treatment coverage in Europe also 
needs to be better documented, and much remains to be 
done in the sharing of best practice. The lack of dedicated 
programmes might be failing to encourage amphetamine 
or methamphetamine users to seek treatment, especially 
at early stages of use. In addition, the availability of such 
programmes could help bring more users into treatment; 
as was found for problem cannabis users in Germany and 
France, when these countries expanded the availability 
of dedicated treatment programmes. Such measures may 
be particularly useful in those countries that have recently 
seen a growth in the numbers of problem amphetamine 
and methamphetamine users, especially injectors  (Talu et 
al., 2009).
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Introduction
An overall increase in cocaine use and cocaine seizures 
has been observed in the European Union during the last 
decade, although this has been largely confined to western 
Member States, and major differences exist between 
countries. The data available also indicate considerable 
diversity among cocaine users, both in terms of patterns of 
use and in terms of sociodemographics. Those who only 
experiment with the substance on one or a few occasions 
make up the largest group. Another group includes socially 
integrated regular users who, in some countries, account 
for a relatively large number of young people. Some of 
them will intensify their use of cocaine, or use it over a 
long period, which may lead to chronic health and social 
problems and to the need for treatment. A third set of users 
includes members of socially excluded groups, including 
current and former opioid users. Most of them have 
intensive patterns of cocaine use, possibly using crack or 
injecting the drug, which may perpetuate or exacerbate 
existing health and social problems, and may complicate 
their treatment for opioid use. Because of the diversity of 
profiles among cocaine users, assessing the prevalence of 
the drug’s use, its health and social consequences and the 
necessary responses presents a unique set of challenges.
Supply and availability
Production and trafficking
Cultivation of coca bush, the source of cocaine, continues 
to be concentrated in a few countries in the Andean 
region (89). The UNODC (2009) estimated for the year 
2008 that the total cultivation of coca bush translated 
into a potential production of 845 tonnes of pure cocaine 
hydrochloride, with Colombia accounting for 51 %, Peru 
36 % and Bolivia 13 %. Global cocaine production is 
estimated to have fallen by 15 % in 2008, mainly due to 
falling cocaine production in Colombia — from 600 tonnes 
in 2007 to 430 tonnes in 2008. Cocaine production in 
Peru and Bolivia, in contrast, continued to increase slightly.
Most of the process to convert coca leaves into cocaine 
hydrochloride remains located in Colombia, Peru and 
Chapter 5
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Table 7: Production, seizures, price and purity of cocaine and crack cocaine
Cocaine Crack (1)
Global production estimate (tonnes) 845 n.a.
Global quantities seized (tonnes) 710 (2) 0.8
Quantity seized (tonnes) 
EU and Norway  
(Including Croatia and Turkey)
76.4
(76.7)
0.08
(0.08)
Number of seizures 
EU and Norway  
(Including Croatia and Turkey)
91 400
(92 000)
9 500
(9 500)
Mean retail price (EUR per gram) 
Range 
(Interquartile range) (3)
44–88
(58–67)
20–112
Range of mean purity (%) 22–57 35–98
(1) Due to the small set of countries reporting information, data should be interpreted with caution.
(2) UNODC estimates this figure to be equivalent to 412 tonnes of pure cocaine.
(3) Range of the middle half of the reported mean prices.
NB: All data for 2007, except global production estimates which are for 2008; n.a., data not available. 
Sources: UNODC World drug report (2009) for global values, Reitox national focal points for European data.
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(90) See Tables SZR-9 and SZR-10 in the 2009 statistical bulletin.
Bolivia, although it may also occur in other South 
American countries. Colombia’s importance in the 
production of cocaine is corroborated by information 
on laboratories dismantled and seizures of potassium 
permanganate, a chemical reagent used in the synthesis 
of cocaine hydrochloride. In 2007, 2 471 cocaine 
laboratories were dismantled (78 % of the world total) 
and a total of 144 tonnes of potassium permanganate 
was seized in Colombia (94 % of global seizures) (INCB, 
2009a). 
The available information suggests that cocaine continues 
to be trafficked to Europe via different routes (EMCDDA, 
2008d). Cocaine consignments transit through South 
and Central American countries, such as Argentina, 
Brazil, Ecuador, Mexico and Venezuela, before reaching 
Europe. Caribbean countries are also frequently used in 
the transhipment of the drug to Europe. On these routes, 
cocaine is smuggled through commercial flights or by 
sea. In recent years, an alternative route through West 
Africa has been identified. From there, cocaine is often 
transported to Europe by fishing and sailing vessels, 
though trafficking by air or overland through north Africa 
has also been reported (Europol, 2007).
Other transiting countries have also been mentioned in 
recent years. These include South Africa, Russia, but also 
countries in central and eastern Europe, where the number 
of cocaine seizures increased from an estimated 412 
cases in 2002 to 1 065 in 2007. Belgium, Spain, France, 
Italy, the Netherlands, Portugal and the United Kingdom 
have been mentioned as important transit countries for 
cocaine shipments inside Europe.
Seizures
Cocaine is the most trafficked drug in the world after 
herbal cannabis and cannabis resin. In 2007, global 
seizures of cocaine remained stable at about 710 tonnes. 
South America continued to report the largest amount 
seized, accounting for 45 % of the global figure, followed 
by North America with 28 %, and west and central 
Europe with 11 % (UNODC, 2009).
In Europe, the number of cocaine seizures has been on 
the increase for the last 20 years, and more notably 
since 2003. In 2007, the number of cocaine seizures 
increased to 92 000 cases, though the total quantity 
recovered dropped to 77 tonnes, down from 121 tonnes 
in 2006. The fall in the total amount of cocaine seized is 
largely accounted for by Portugal, and to a lesser extent 
Spain and France, reporting smaller quantities seized in 
2007 compared to the previous year (90). In 2007, Spain 
continued to be the country reporting both the largest 
quantity of cocaine seized and the highest number of 
seizures of the drug — about half of the total — in Europe.
Purity and price
The mean purity of cocaine in Europe ranged between 
22 % and 57 % in 2007 (91). Most of the countries with 
sufficient data for analysis of trends over time report a 
decline in the purity of cocaine over the period 2002–07, 
with the exception of Spain and Portugal. 
In 2007, the mean retail price of cocaine ranged from  
EUR 44 to EUR 88 per gram among the 19 countries 
reporting data, with about half of them reporting mean 
prices of between EUR 58 and EUR 67 per gram. For 
those countries reporting sufficient data to make a 
comparison, cocaine sold on the street became cheaper 
between 2002 and 2007. 
Laws to counter drug trafficking in the high seas
Success in disrupting drug trafficking at sea relies on 
cooperation between states, and this is facilitated by two 
international conventions. 
Under Article 108 of the International Convention on the 
Law of the Sea (1982), a state that suspects that a ship 
flying its flag (1) is involved in drug trafficking can request 
the help of other states to suppress such trafficking. Further 
cooperation is envisaged under Article 17 of the 1988 UN 
Convention against trafficking. This convention establishes 
a mechanism that allows any state, having reasonable 
grounds for suspecting that a ship registered in another 
country is engaged in drug trafficking, to request the ship’s 
flag state for permission to board the vessel, search for and 
seize any drugs, and subsequently prosecute the offenders. 
These acts may take place anywhere outside territorial 
waters. Competent national authorities are nominated 
to act as contact points, permanently on-call, in order 
to reply to such requests as soon as possible. Requests 
may be granted, granted with conditions or refused. The 
interdiction can be carried out only by warships or military 
aircraft, or other ships or aircraft clearly identifiable as 
being on government service and authorised to that effect. 
The actual boarding and subsequent actions are carried 
out by a team of law enforcement officers from the 
requesting state, known as a law enforcement detachment 
(LEDET). When coordinated by intergovernmental agencies 
such as MAOC-N (Maritime Analysis Operations Centre 
— Narcotics), a LEDET is sometimes carried by the 
warship of another country. In this case, to comply with the 
identification requirement, helicopters and small boats used 
during the boarding operation will temporarily fly the flag 
of the LEDET’s state rather than that of their warship.
(1) Jurisdiction over a ship and its crew is assumed by the state in 
which the vessel is registered (the ‘flag state’).
62
Annual report 2009: the state of the drugs problem in Europe
(91) For purity and price data, see Tables PPP-3 and PPP-7 in the 2009 statistical bulletin.
(92) See Figure GPS-16 in the 2009 statistical bulletin.
(93) See Figure GPS-13 in the 2009 statistical bulletin.
(94) See Figure GPS-15 and Tables GPS-14, GPS-15 and GSP-16 for all years; Tables GPS-17, GPS-18 and GPS-19 for latest data in the 2009 statistical 
bulletin.
Prevalence and patterns of use
Cocaine use among the general population
Overall, cocaine remains the second most used illicit drug 
in Europe, after cannabis, though levels of use vary greatly 
between countries. It is estimated that around 13 million 
Europeans have used it at least once in their lifetime, on 
average 3.9 % of adults aged 15–64 years (see Table 8 
for a summary of the data). National figures vary from 
0.1 % to 8.3 %, with 12 out of 23 countries, including most 
central and eastern European countries, reporting low 
levels of lifetime prevalence among all adults (0.5–2 %). 
It is estimated that around 4 million Europeans have used 
the drug in the last year (1.2 % on average), although 
again with variation between countries. Recent national 
surveys report last year prevalence estimates of between 
zero and 3.1 %; though in 18 out of 24 countries levels 
of use do not exceed 1 %. The prevalence estimate for 
last month cocaine use in Europe represents about 0.4 % 
of the adult population or around 1.5 million individuals. 
These estimates are likely to be conservative.
Overall, cocaine use appears to be concentrated in a 
few countries, notably Denmark, Spain, Italy, Ireland 
and the United Kingdom, while use of the drug remains 
relatively low elsewhere in Europe. In countries where 
amphetamines dominate the market in illicit stimulant 
drugs, estimates of cocaine use are low in nearly all 
cases. Conversely, in most countries where cocaine is the 
main illicit stimulant, low levels of amphetamine use are 
reported.
Only a small proportion of those who have used cocaine 
at least once in their life appear to develop intensive 
patterns of use. Data from general population surveys 
suggest high discontinuation rates among cocaine users. 
In countries where lifetime prevalence is above 2 %, most 
adults who have ever used cocaine (80–95 %) have not 
used it within the last month (92). 
Cocaine use among young adults
In Europe, it is estimated that 7.5 million young adults (15–
34 years), or an average of 5.6 %, have used cocaine 
at least once in their life. National figures vary from 
0.1 % to 12.0 %. The European average for last year use 
of cocaine among this age group is estimated at 2.2 % 
(3 million) and for last month use at 0.8 % (1 million).
Use is particularly high among young males (15–34 
years), with last year prevalence of cocaine use reported 
at between 4.2 % and 7.7 % in Denmark, Spain, Ireland, 
Italy and the United Kingdom (93). In most countries, the 
male to female ratio for last year prevalence of cocaine 
use among young adults is at least 2:1. 
Last year prevalence of cocaine use among 15- to 
24-year-olds is estimated at 2.2 %, which translates into 
1.5 million users in Europe. In contrast to the prevalence 
estimates for cannabis or ecstasy use, which are highest 
among the 15–24 age group, measures of more recent 
cocaine use (last year and last month) are similar among 
the 15–34 and the 15–24 age groups (94).
Cocaine use is also associated with alcohol use and 
certain lifestyles. For example, an analysis of data from 
the 2007/08 British Crime Survey found that among 
16- to 24-year-olds who made nine or more visits to a 
pub in the last month, 13.5 % report last year use of 
cocaine, compared with 1.7 % among those who had 
Understanding falling cocaine prices in Europe 
Since 2000, cocaine prices adjusted for inflation have 
been falling in Europe, while the demand for this substance 
has increased, as shown by the prevalence of cocaine use 
in the general population and among problem drug users. 
This counter-intuitive finding could be explained by several 
factors. An increase in the supply of cocaine to Europe, 
reflected in rising volumes of seizures, is certainly a key 
factor here. The search for an alternative to the United 
States’ market, by South American cocaine traffickers, 
may be a ‘push’ factor driving the increased targeting 
of the European market. Additionally, a ‘pull’ factor may 
have been the growing demand for cocaine in Europe. 
The increased volume of European cocaine consumption 
together with the relative strength of European currencies 
compared to the US dollar could have compensated for 
declining prices and, possibly, smaller profit margins. 
Other factors, however, might also have influenced the price 
of cocaine. Technological developments and the use of new 
trafficking routes, such as the West African route, where 
drug control is poorly enforced and which provides low-paid 
traffickers, could have led to a decrease in transportation 
costs and a reduction of trafficking risks. More competition 
inside the cocaine market (Desroches, 2007) might also 
have influenced the drug’s price in Europe. 
The lack of data in this area makes this analysis necessarily 
speculative and underlines the importance of obtaining a 
better understanding of the factors that influence Europe’s 
drug market. The EMCDDA is committed to continue 
developing collaborations and research in this area.
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not visited a pub. Visiting nightclubs was also associated 
with increased cocaine use, as nearly 10 % of the 16- to 
24-year-olds who visited a club on four or more occasions 
during the last month report last year use of cocaine, 
compared with 3.3 % among those who had not visited 
a club. The survey also reported low levels of crack use, 
even among cocaine users, confirming findings from other 
studies that report differences in the profiles of the users of 
these two substances (Hoare and Flatley, 2008). Studies 
conducted in recreational settings also report higher 
prevalence levels of cocaine use than in the general 
population (EMCDDA, 2007a). In addition, a recent 
Table 8: Prevalence of cocaine use in the general population — summary of the data
Age group Time frame of use
Lifetime Last year Last month
15–64 years
Estimated number of users in Europe 13 million 4 million 1.5 million
European average 3.9 % 1.2 % 0.4 %
Range 0.1–8.3 % 0.0–3.1 % 0.0–1.1 %
Lowest-prevalence countries Romania (0.1 %)
Lithuania, Malta (0.4 %)
Greece (0.7 %)
Romania (0.0 %)
Greece (0.1 %)
Czech Republic, Hungary,  
Poland (0.2 %)
Czech Republic, Greece,  
Estonia, Romania (0.0 %)
Malta, Lithuania, Poland,  
Finland (0.1 %)
Highest-prevalence countries Spain (8.3 %)
United Kingdom (7.6 %) 
Italy (6.8 %)
Ireland (5.3 %)
Spain (3.1 %) 
United Kingdom (2.3 %)
Italy (2.2 %)
Ireland (1.7 %)
Spain (1.1 %) 
United Kingdom (1.0 %)
Italy (0.8 %)
Ireland (0.5 %)
15–34 years
Estimated number of users in Europe 7.5 million 3 million 1 million
European average 5.6 % 2.2 % 0.8 %
Range 0.1–12.0 % 0.1–5.5 % 0.0–2.1 %
Lowest-prevalence countries Romania (0.1 %)
Lithuania (0.7 %)
Malta (0.9 %)
Greece (1.0 %)
Romania (0.1 %)
Greece (0.2 %)
Poland (0.3 %)
Hungary, Czech Republic (0.4 %)
Estonia, Romania (0.0 %)
Czech Republic, Greece,  
Poland (0.1 %)
Highest-prevalence countries United Kingdom (12.0 %)
Spain (11.8 %)
Denmark (9.5 %)
Ireland (8.2 %)
Spain (5.5 %)
United Kingdom (4.5 %)
Denmark (3.4 %)
Ireland, Italy (3.1 %)
United Kingdom (2.1 %)
Spain (1.9 %)
Italy (1.2 %)
Ireland (1.0 %)
15–24 years
Estimated number of users in Europe 3 million 1.5 million 0.6 million
European average 4.4 % 2.2 % 0.9 %
Range 0.1–9.9 % 0.1–5.6 % 0.0–2.5 %
Lowest-prevalence countries Romania (0.1 %)
Greece (0.6 %)
Lithuania (0.7 %)
Malta, Poland (1.1 %)
Romania (0.1 %)
Greece (0.2 %)
Poland (0.3 %)
Czech Republic (0.4 %)
Estonia, Romania (0.0 %)
Greece (0.1 %)
Czech Republic, Poland,  
Portugal (0.2 %)
Highest-prevalence countries United Kingdom (9.9 %)
Spain (9.3 %)
Denmark (9.2 %)
Ireland (7.0 %)
Denmark (5.6 %)
Spain (5.4 %)
United Kingdom (5.0 %)
Ireland (3.8 %)
United Kingdom (2.5 %)
Spain (1.7 %)
Italy (1.2 %)
Ireland (1.1 %)
European prevalence estimates are based on weighted averages from the most recent national surveys conducted from 2001 to 2008 (mainly 2004–08), therefore they cannot 
be attached to a single year. The average prevalence for Europe was computed by a weighted average according to the population of the relevant age group in each country. In 
countries for which no information was available, the average EU prevalence was imputed. Populations used as basis: 15–64 (334 million), 15–34 (133 million) and 15–24  
(63 million). The data summarised here are available under ‘General population surveys’ in the 2009 statistical bulletin.
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(95) See Table EYE-12 in the 2009 statistical bulletin. 
internet survey conducted among fans of electronic music 
in the Czech Republic reported that 30.9 % of respondents 
had used cocaine.    
The 2008 Eurobarometer survey, which was conducted 
in the 27 EU Member States, shows that 85 % of 15- to 
25-year-olds perceive cocaine use as a high risk to a 
person’s health. The proportions of respondents perceiving 
a similar level of health risk from using other substances 
are much lower: 40 % for cannabis, 28 % for tobacco and 
24 % for alcohol. Only heroin use is perceived as a high 
risk by a greater proportion of respondents. There is little 
variation between countries, and 95 % of the respondents 
considered that cocaine should continue to be banned 
(European Commission, 2008b).
Cocaine use among school students
Estimates of the prevalence of cocaine use among school 
students are much lower than those for cannabis use. 
Lifetime prevalence of cocaine use among 15- to 16-year-
old school students in the ESPAD survey is between 1 % 
and 2 % in half of the 28 reporting countries. Most of the 
remaining countries report prevalence levels of between 
3 % and 4 %, while France, Italy and the United Kingdom 
report 5 %. Lifetime prevalence of cocaine use among 
males is higher than that among females in most countries, 
and the highest levels (6 %) are reported by France and 
Italy (95).
International comparisons 
Overall, the estimated last year prevalence of cocaine 
use is lower among young adults in the European Union 
than among their counterparts in Australia and the United 
States. However, two countries, Spain and the United 
Kingdom (England and Wales), report higher figures than 
Australia, and only Spain reports a higher estimate than 
that of the United States (Figure 8). 
Figure 8: Last year prevalence of cocaine use among young adults (15–34) in Europe, Australia and the USA
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(1) England and Wales.
NB: Data are from the last survey available for each country. The European average prevalence rate was calculated as the average of the 
national prevalence rates weighted by national population of 15- to 34-year-olds (2006, taken from Eurostat). US and Australian data have 
been recalculated from original survey results to the age band 15–34 years. See Figure GPS-20 in the 2009 statistical bulletin for further 
information.
Sources: Reitox national focal points.
 SAMHSA (USA), Office of Applied Studies (http://oas.samhsa.gov/nhsda.htm#NHSDAinfo). National survey on drug use and health, 2007.
 Australian Institute of Health and Welfare 2008. 2007 National Drug Strategy Household Survey: detailed findings. Drug statistics series 
No 22. Cat. No PHE 107. Canberra: AIHW (http://www.aihw.gov.au/publications/phe/ndshs07-df/ndshs07-df.pdf).
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(96) Denmark also observed an increase, but during a different time frame.
Trends in cocaine use
In simple terms, trends in cocaine use in Europe have 
followed different patterns. In the two countries with the 
highest prevalence of cocaine use (Spain and the United 
Kingdom), the use of the drug increased dramatically in 
the late 1990s, before moving to a more stable, though 
still generally upward, trend. In a second group of 
countries, including Denmark, Ireland and Italy, increasing 
prevalence has been less pronounced and occurred 
somewhat later.  Levels of use in these three countries 
are nevertheless high compared to other European 
countries. Elsewhere in Europe, the picture is difficult to 
interpret, with low prevalence levels overall and with both 
small increases and small decreases observed in some 
countries. Of the 11 countries for which it is possible 
to analyse the trend from 2002 and 2007, last year 
prevalence among young adults (15–34 years) increased 
by at least 15 % of the initial value in five countries 
(Ireland, Italy, Latvia, Portugal, United Kingdom) (96), 
decreased in two countries (Hungary, Poland), and 
was stable in four (Germany, Spain, Slovakia, Finland) 
(Figure 9). 
In the ESPAD school surveys carried out in 2007, lifetime 
prevalence of cocaine use among 15- to 16-year-old 
school students increased by at least two percentage 
points since 2003 in France, Cyprus, Malta, Slovenia and 
Slovakia. The Spanish school survey reported a decrease 
of two percentage points between 2004 and 2007. 
Health consequences of cocaine use
The extent of the health consequences of cocaine use is 
likely to be underestimated. This is partly due to the often 
unspecific or chronic nature of the pathologies typically 
arising from long-term use of cocaine, and partly to the 
difficulties in establishing causal links between the illness 
and the use of the drug. Regular cocaine use, including 
by snorting, can be associated with cardiovascular, 
neurological and psychiatric problems, and with increased 
risk of accidents and violence. Concomitant use of other 
substances, including alcohol, can also increase some 
cocaine related problems (see EMCDDA, 2007a).  
A survey carried out in the United States estimated that 
frequent cocaine users had a seven-fold higher risk of non-
fatal myocardial infarction than non-users (Qureshi et al., 
2001). Overall, it was estimated that a quarter of non-fatal 
myocardial infarctions in persons aged 18–45 years were 
attributable to ‘frequent cocaine use’. 
Recent reports show that in countries with relatively 
high prevalence levels of cocaine use, the drug appears 
to be involved in the majority of drug-related hospital 
emergencies. The American Drug Abuse Warning 
Figure 9: Trends in last year prevalence of cocaine use among young adults (aged 15–34)
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NB: See Figure GPS-14 (part ii) in the 2009 statistical bulletin for further information.
Sources: Reitox national reports (2008), taken from population surveys, reports or scientific articles.
66
Annual report 2009: the state of the drugs problem in Europe
(97) See ‘Crack cocaine use in Europe’, p. 67. 
(98) See Figure TDI-2 and Table TDI-5 (part i) and (part ii) in the 2009 statistical bulletin; data for Spain refer to 2006.
(99) Only clients reporting primary use of opioids, cannabis, cocaine and other stimulants are included.
(100) See Figures TDI-1 and TDI-3 and Table TDI-3 (part ii) in the 2009 statistical bulletin.
Network (DAWN) estimated that cocaine, alone or in 
combination with other drugs, was involved in six out of 
every 10 drug-related emergency visits in 2006. In Spain, 
the national reporting system of hospital emergencies 
related to non-medical use of psychoactive substances 
found that, in 2006, cocaine was the substance most 
frequently reported (59 %); followed by cannabis (31 %), 
sedatives (28 %) and heroin (22 %), with alcohol being 
frequently associated with all these substances. In a 
study among patients attending a hospital emergency 
department in Barcelona for problems directly related 
to cocaine use, the main complaints were anxiety or 
agitation (48 %) and thoracic pain or palpitations (25 %). 
Cocaine injection and crack use are associated with the 
highest health risks (including cardiovascular and mental 
health problems, health deterioration). These are generally 
aggravated by social marginalisation and additional 
specific problems, such as the risks associated with 
injection. The concomitant use of opioids and cocaine 
appears to be linked to a higher risk of opioid overdose 
(EMCDDA, 2007a).
Dependence is one of the negative consequences of 
cocaine use for the individual. A study conducted in the 
United States showed that about 5 % of cocaine users 
can become dependent in the first year of use, though not 
more than around 20 % of users developed dependence 
in the long term (Wagner and Anthony, 2002). Another 
study showed that, among those who become dependent, 
close to 40 % recover without drug or alcohol treatment 
(Cunningham, 2000). There is also evidence that many 
cocaine users controlled their use of the drug by setting 
rules, for example, about the amount, frequency or context 
of use (Decorte, 2000).
Problem cocaine use and treatment demand
National estimates of problem cocaine use (injection or 
long duration/regular use) are available only for Spain 
and Italy, while regional and crack cocaine estimates (97) 
are available for the United Kingdom. In Italy, in 2007, 
there were estimated to be between 3.8 and 4.7 
problem cocaine users per 1 000 adults. According 
to the most recent data for Spain, in 2002 there were 
between 4.5 and 6 problem cocaine users per 1 000 
adult population (15–64 years). Estimates of problem 
cocaine users probably underestimate the population 
in need of treatment or brief interventions, because 
socially integrated problem cocaine users might be under-
represented in the data sources used.
Cocaine, mainly powder cocaine, was cited as the 
principal reason for entering treatment by about 17 % 
of all drug treatment clients in 2007, corresponding to 
around 61 000 reported cases in 25 European countries. 
Among those entering treatment for the first time, the 
proportion reporting cocaine as their primary drug is 
higher (22 %).
There are wide differences between countries regarding 
the proportion of cocaine clients among both all and new 
clients. Spain reports the highest proportions among all 
clients (45 %) and new clients (60 %), followed by the 
Netherlands (32 % and 29 %) and Italy (23 % and 26 %). 
In Belgium, Ireland, Cyprus, Luxembourg and the United 
Kingdom, cocaine clients represent between 11 % and 
13 % of all drug clients and between 11 % and 19 % 
of new clients; elsewhere in Europe, cocaine accounts 
for less than 10 % of drug treatment clients, with seven 
countries reporting less than 1 % (98). 
The number of clients entering drug treatment for 
primary cocaine use has been increasing in Europe for 
several years, though the trend is strongly influenced by 
a few countries. Between 2002 and 2007, the largest 
proportional increases among new clients were reported 
by Spain, Ireland and Italy. In those countries with 
sufficient data to analyse trends over time, the number 
of all clients entering treatment citing cocaine as their 
primary drug increased as a proportion from 13 % to 
19 % (based on 18 countries) (99). For new treatment 
clients, the proportion rose from 17 % to 25 % (based on 
19 countries). Since 2005, among the countries with the 
highest proportions of cocaine clients, Spain and Italy 
report a stable situation, while the Netherlands shows a 
falling proportion of new clients entering treatment for 
cocaine. However, the proportion is now increasing in 
other countries such as Denmark, Ireland, Greece and 
Portugal (100).
Profile of treatment clients
Nearly all cocaine clients are reported by outpatient 
treatment centres, although some cocaine users might be 
treated in private clinics, which are almost not represented 
in the current monitoring system. 
Cocaine clients have one of the largest male to female 
ratios (five men for every woman) and one of the highest 
mean ages (around 32 years) among drug treatment 
clients. This is particularly the case in some countries with 
large numbers of primary cocaine clients, especially Italy 
where the sex ratio is 8:1 and the mean age 35 years. 
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(101) See Tables TDI-10, TDI-11 (part iii), TDI-21 and TDI-103 (part ii) in the 2009 statistical bulletin.
(102) See Table TDI-17 (part iv) in the 2009 statistical bulletin.
(103) See the ‘Selected issue’ on polydrug use.
(104) See ‘Crack cocaine use in Europe’, and Tables TDI-7 and TDI-115 in the 2009 statistical bulletin.
Almost half the cocaine clients start using the drug before 
the age of 20, and 88 % before the age of 30. Long 
time lags (9–12 years) between first cocaine use and 
first treatment entry are reported in Spain, Italy and the 
Netherlands (101). 
Most cocaine clients snort (55 %) or smoke (32 %) the 
drug and less than 7 % report injecting it (102). An analysis 
carried out in 14 countries in 2006 revealed that around 
63 % of cocaine clients are polydrug users. Among them, 
42 % also use alcohol, 28 % cannabis and 16 % heroin. 
Cocaine is also often mentioned as a secondary drug, 
especially among clients with a primary heroin problem 
(28 %) (103).
In 2007, around 8 000 clients are reported to have 
entered outpatient treatment for primary use of crack 
cocaine, representing 15 % of all cocaine clients and 
2.7 % of all drug clients in outpatient treatment. Most 
crack clients (around 6 500) are reported by the United 
Kingdom, where they account for 45 % of the cocaine 
clients in treatment. Almost one quarter (22 %) of primary 
crack clients also use heroin, and these clients report high 
levels of unemployment and homelessness (104). 
Overall, two main groups of cocaine clients have been 
identified in treatment: socially integrated individuals 
using powder cocaine; and a more marginalised group of 
clients, using cocaine, often crack-cocaine, in combination 
with opioids. The first group typically reports snorting the 
drug, and sometimes consuming it in conjunction with 
other substances such as alcohol or cannabis, but not 
with opioids. Some members of this group are referred 
to treatment by the criminal justice system. The second 
group often reports injecting drugs, uses both cocaine and 
opioids, sometimes smokes crack, and presents precarious 
health and social conditions. It includes former heroin 
users re-entering drug treatment for cocaine use.
Treatment and harm reduction 
Treatment
In Europe, public drug treatment facilities are mostly 
oriented towards the needs of opioid users, and those 
focusing on the treatment of cocaine users are rare and 
often private. Some countries (e.g. Ireland, Italy, Spain), 
however, have implemented strategies or treatment 
programmes targeting cocaine users, and France is in the 
process of developing such programmes. 
The heterogeneity of cocaine users, and of their problems 
and needs, complicates the organisation and delivery 
of treatment services to those who need them. Certain 
populations of cocaine users are hard to reach, and 
therefore difficult to get into treatment. For instance, 
marginalised cocaine injectors and crack users often 
do not seek treatment voluntarily. For this reason, in 
Ireland outreach work and other interventions are 
recommended in order to attract into treatment users who 
would otherwise not be reached (Connolly et al., 2008). 
Outreach treatment programmes can also be beneficial 
for certain groups. An example of this is provided by 
Crack cocaine use in Europe
Cocaine is available in two forms in Europe: as cocaine 
powder (cocaine HCI, a hydrochloride salt) and the less 
commonly used crack cocaine (a free base). Crack is 
typically smoked, and is known for inducing an intense 
‘high’ that may lead to problematic patterns of use. In 
general, it is manufactured from cocaine HCl in locations 
close to where it is retailed and used.
The use of crack started to spread in the United States in 
the mid-1980s, mainly in deprived inner city sections of 
metropolitan areas, disproportionately affecting ethnic 
minorities. It has been feared that a similar phenomenon 
could happen in Europe but, until now, a serious crack 
epidemic has not been observed. 
Crack cocaine is, however, used in some European 
cities, although it is difficult to know the exact size of the 
phenomenon. Reports on the situation in London (GLADA, 
2004) and Dublin (Connolly et al., 2008) also suggest 
that increases can take place. In London, crack use is 
considered to be a major component of the city’s drugs 
problem, and its increase since the mid 1990s is mainly 
attributed to a growing population of opioid users who 
also use crack. 
Most of the treatment demands related to crack and most 
of the seizures of the drug are reported by the United 
Kingdom. One study has estimated the number of problem 
crack cocaine users in England at 5.2–5.6 per 1 000 adult 
population in 2006–07. Sizable crack problems have also 
been reported by cities in other European countries.
Crack use occurs mainly among marginalised and 
disadvantaged groups such as sex workers and problem 
opioid users, and some countries report it among specific 
ethnic minorities (e.g. France, Netherlands, United 
Kingdom). Among socially integrated individuals, including 
regular powder cocaine users, crack use is very unusual 
(Prinzleve et al., 2004). Nevertheless, the persistence of 
crack use in some groups and cities underlines the risk of 
its spread to larger populations.
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a Dutch study targeting marginalised crack users. The 
treatment programme achieved high levels of compliance 
and treatment satisfaction among its clients. Those treated 
reported improvements in health, living conditions, family 
and social relations and psychiatric status (Henskens et al., 
2008). 
Socially integrated cocaine users may also be difficult to 
get into treatment. For example, they may not find their 
needs addressed in treatment services where opioid 
users are the main clientele. Measures to overcome these 
problems are reported by some countries. For example, 
in Italy, ‘Progetto nazionale cocaina’, launched in 2007, 
provides specialised services with opening times more 
suitable for socially integrated cocaine users and their 
families (e.g. after work). A similar approach is also 
reported in Ireland, where specific programmes are 
developed to attract powder cocaine users. 
It is also important to maintain problem cocaine and crack 
users in treatment, as intensive cocaine use is associated 
with behavioural, social and psychological dysfunctions 
(e.g. impulsive and aggressive behaviour) and, in 
some groups, with chaotic lifestyles and severe mental 
and physical deterioration. Thus, maintaining regular 
attendance at therapy sessions and meaningful therapeutic 
dialogue is reported as difficult by professionals (Connolly 
et al., 2008). Use of cocaine can also disrupt treatment for 
dependence on other drugs and jeopardise successfully 
achieved abstinence from heroin. In Germany for 
example, concomitant cocaine use has been identified 
as a decisive factor in those dropping out of opioid 
substitution treatment.
Attracting and maintaining users in treatment is also 
difficult in a context where there is no particular 
psychosocial intervention with strong evidence of 
effectiveness and no effective pharmacotherapy available 
to help dependent users maintain abstinence or reduce 
use during this period. 
These difficulties can be tackled by the development 
of specific treatment programmes and training courses 
adapted to the problems associated with cocaine and 
crack use. Cocaine-specific training for treatment staff 
is reported from Ireland, Italy and the United Kingdom. 
In addition, 11 Member States, including all those with 
high levels of cocaine use and treatment demand, report 
that specific treatment programmes, alongside traditional 
treatment services, are available for cocaine or crack 
cocaine users. However, while national experts from Italy, 
Portugal, Slovenia and the United Kingdom estimated 
that these programmes were available to a majority of 
cocaine users in need of treatment, experts from Denmark, 
Germany, Ireland, Austria, the Netherlands, France 
and Spain estimated that they were available only to a 
minority of them. 
Following a period during which almost all the research 
originated in the United States, several studies on the 
treatment of cocaine dependence are now carried out 
in Europe. In the United Kingdom, a clinical trial is 
investigating the effectiveness of cognitive behavioural 
therapy in conjunction with contingency management (see 
EMCDDA, 2008b) in primary cocaine users. According to 
a recent Cochrane review, this combination has yielded 
the best results for the treatment of stimulant dependence 
(Knapp et al., 2007). Another clinical trial in the United 
Kingdom is investigating the efficacy of modafinil, in 
conjunction with voucher-based contingency management, 
among patients receiving opioid substitution treatment 
and using crack cocaine. Modafinil has already shown 
therapeutic potential in several trials as a substitute agent 
for stimulant dependence. 
In the Netherlands, five clinical trials are currently 
investigating the efficacy of a number of pharmaceutical 
agents for treating cocaine dependence, including 
dexamphetamine and modafinil. Another Dutch clinical 
trial investigated the combination of the community 
reinforcement approach with contingency management 
in opioid substitution clients with cocaine dependence. 
The results showed a significant reduction of cocaine 
consumption compared with the standard treatment.
Finally, a joint Spanish and Italian multi-site study is 
investigating the efficacy of the cocaine vaccine TA-CD. 
It is the largest trial conducted on this vaccine to date, 
with several hundred volunteers participating. Initial 
safety studies of the TA-CD vaccine in the US have shown 
reductions in the subjective effects of cocaine and in the 
use of the drug, and better treatment retention. 
Harm reduction
Harm-reduction interventions targeting problem crack 
and cocaine users is a new area of work in many 
Member States. One reason for the limited provision of 
interventions in this field, in particular for crack users, 
might be a lack of knowledge among key workers about 
the drug, the target group and their needs. 
Member States usually provide cocaine-injecting users 
with the same services and facilities as are provided 
to opioid users, including: recommendations for safer 
use, training for safer injecting, and needle and syringe 
programmes. However, cocaine injecting can be 
associated with higher risks of equipment sharing and 
with frequent injection, which can lead to vein collapse 
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and to injecting in higher-risk parts of the body (e.g. 
the legs, hands, feet and groin). Therefore, safer use 
recommendations should be adapted to these specific 
risks. In some countries (e.g. Belgium, France), clean crack 
pipes are also provided in some low-threshold agencies.
Harm-reduction interventions targeting cocaine users in 
recreational settings focus mainly on raising awareness. 
Programmes offer advice and information to young people 
on the risks associated with alcohol and drug use in general, 
usually including material on the risks of cocaine use. 
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Introduction
Heroin use, particularly injecting the drug, has been 
closely associated with problem drug use in Europe since 
the 1970s. Today, this drug still accounts for the greatest 
share of morbidity and mortality related to drug use in the 
European Union. A decline in heroin use and associated 
problems has been observed in the last 10 years, though 
more recent data suggest that, in some countries, the trend 
may have changed direction. In addition, reports of the 
use of synthetic opioids, such as fentanyl, and the injection 
of stimulant drugs, such as cocaine or amphetamines, 
reflect the increasingly multi-faceted nature of problem 
drug use in Europe.
Supply and availability
Two forms of imported heroin have historically been 
offered on the illicit drugs market in Europe: the commonly 
available brown heroin (its chemical base form), which 
comes mainly from Afghanistan; and white heroin (a salt 
form), which typically originates from south-east Asia, 
though this form is considerably less common (105). In 
addition, some opioid drugs are produced within Europe, 
principally home-made poppy products (e.g. poppy straw, 
poppy concentrate from crushed poppy stalks or heads) in 
some east European countries (e.g. Latvia, Lithuania).
Production and trafficking
Heroin consumed in Europe originates predominantly 
in Afghanistan, which accounts for most of the global 
illicit opium output. The other producing countries are 
Myanmar, which mainly supplies markets in east and 
south-east Asia, Pakistan, Laos, followed by Mexico and 
Colombia, which are considered the largest suppliers 
of heroin to the United States (UNODC, 2009). Global 
opium production is estimated to have decreased from 
a peak in 2007, mainly due to a decrease in Afghan 
production from 8 890 tonnes to some 8 000 tonnes in 
2008. The most recent estimate of global potential heroin 
production is 735 tonnes in 2007 (UNODC, 2009). The 
rising number of laboratories dismantled in Afghanistan 
over the last few years suggests that opium is increasingly 
being transformed into morphine or heroin in the country 
itself. However, large seizures of opium and morphine 
in neighbouring countries (Pakistan, Iran) indicate 
that significant processing is also taking place outside 
Afghanistan (CND, 2008; UNODC, 2009).
Heroin enters Europe mainly by two major trafficking 
routes: the historically important Balkan route and its 
several branches, following transit through Pakistan, 
Iran and Turkey, where the largest quantity is seized; 
and the ‘northern route’ via central Asia and the Russian 
Federation, with heroin trafficked for example to Poland 
directly by train (INCB, 2009a) or to Norway via 
Lithuania. Secondary trafficking routes were reported for 
south-west Asian heroin, for example from Afghanistan 
and Pakistan by air through countries in the Middle 
(105) For information on the sources of data for drug supply and availability, see p. 39.
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Table 9: Production, seizure, price and purity  
of heroin
Production and seizures Heroin
Global potential production estimate (tonnes) (1) 735
Global quantity seized 
Heroin (tonnes) 
Morphine (tonnes)
65
27
Quantity seized (tonnes) 
EU and Norway  
(Including Croatia and Turkey)
8.8
(22)
Number of seizures 
EU and Norway  
(Including Croatia and Turkey)
56 000
(58 000)
Price and purity in Europe Brown heroin
Mean retail price (EUR per gram)
Range
(Interquartile range) (2)
14–119
(35–77)
Mean purity (%)
Range
(Interquartile range) (2)
9–50
(16–27)
(1) The UNODC figure is based on its estimate of the global output of illicit 
opium (8 870 tonnes in 2008) (UNODC, 2009).
(2) Range of the middle half of the reported mean price or purity.
NB: Data are for 2007, except for the global potential production estimate.
Sources: UNODC World drug report (2009) for global values, Reitox national 
focal points for European data.
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(106) See Tables SZR-7 and SZR-8 in the 2009 statistical bulletin. Note that where data for 2007 is absent, the corresponding data for 2006 are used to 
estimate European totals. This analysis is preliminary as data for the United Kingdom are not yet available for 2007.
(107) See Tables PPP-2 and PPP-6 in the 2009 statistical bulletin for purity and price data.
East and East Africa to illicit markets in Europe (INCB, 
2009a; WCO, 2008). Heroin from south-west Asia is also 
smuggled directly to Europe (United Kingdom) by air from 
Pakistan. Within the European Union, the Netherlands 
and, to a lesser extent, Belgium play an important role as 
secondary distribution hubs (Europol, 2008).
Seizures
Worldwide reported seizures of opium increased markedly 
in 2007 to 510 tonnes, with Iran accounting for 84 % of 
the total. Global reported seizures of morphine decreased 
sharply to 27 tonnes, while global heroin seizures 
increased slightly to 65 tonnes. The largest seizures of 
heroin were reported by Iran (25 % of the world total), 
followed by Turkey and Afghanistan (UNODC, 2009).
In Europe, an estimated 58 000 seizures resulted in the 
interception of 22 tonnes of heroin in 2007. The United 
Kingdom continued to report the highest number of 
seizures, while Turkey again reported the greatest quantity 
seized, with 13.2 tonnes recovered in 2007 (106). Data for 
the years 2002–07 from 25 reporting countries indicate 
that after a fall in the first year, the number of seizures has 
increased steadily since 2003. The overall trend in the 
quantity of heroin intercepted in Turkey differs from that 
observed in the European Union. While Turkey reported a 
five-fold increase in the quantity of heroin seized between 
2002 and 2007, the amount seized in the European Union 
has shown an overall decline during this period, albeit 
with an increase from 2006 to 2007.
Global seizures of acetic anhydride (used to manufacture 
heroin) increased to 56 300 litres in 2007, with almost 
half of it recovered in Russia (25 000 litres), followed by 
Turkey (13 300 litres) and Slovenia (6 500 litres) (INCB, 
2009b). The INCB estimates that ‘almost 80 %’ of the 
acetic anhydride used in Afghan heroin laboratories is 
smuggled through eastern and south-eastern Europe, and 
encourages the EU Commission and EU Member States to 
prevent the diversion of acetic anhydride from the internal 
market (INCB, 2009a). 
Purity and price
In 2007, for most reporting countries the mean purity of 
brown heroin tested ranged between 15 % and 30 %, 
although values under 15 % were reported in France 
(12 %) and Austria (9 %), and higher ones in the United 
Kingdom (50 %) and Norway (35 %). The typical purity of 
white heroin was generally higher (30–50 %) in the few 
European countries reporting data (107).
The retail price of brown heroin continued to be higher 
in the Nordic countries than in the rest of Europe, with 
Sweden reporting a mean price of EUR 119 per gram 
and Denmark EUR 96. In 10 other countries, the retail 
price of brown heroin ranged between EUR 30 and 
EUR 80 per gram, while in Turkey the mean price for 
a gram of the substance was EUR 15. Over the period 
2002–07, the retail price of brown heroin fell in seven 
of the 12 European countries reporting time trends, 
and increased in five. The retail price of white heroin 
is reported only by a few European countries, where it 
ranged between EUR 31 and EUR 151 per gram. 
Prevalence estimates of problem opioid use 
Data in this section are derived from the EMCDDA 
problem drug use (PDU) indicator, which includes mainly 
injecting drug use and the use of opioids, although in a 
few countries users of amphetamines or cocaine constitute 
an important component. It is worth noting that many 
countries report that most ‘problem opioid users’ could be 
described as polydrug users who also use opioids. Given 
the relatively low prevalence and the hidden nature of this 
Heroin prices at different levels of the market
Monitoring drug prices is an important tool for 
understanding drug markets. The EMCDDA collects data 
on retail prices, usually expressed in euros per gram, dose 
or pill. Based on this information, it is possible to estimate 
the typical price paid by a user to obtain a given drug in 
a European country. Changes in prices over time can point 
to possible changes in the supply of or demand for drugs. 
Information on wholesale prices, that is the price paid by 
drug dealers to the major distributors in the market where 
the drug is consumed, is another useful indicator that can 
allow insights into the profits of the market. 
Comparable data on both wholesale and retail prices 
for 2007 are available for only a few countries (Czech 
Republic, Germany, Spain, Romania, United Kingdom). 
Among these countries, the reported wholesale price of 
heroin ranges from EUR 12.5 to EUR 35.8 per gram, and 
the mean retail price, where available, ranges from EUR 
36 to EUR 62.7. At both wholesale and retail levels of 
the market, the lowest prices are reported for Romania 
and the highest for Spain. The ratio between retail and 
wholesale price also varies considerably, from 1.6:1 in the 
Czech Republic to 2.8:1 in the United Kingdom. Possible 
differences in drug purity, either between countries, market 
levels or over time, necessitate caution when making 
comparisons. Nonetheless, analysis in this area can be 
informative, especially in respect to trends over time as it 
can point to important changes taking place in the market.
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(108) This estimate has been adjusted from 1.5 to 1.4 million on the basis of new data. Because of large confidence intervals and the fact that the estimate 
is based on data from different years, it is not possible to conclude that the new estimate indicates a decrease in the prevalence of problem opioid 
use in Europe. 
(109) See Table TDI-5 (part ii) in the 2009 statistical bulletin. 
(110) See Table TDI-113 in the 2009 statistical bulletin.
(111) See ‘Misuse of prescription opioids’, p. 76.
(112) See Table TDI-38 in the 2009 statistical bulletin.
(113) See the 2009 ‘Selected issue’ on polydrug use.
type of drug use, statistical extrapolations are required 
to obtain prevalence estimates from the available data 
sources. 
Estimates of the prevalence of problem opioid use in 
European countries during the period 2002–07 range 
roughly between one and six cases per 1 000 population 
aged 15–64; overall prevalence of problem drug use is 
estimated to range from under three cases to 10 cases 
per 1 000. The countries reporting the lowest well-
documented estimates of problem opioid use are the 
Czech Republic, Latvia, Poland and Finland (though both 
the Czech Republic and Finland have large numbers 
of problem users of amphetamines), while the highest 
estimates are reported by Malta, Italy, Austria and Spain 
(Figure 10). 
The average prevalence of problem opioid use in the 
countries providing data is estimated to be between 3.6 
and 4.6 cases per 1 000 of the population aged 15–64. 
Assuming that this reflects the EU as a whole, it implies 
some 1.4 million (1.2–1.5 million) problem opioid users in 
the EU and Norway in 2007 (108). Problem opioid users 
who are in prisons, especially those with longer sentences, 
may be under-represented in this estimate.
Opioid users in treatment 
Opioids, mainly heroin, continue to be cited as the 
principal drug by the majority of those seeking treatment 
in Europe. However, considerable differences exist across 
Europe in the proportion of drug users entering treatment 
for problems related to these drugs; with opioid clients 
accounting for more than 90 % of those entering treatment 
in Bulgaria and Slovenia, between 50 % and 90 % in 
15 countries, and between 10 % and 49 % in a further 
nine (109). Overall, of the around 325 000 treatment 
entries for which the primary drug is known, 49 % cited 
heroin as their primary drug; if other opioids are included, 
this figure rises to 55 % of these clients (110). In some 
countries, both the proportion and the number of treatment 
entries related to opioids other than heroin have increased 
in recent years (111).
Many opioid users are enrolled in programmes providing 
long-term care. This is reflected in a higher proportion 
of primary opioid users among drug users already in 
treatment. A recent analysis of data on clients in drug 
treatment in 14 countries found that primary opioid users 
accounted for 61 % of all drug clients in treatment, but 
only for 38 % of clients entering treatment for the first 
time (112). The percentage of primary opioid users among 
those clients who were in treatment for more than 1 year 
was reported to be over 50 % in all countries participating 
in the study. 
Clients entering treatment for primary opioid use often 
report the use of other drugs. In 2006, an analysis of data 
from 14 countries found that 59 % of heroin clients use a 
secondary drug, mainly cocaine (28 %), cannabis (14 %) 
and alcohol (7 %) (113).
Figure 10: Estimates of the annual prevalence of problem opioid 
use (cases per 1 000 population aged 15–64)
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NB: The symbol indicates a point estimate; a bar indicates an 
estimation uncertainty interval: a 95 % confidence interval, 
or one based on sensitivity analysis. Target groups may vary 
slightly, owing to different estimation methods and data sources; 
therefore, comparisons should be made with caution. Non-
standard age ranges were used in the studies from Finland (15–
54), Malta (12–64) and Poland (all ages). All three rates were 
adjusted to the population aged 15–64, assuming that drug 
use in other age groups will be negligible. For Germany and 
Cyprus, the interval represents the highest and lowest bounds of 
all existing estimates, and the point estimate a simple average 
of the midpoints. Methods of estimation are abbreviated: CR = 
capture–recapture; TM = treatment multiplier; MI = multivariate 
indicator; MM = mortality multiplier; CM = combined methods; 
OT = other methods. See Figure PDU-1 (part ii) in the 2009 
statistical bulletin for further details.
Sources: Reitox national focal points.
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(114) See Tables PDU-6 (part ii) and PDU-102 in the 2009 statistical bulletin for full information, including confidence intervals.
(115) See Table TDI-3 in the 2009 statistical bulletin.
(116) See Table DRD-2 (part i) in the 2009 statistical bulletin.
Trends in problem opioid use
The limited number of repeated estimates of the incidence 
and prevalence of problem opioid use, together with 
the statistical uncertainty around individual estimates, 
contributes to the difficulty of monitoring time trends. Data 
from nine countries with repeated prevalence estimates 
during the period 2002–07 suggest a relatively stable 
situation. An apparent increase observed in Austria until 
the year 2005 has not been confirmed in recent data. 
Elsewhere, information exists that may point to recent 
changes. In Cyprus, an estimate made in 2007 indicates 
that there has been a significant increase in problem 
opioid use, which has been linked with an increase in 
foreign nationals in treatment (114). Information from the 
French ‘TREND’ system, which relies both on qualitative 
and quantitative data, points to the diffusion of heroin to 
new groups of users, which worryingly includes socially 
integrated individuals and visitors to ‘techno’ parties. 
Where adequate and up to date estimates of the 
incidence and prevalence of problem opioid use are 
not available, it may still be possible to analyse trends 
over time using other, mainly indirect, indicators such 
as treatment demand data. Based on a sample of 
19 countries, the overall number of primary heroin users 
entering treatment increased between 2002 and 2007. 
Focusing on a more recent time frame, users entering 
treatment for primary heroin use increased both in number 
and as a proportion of all drug clients in eight countries 
between 2006 and 2007. These increases often followed 
marked decreases in previous years. Furthermore, since as 
early as 2004, 10 countries report increases in both the 
number and proportion of new clients entering treatment 
with heroin as the primary drug (115). 
Other indicators support this analysis. Data on drug-
induced deaths in 2007, which are mostly associated 
with opioid use, provide no indication of a return to the 
decreasing trend observed until 2003 (see Chapter 7). 
More than half of the reporting countries recorded 
increasing numbers of drug-induced deaths between 2006 
and 2007 (116). Similarly, a decline noted in the number of 
heroin seizures in the European Union until 2003 has now 
been replaced by a steady increase. In the most recent 
data on drug law offences, an increase in the number of 
heroin-related cases may also be observed.
The available data suggest that the downward trend in 
opioid indicators observed until 2003 has levelled off. 
This is perhaps most clearly visible since 2003 among 
seizures and drug-induced deaths, and after 2004 in new 
treatment demands related to heroin use. These changes 
have occurred alongside increased opium production 
in Afghanistan, raising concerns that these events might 
be linked through increased availability of heroin on the 
European market. 
Injecting drug use
Prevalence of injecting drug use
Injecting drug users are among those at highest risk of 
experiencing health problems from their drug use, such 
as blood-borne infections (e.g. HIV/AIDS, hepatitis) or 
drug-induced deaths. Only 12 countries were able to 
provide recent estimates of the levels of injecting drug 
Incidence of problem opioid use
Monitoring the incidence of problem drug use — the 
number of individuals who start using a substance during 
a given year and who become problem drug users — is 
necessary in order to track trends in Europe’s drug situation 
and to devise suitable policies and interventions. 
The EMCDDA has been stimulating research into estimating 
the incidence of problem drug use and has recently 
published guidelines on this topic (Scalia Tomba et al., 
2008). It has also launched, in collaboration with the 
University of Zurich, a study to test a new ‘one-day’ 
method using the distribution of ‘latency time’ (time to 
treatment) in a cross-sectional sample of treated heroin 
users. The method uses a function that describes the 
probability of being in substitution treatment (General 
Inclusion Function, GIF) when no regulations restrict 
access to treatment, taking into account latency time, 
mortality and rates of drug use cessation. Estimates can be 
derived from treatment data for a single day, whereas the 
established methods need long time series covering at least 
8 to 10 years. 
The study was conducted in six EU Member States (Spain, 
Italy, Malta, Netherlands, Slovakia, United Kingdom) and 
suggested that the GIF method allows the estimation of 
incidence of problem heroin use, even with incomplete 
substitution treatment data sets. In at least five regions, the 
incidence estimates allowed the derivation of prevalence 
estimates that were in a good accordance with other 
existing estimates (e.g. by the capture–recapture method).
The GIF method seems to be robust and might, in addition 
to incidence estimates, also provide cost-effective estimates 
of problem opioid use prevalence as well as of substitution 
treatment coverage, and their change over time. Future 
work might include studies in other EU countries, analyses 
of spatial differences and by gender and routes of 
administration. 
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(117) See Figure PDU-2 in the 2009 statistical bulletin.
(118) See Table PDU-6 (part iii) in the 2009 statistical bulletin.
(119) See Figure PDU-3 in the 2009 statistical bulletin.
(120) See Tables PDU-104, TDI-5 and TDI-17 (part v) in the 2009 statistical bulletin.
(121) See Tables TDI-17 (part v) and TDI-38 in the 2009 statistical bulletin.
(122) See Tables TDI-4 and TDI-5 in the 2006 and 2009 statistical bulletins.
use (117), despite their importance for public health. 
Improving the level of information available on this special 
population continues to be an important challenge for the 
development of health monitoring systems in Europe. 
The available estimates suggest large differences 
between countries in the prevalence of injecting drug use. 
Estimates range from less than one to five cases per 1 000 
population aged 15–64 for most of the countries, with an 
exceptionally high level of 15 cases per 1 000 reported in 
Estonia. 
The lack of data makes drawing conclusions on time 
trends in the prevalence of injecting difficult, although the 
available data suggest a stable situation in the Czech 
Republic, Greece, the United Kingdom and Norway (118). 
An increase was also observed in Cyprus.
Data from infectious disease surveys may also provide 
information on national differences and changes over time 
regarding drug injection. Comparisons between countries 
should, however, be made with caution due to the variety 
of recruitment settings used. Relatively high proportions 
(above 20 %) of new injecting drug users (injecting for less 
than 2 years) have been found in three countries, possibly 
indicating significant new recruitment into injecting. In 
10 other countries, this proportion was under 10 % (119). 
Another indicator of more recent initiation into injecting is 
the proportion of young injectors (under age 25) found in 
samples. These accounted for more than 40 % of injectors 
sampled in the Czech Republic, Estonia, Latvia, Lithuania, 
Austria, Romania and Slovakia, whereas less than 20 % of 
injectors sampled were under 25 years of age in 11 other 
countries. 
Injecting among opioid users 
Injecting is frequently reported as the usual mode of 
administration by opioid users entering treatment, 
accounting for over half of opioid clients in most countries, 
between 25 % and 50 % in seven countries and less than 
25 % in five countries. The lowest proportions of injectors 
among opioid users entering treatment are reported 
by Denmark and the Netherlands, and the highest by 
Lithuania, Latvia and Romania (120). Treatment reports 
also suggest that among opioid users, the popularity of 
injecting may vary considerably within countries. For 
example, in the autonomous communities of Spain the 
proportion of injectors among new opioid clients ranges 
from 0.9 % to 47.2 %.
Among opioid users entering treatment for the first 
time, the proportion reporting injecting the drug (42 %) 
is lower than that among all opioid users entering 
treatment (44 %). This is the case in almost all of the 
22 reporting countries. An analysis of the data on drug 
users in treatment in 14 countries found that injection 
among all drug users in treatment remains high, at 62 %, 
though there are some notable exceptions, such as the 
Netherlands with a value of 6.1 % (121).
The proportion of injectors among heroin users entering 
treatment continued to decrease in 2007. This trend is now 
evident in some countries where it had not previously been 
observed (e.g. Czech Republic, Germany). Between 2002 
and 2007, the proportion of injectors among primary 
opioid clients entering treatment has decreased in most 
countries, with statistically significant declines reported in 
13 countries. Two countries, however, report an increase 
over this period (Bulgaria, Slovakia) (122).
Other studies generally confirm a declining trend of 
injection among opioid users. In France, for example, a 
decrease in the prevalence of injecting has been observed 
in the treatment data since 2001, and studies reveal 
that initiation of heroin use has become increasingly 
EMCDDA ‘Selected issue’ on injecting drug use
Injecting drug use is one of the main determinants of 
serious public health problems among drug users, including 
HIV/AIDS, hepatitis C and overdose. Across Europe, the 
prevalence and trends of injecting drug use vary between 
Member States, and may change over time. Alternative 
routes of administration (e.g. smoking) may co-exist with 
drug injecting, and drug users may alter their route of 
administration. 
The ‘Selected issue’ focuses on the situation and trends 
of injecting drug use and on specific interventions that 
target injecting drug users in Europe. The publication also 
discusses the possible mechanisms behind decreases of 
drug injecting observed in some countries or regions, 
and why levels may still be high (or increasing) in other 
regions. It also discusses interventions and policies that aim 
to reduce injecting and those that may promote users to 
adopt less harmful routes of administration.
This ‘Selected issue’ is available in print and on the 
Internet in English only (http://www.emcdda.europa.
eu/publications/selected-issues/injecting-drug-use) from 
December 2009.
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(123) See Tables TDI-10, TDI-32 and TDI-103 in the 2009 statistical bulletin. 
(124) See Tables TDI-5 and TDI-21 in the 2009 statistical bulletin.
(125) See also ‘Co-morbidity: drug use and mental disorders’.
(126) See Tables TDI-11, TDI-33, TDI-107 and TDI-109 in the 2009 statistical bulletin.
associated with snorting, and injection now appears to 
occur at a later stage of the drug using career than it did 
in the past. 
Treatment of problem opioid use
The mean age of clients entering outpatient treatment for 
primary opioid use is 33 years and almost all countries 
have reported an increase since 2003 (123). Female clients, 
opioid users entering treatment for the first time and those 
in the Member States that have joined the EU since 2004 
are on average younger than their counterparts. 
Female drug users are identified as being a particularly 
vulnerable group. Overall, the male to female ratio among 
opioid clients is 3.5:1, though females make up a higher 
proportion of opioid clients in northern countries (e.g. 
Sweden, Finland) and a lower proportion in southern 
countries (e.g. Greece, Italy, Portugal) (124).
Opioid users entering treatment report higher rates 
of unemployment and lower levels of educational 
attainment than other clients (see Chapter 2). High levels 
of psychiatric disorders are reported  in this population; 
for example an Italian study found that most (72 %) drug 
treatment clients with a concomitant psychiatric morbidity 
were primary opioid users (125).
Almost all opioid users entering treatment report initiation 
before the age of 30 and about half before the age of 20. 
An average time lag of about 8 years is reported between 
first use of opioids and first contact with drug treatment (126).
Misuse of prescription opioids
Opioid analgesics are the most powerful drugs available 
for the management of severe and chronic pain. Opioids 
are also used as substitution drugs in the management 
of opioid dependence. These drugs, available on 
prescription, can be misused and this may lead to adverse 
health effects such as dependence, overdose and harms 
associated with injection. Prescription opioids may enter 
the illicit drug market through the diversion of substitution 
drugs from their proper use. Internet pharmacies seem 
also to play a substantial role in the availability of 
prescription opioids in the United States (INCB, 2009a), 
but their role in Europe appears to be limited. In Europe, 
the expansion in the prescription of substitution drugs to 
opioid-dependent drug users has been accompanied by 
increasing reports of the misuse of these drugs.
Opioids other than heroin are reported as the primary drug 
by about 5 % (17 810) of clients entering drug treatment 
in Europe. The most frequently reported substances are: 
buprenorphine, which in Finland is recorded as the primary 
drug for 41 % of all treatment demands and in France 
for 7 %; methadone, which accounts for 18.5 % of all 
treatment demands in Denmark; and other prescription 
opioids in Latvia, Austria and Sweden, where they account 
for between 5 % and 15 % of all treatment demands (1). 
The Czech Republic also reported an estimated 4 250 
problem buprenorphine users in 2007. This mainly reflected 
a shift in the substances used by problem heroin users, but 
not an increase in the overall prevalence of problem opioid 
use. The German Phar-Mon system, which monitors a wide 
range of medications that have potential for misuse, also 
recorded an increase in the misuse of prescription opioids, 
where substitution drugs play a more important role than 
analgesics (Roesner and Küfner, 2007).
The misuse of prescription opioids raises important issues 
regarding the prevention of diversion of substitution drugs 
and opioid analgesics to the illicit market. At the same 
time, care must be taken to ensure that the legitimate use of 
these substances is not compromised (Cherny et al., 2006).
(1) See Table TDI-113 in the 2009 statistical bulletin.
Co-morbidity: drug use and mental disorders
Co-morbidity is the often unrecognised co-occurrence 
of drug use problems and psychiatric disorders in the 
same individual. Studies have identified both an elevated 
prevalence of psychiatric problems among patients in drug 
treatment and an elevated prevalence of drug problems 
among patients in psychiatric services (EMCDDA, 2005). 
The mental disorders most commonly reported among drug 
users in Europe include depression, anxiety, schizophrenia, 
personality disorders, attention deficit and hyperactivity. 
Specific treatment for drug users with co-morbidity in 
Europe remains limited. National experts report that 
specific programmes exist in 18 countries, but in 14 of 
these they are available only to a minority of clients in 
need. In seven other countries, there are no dedicated 
programmes at all, but five of them plan to develop such 
programmes in the next 3 years. 
A European prospective multi-centre study (Isadora) has 
recently been conducted involving dual-diagnosis patients 
from acute psychiatric wards (1). Its findings highlight the 
difficulties of comparative analyses in this area, underlining 
the need for a more harmonised approach for diagnosis, 
treatment and study of co-morbidity in Europe (Baldacchino 
et al., 2009). 
(1) http://isadora.advsh.net/
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Treatment provision and coverage
Treatment for opioid users is mostly conducted in 
outpatient settings, which can include specialist centres, 
general practitioners and low-threshold facilities (see 
Chapter 2). In a few countries, inpatient centres are a 
major component of the drug treatment system, notably 
in Bulgaria, Greece, Finland and Sweden (127). The range 
of options available in Europe for the treatment of opioid 
dependence is broad and increasingly differentiated, 
though it varies geographically in terms of accessibility 
and coverage. Drug-free and substitution treatment for 
opioid use are available in all EU Member States, Croatia 
and Norway. In Turkey, the future use of substitution 
treatment is currently under study. 
Drug-free treatment is a therapeutic approach, which 
generally requires individuals to abstain from all 
substances, including substitution medication. Patients 
participate in daily activities and receive intensive 
psychological support. While drug-free treatment can take 
place in both outpatient and inpatient settings, the type 
most commonly reported by Member States is residential 
programmes that apply therapeutic community principles 
or the Minnesota model.
Substitution treatment, generally integrated with 
psychosocial care, is typically provided at specialised 
outpatient centres. Thirteen countries report that 
substitution treatment is also provided by general 
practitioners, usually under shared-care arrangements with 
specialised treatment centres (see Figure 11). In the Czech 
Republic, France, the Netherlands, Portugal, the United 
Kingdom and Croatia, any general practitioner may 
provide substitution treatment, while in Belgium, Denmark, 
Germany, Ireland, Luxembourg, Austria and Norway, 
only those that are specifically trained or accredited are 
entitled to provide it. A number of countries report that, 
by improving geographical coverage, reducing waiting 
times and facilitating access to treatment, the involvement 
of general practitioners has helped to improve the 
availability and coverage of substitution treatment (Czech 
Republic, Germany, France, Austria, United Kingdom).
According to expert estimates, the availability of opioid 
substitution treatment is relatively high in 16 countries, 
where it is available to at least half of opioid users (see 
Chapter 2). In those countries, drug-free treatment is 
the treatment of choice for between 10 % and 25 % of 
opioid users. In a further 10 countries (Estonia, Greece, 
Latvia, Lithuania, Hungary, Poland, Romania, Slovakia, 
Finland, Norway), substitution treatment is estimated to 
be available to a minority of opioid users. This might be 
because drug-free treatment is the treatment of choice, 
especially for younger or first-time clients, or due to 
difficulties in gaining access to substitution treatment. 
In Greece for example, the waiting time for opioid 
substitution treatment is on average more than 3 years.  
Provision of psychosocial care is considered essential 
to ensuring the effectiveness of substitution treatment. 
According to expert estimates, it is provided to almost 
all substitution clients in seven countries (Greece, Italy, 
Latvia, Portugal, Romania, Slovakia, United Kingdom) 
and to a majority of them in a further 14 countries. In four 
countries (Estonia, Luxembourg, Hungary, Netherlands), it 
is estimated to be provided only to a minority of clients in 
substitution treatment. 
The total number of clients receiving substitution treatment 
in the EU, Croatia and Norway is estimated to be about 
650 000 in 2007, up from 560 000 in 2005 and 500 000 
in 2003. The available data suggest an increase in all 
countries except Spain, where the numbers receiving 
substitution treatment have been declining since 2002, and 
France, Luxembourg, Hungary and the Netherlands, where 
small decreases or stable figures are reported. Among the 
countries that have expanded their provision of substitution 
treatment, the highest rates of increase have been seen 
in Estonia, where the number of clients increased within 
5 years from 60 to more than 1 000, and Bulgaria, where 
the number of treatment places increased from 380 to 
nearly 3 000 between 2003 and 2007. The number of 
clients in substitution treatment has also more than doubled 
Figure 11: Provision of opioid substitution treatment by office-
based general practitioners (GPs)
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Role of GPs in provision of
substitution treatment
NB: The percentage of substitution treatment clients receiving 
their treatment from general practitioners in the Community is 
indicated on the map.
Sources: Reitox national focal points.
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(128) See Figure HSR-1 in the 2009 statistical bulletin. 
over this period in the Czech Republic, Latvia, Finland and 
Norway, while increases in excess of 40 % are reported by 
Greece, Poland, Portugal, Romania and Sweden.
A simple comparison of the estimated number of problem 
opioid users and of delivered treatments suggests that 
more than 40 % could be receiving substitution treatment. 
However, there is still a lack of precision in both data 
sets, and this estimate should be viewed with caution. 
Comparisons are difficult for the same reason, though 
available data indicate that the proportion of problem 
opioid users receiving substitution treatment differs 
considerably between countries, with estimated rates 
ranging from 5 % to over 50 % (128).
Most substitution clients in Europe receive methadone 
(70 %), but the number of countries where it is the only 
prescribed substance is decreasing, with buprenorphine 
now available in all but four EU Member States (Bulgaria, 
Spain, Hungary, Poland). In the Czech Republic, 
France, Latvia and Sweden, more than 50 % of those 
on substitution treatment are prescribed buprenorphine. 
Additional options include slow-release morphine 
(Bulgaria, Austria, Slovenia) and codeine (Germany, 
Austria, Cyprus). A new buprenorphine–naloxone 
combination was approved for the EU market in 2006 and 
is reported to have since been introduced in 11 countries. 
Six European countries also provide heroin-assisted 
treatment to users who do not benefit sufficiently from 
other treatments.
Treatment effectiveness, quality and standards 
Reviews of randomised controlled trials and observational 
studies conclude that substitution treatment with either 
methadone or buprenorphine can be effective in the 
management of opioid dependence. Overall, this type of 
treatment has been linked to a number of positive outcomes 
including: retention in treatment, reductions in illicit opioid 
use and injecting, reductions of mortality and criminal 
behaviour, and stabilisation and improvement of health 
and social conditions of chronic heroin users. In addition, 
recent randomised controlled trials have found heroin 
assisted treatment to be effective in reducing illicit drug 
use, improving physical or mental health and reducing 
criminal behaviour among clients considered as hard to 
treat or having failed with other treatment modalities.
Psychosocial and psychotherapeutic interventions 
combined with pharmacotherapy have also been shown 
to be effective in treatment outcome studies (Schulte et 
al., 2008). These approaches aim to increase treatment 
motivation, prevent relapse and reduce harm. In addition, 
they may provide advice and practical support to clients 
who have to address their housing, employment and 
family related problems in parallel to treating their opioid 
dependence. 
A set of minimum requirements and international 
guidelines for psychosocially assisted pharmacological 
treatment of persons dependent on opioids was recently 
developed by WHO (2009). This document is a response 
to a resolution from the United Nations Economic and 
Social Council (Ecosoc) and it is based on systematic 
reviews of the scientific literature and consultations with 
a range of renowned experts from different parts of the 
world. Guidelines for substitution treatment have also been 
developed by most European countries (see Chapter 2).
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Drug-related infectious diseases 
Infectious diseases such as HIV and hepatitis B and C are 
among the most serious health consequences of drug use. 
Even in countries where HIV prevalence in injecting drug 
users is low, other infectious diseases including hepatitis 
A, B and C, sexually transmitted diseases, tuberculosis, 
tetanus, botulism and human T-lymphotropic virus may 
disproportionately affect drug users. The EMCDDA is 
systematically monitoring HIV and hepatitis B and C 
among injecting drug users (prevalence of antibodies, or 
other specific markers in the case of hepatitis B) (129). 
HIV and AIDS
By the end of 2007, the incidence of reported HIV 
infection among injecting drug users appears to have 
remained low in most countries of the European Union, 
and the overall EU situation appears relatively positive in 
a global context. This may, at least partly, follow from the 
increased availability of prevention, treatment and harm-
reduction measures, including substitution treatment and 
needle and syringe programmes. Other factors, such as 
the decline in injecting drug use that has been reported 
in some countries, may also have played an important 
role. Nonetheless, in some parts of Europe, data suggest 
that HIV transmission related to injecting drug use still 
continued at relatively high rates in 2007, underlining the 
need to ensure the coverage and effectiveness of local 
prevention practice.
Trends in HIV infection 
Data on newly reported cases related to injecting drug 
use for 2007 suggest that infection rates are still generally 
falling in the European Union, following the peak in 
2001–02, which was due to outbreaks in Estonia, Latvia 
and Lithuania (130). In 2007, the overall rate of newly 
reported infections among injecting drug users in the 24 
EU Member States for which national data are available 
was 4.7 cases per million population, slightly down from 
5.0 in 2006 (131). Of the three countries reporting the 
highest rates of newly reported infections, Portugal and 
Estonia continued their downward trends, although in 
Portugal this trend seems to be levelling off. In contrast, in 
Latvia an increase from 47.1 cases per million population 
in 2006 to 58.7 cases per million in 2007 was reported 
(Figure 12). 
Overall, marked increases in new HIV infection have not 
been observed between 2002 and 2007, and reported 
rates remain low. However, in Bulgaria and Sweden, the 
rate of newly reported infections accelerated — from 0.3 
new cases per million population in 2002 to 5.6 cases in 
2007 in Bulgaria, and in Sweden from 3.5 new cases per 
million in 2002 to a peak of 6.7 cases in 2007 before 
returning to previous levels in 2008 — suggesting the 
continued potential for HIV outbreaks among injecting 
drug users.
Trend data from HIV prevalence monitoring in samples 
of injecting drug users are an important complement 
to data from HIV-case reporting. Prevalence data are 
(129) For details on methods and definitions, see the 2009 statistical bulletin. 
(130) See Table INF-104 in the 2009 statistical bulletin.
(131) National data are not available for Spain, Italy and Austria. 
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Figure 12: Trends in five EU Member States with high rates of 
newly reported HIV infections in injecting drug users
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NB: For Estonia, the value for 2002 is off-scale (516 cases per 
million). For further information, see Table INF-104 in the 2009 
statistical bulletin.
Sources: ECDC and WHO Europe.
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(132) See Table INF-108 in the 2009 statistical bulletin.
(133) See Tables INF-109 and INF-110 in the 2009 statistical bulletin.
(134) See Figure INF-1 in the 2009 statistical bulletin.
(135) See Tables INF-111 to INF-113 in the 2009 statistical bulletin.
available from 25 countries over the period 2002–07 (132). 
In 11 countries, HIV prevalence remained unchanged 
during the period. In six countries (Bulgaria, Germany, 
Spain, Italy, Latvia, Portugal) HIV prevalence showed 
statistically significant decreases, all based on national 
samples. Regional increases were reported, however, in 
two of these countries: in Bulgaria, one city, Sofia; and in 
Italy, three out of 21 regions. In two countries (Lithuania, 
Poland) HIV prevalence showed statistically significant 
increases, both based on national samples.
The comparison of trends in newly reported infections 
related to injecting drug use with trends in HIV prevalence 
among injecting drug users suggests that the incidence of 
HIV infection related to injecting drug use is declining in 
most countries at national level. 
However, the high annual rate of new HIV diagnoses 
related to injecting drug use in Estonia, Latvia and 
Portugal suggests that transmission is still occurring in 
these countries at relatively high levels, even if the rates 
are now declining in Estonia and Portugal. For Estonia, 
recent transmission is supported by 2005 prevalence 
data, which suggest that around a third of new injecting 
drug users (those injecting for less than 2 years) were HIV 
positive. Further indications of ongoing HIV transmission 
are provided by reports of prevalence levels of over 5 % 
among young injecting drug users (samples of 50 or more 
injecting drug users under age 25) in several countries: 
Spain (national data, 2006), France (five cities, 2006), 
Estonia (two regions, 2005), Lithuania (one city, 2006) 
and Poland (one city, 2005) (133). 
AIDS incidence and access to HAART 
Information on the incidence of AIDS, though not a good 
indicator of HIV transmission, is important for showing the 
new occurrence of symptomatic disease. High incidence 
rates of AIDS in some European countries may indicate 
that many injecting drug users infected with HIV do not 
receive highly active antiretroviral treatment (HAART) at a 
sufficiently early stage in their infection to obtain maximum 
benefit from the treatment.
Estonia is the country with the highest incidence of AIDS 
related to injecting drug use, with an estimated 33.5 new 
cases per million population in 2007, up from 17.1 new 
cases per million in 2006. Relatively high levels of AIDS 
incidence are also reported for Latvia, Spain, Portugal 
and Lithuania: 13.2, 8.8, 8.6 and 6.2 new cases per 
million, respectively. Among these four countries, the trend 
is downward in Spain, Latvia and Portugal, but not in 
Lithuania (134).
Hepatitis B and C
While high prevalence levels of HIV infection are found 
only in some EU Member States, viral hepatitis and, in 
particular, infection caused by hepatitis C virus (HCV), is 
more highly prevalent in injecting drug users across Europe. 
HCV antibody levels among national samples of injecting 
drug users in 2006–07 vary from around 18 % to 95 %, 
with half of the countries reporting levels in excess of 40 %. 
Three countries (Bulgaria, Czech Republic, Slovenia) report 
a prevalence of under 25 % in national samples of injecting 
drug users (135); though infection rates at this level still 
constitute a significant public health problem.
Within countries, HCV prevalence levels can vary 
considerably, reflecting both regional differences and the 
characteristics of the sampled population. For example, in 
the United Kingdom, local studies report levels between 
HIV among injecting drug users in the European 
Union and neighbouring countries: increasing 
trends in the East
The HIV epidemic among injecting drug users continues to 
develop differently across Europe. In the countries of the 
European Union, the rates of reported newly diagnosed 
cases of HIV infection in injecting drug users are mostly 
at stable and low levels, or in decline. However, in 
many of the former Soviet republics, rates increased in 
2007 (Wiessing et al., 2008b), suggesting that existing 
prevention measures may be insufficient and in need of 
strengthening.
In those eastern countries where some declines had 
occurred since the peak year of 2001 (Russia, Belarus), new 
increases have been noted in more recent years. In 2007, 
newly diagnosed and reported rates of HIV infection among 
injecting drug users varied from zero in Turkmenistan to 80 
cases per million population in Kazakhstan and 152 cases 
per million in the Ukraine. The most recent figure for Russia 
is 78 cases per million in 2006. 
In absolute terms, Ukraine reports the largest number of 
newly reported cases of HIV among injecting drug users 
in 2007 (7 087 cases), followed by Uzbekistan (1 816 
cases) and Kazakhstan (1 246 cases), while in 2006, 
Russia reported 11 161 cases. Several other former 
Soviet republics, with overall lower numbers and rates, 
show an increasing trend in reported cases, suggesting 
that epidemics may be taking place among injecting 
drug users. These countries include Azerbaijan, Belarus, 
Georgia, Kyrgyzstan, Moldova and Tajikistan. 
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(136) See Figure INF-6 (part ii) and (part iii) in the 2009 statistical bulletin.
(137) See Table INF-115 in the 2009 statistical bulletin.
(138) See Tables INF-105 and INF-106 in the 2009 statistical bulletin.
(139) See Table HSR-6 in the 2009 statistical bulletin.
29 % and 60 %, while in Italy, different regional estimates 
range from around 36 % to 92 %. 
Recent studies (2006–07) show a wide range of 
prevalence levels among injecting drug users under 
25 years and those injecting for less than 2 years, 
suggesting different levels of HCV incidence in those 
populations across Europe (136). Nonetheless, these studies 
also indicate that many injectors contract the virus early 
in their injecting career and that therefore there is only a 
small time window for initiating effective HCV prevention 
measures. 
The prevalence of antibodies to hepatitis B virus (HBV) 
also varies to a great extent, possibly partly due to 
differences in vaccination levels, although other factors 
may play a role. The most complete data set available is 
that for the antibody to the hepatitis B core antigen (anti-
HBc), which indicates a history of infection. For 2006–07, 
three of the 10 countries providing data on injecting drug 
users report anti-HBc prevalence levels of over 40 % (137).
Trends over time in notified cases of hepatitis B and C 
show different pictures, but these are difficult to interpret. 
However, some insight into the epidemiology of these 
infections may be provided by the proportion of injecting 
drug users among all notified cases where risk factors 
are known (Wiessing et al., 2008a). For hepatitis B, the 
proportion of injecting drug users has declined between 
2002 and 2007 in four out of 17 countries. In the case 
of hepatitis C, the proportion of injecting drug users 
among notified cases has declined in seven countries 
between 2002 and 2007, and has increased in four other 
countries (Czech Republic, Luxembourg, Malta, United 
Kingdom) (138).
Preventing and responding to infectious 
diseases 
Seventeen EU Member States and Turkey report that the 
prevention of infectious diseases among drug users is part 
of their national drug strategy, and six other countries 
report that it is the subject of a specific strategy. Ten of 
these 23 countries also report existing strategies to prevent 
infectious diseases at local or regional level.
EU Member States respond to the spread of infectious 
diseases among drug users by a combination of 
approaches, including: drug treatment; the provision 
of sterile injection equipment; and community-based 
activities that provide information, education, testing and 
behavioural interventions, often through outreach or low-
threshold agencies. Experts from 27 countries reported 
on the level of priority given to selected interventions to 
prevent infectious diseases among drug users (139). Access 
to sterile injecting equipment through needle and syringe 
programmes is reported as a priority by 23 countries, 
testing and counselling for infectious diseases by 16 
countries and the dissemination of information, education 
and communication material by 14 countries.  
Access to sterile syringes is the most frequently reported 
priority, as was found in a similar exercise carried out 
in 2005. An increased number of countries now report 
infectious disease counselling and testing, and targeted 
hepatitis immunisation programmes as a priority.
Interventions
Research has shown that sustained treatment is associated 
with reductions in injecting drug use and related risk 
behaviours, and thereby with protection from HIV 
infection. In most European countries, harm reduction and 
treatment service provision have increased considerably 
since the mid-1990s (Hedrich et al., 2008b). Opioid 
Hepatitis C prevalence as a possible indicator of 
injection-related HIV risk
A group of modellers and epidemiologists brought together 
by the EMCDDA has examined the potential for using 
information on the prevalence of hepatitis C virus (HCV) 
among drug injectors as an indicator of HIV transmission 
risk. HCV is transmitted via needle sharing in similar ways 
to HIV. As HCV is much more infectious, it might reveal the 
overall level of risk behaviour, including needle sharing, 
paraphernalia sharing and changing of injecting partner, 
in populations of injecting drug users where HIV has not 
yet spread.
Analysis of paired HCV and HIV prevalence data has 
shown that HCV prevalence among injectors of up to about 
30 % (95 % confidence interval, 21–38 %) is associated 
with zero or very low prevalence of HIV. At higher levels of 
HCV prevalence, a linear relationship was found between 
HIV and HCV prevalence, and time series data suggest 
that the observed HIV prevalence increases at about half 
the rate of HCV prevalence. 
These results suggest that HCV prevalence could be used 
to help develop targeted prevention and harm-reduction 
interventions among injecting drug users. In addition, it 
might also be used to assess the risk of an HIV outbreak 
in countries where HIV prevalence among injecting drug 
users is still low.
Source: Vickerman et al. (submitted).
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(140) Experts from 26 EU countries, Turkey and Norway rated the level of provision of selected interventions to drug users.
(141) See Table HSR-5 (part i) and (part ii) in the 2009 statistical bulletin. 
(142) See Table HSR-5 (part ii) in the 2009 statistical bulletin. 
substitution treatment is available in all EU Member States, 
Croatia and Norway, but in several countries the provision 
of this intervention remains limited (see Chapters 2 and 6).
Individual counselling on infectious diseases is estimated 
by national experts to have been received in the last year 
by nearly all problem drug users in 17 countries (140). In 
12 countries, this was also the case for HCV testing, while 
experts in 11 countries estimated that most problem drug 
users received practical advice and training in safer use 
and injecting during the past year. Hepatitis B vaccination 
is integrated in the routine immunisation schedules of 
21 out of 28 reporting countries, and in 17 countries, 
specific vaccination programmes targeting drug users in 
the community also exist. Health education activities for 
drug users, involving peer educators, are also reported by 
17 countries.
Needle and syringe programmes exist in all EU Member 
States, Croatia and Norway. The programme in Cyprus, 
however, has hardly been used in 2007. In 15 countries, 
most injecting drug users are estimated to have received 
syringes from such a programme during the last 12 months 
at least once. In 11 countries, only a minority of injectors 
received syringes during the same period, despite nine of 
these countries listing access to sterile injecting equipment 
as a priority measure to prevent the spread of infectious 
diseases.
The number of syringes provided through needle and 
syringe programmes increased between 2005 and 2007 
in 18 of the 26 countries for which data are available. 
Numbers of syringes given out yearly per client varies 
considerably, with examples from around 50 syringes 
per needle and syringe programme clients in Croatia 
and Lithuania, to 200 in Finland and 300 in Romania in 
2007 (141).
The total number of syringes given out in 2007 was 33 % 
higher than in the year 2003 in the 14 countries for 
which reliable data or estimations are available. Ongoing 
increases over this period were reported from Belgium, 
Bulgaria, the Czech Republic, Estonia, Hungary, Austria, 
Slovakia and Finland. The number of syringes supplied in 
Latvia remained the same, while decreases were reported 
in Spain, Lithuania, Luxembourg, Portugal and Poland. 
Data provided from 15 countries show that more than 
125 000 persons have accessed agencies with needle 
and syringe programmes in 2007 (142). Information on 
client access is, however, not available for four of the 
largest EU Member States (Germany, Spain, Italy, United 
Kingdom). A national survey conducted in the 120 French 
‘CAARUD’ harm-reduction centres showed that they had 
been used by an estimated 40 000 individuals in 2007 
(Toufik et al., 2008). In the United Kingdom, a new needle 
exchange monitoring system was established in 2008. 
Low-threshold facilities can provide the opportunity to 
deliver primary health care services and harm reduction 
interventions to hard to reach populations. A recent 
evaluation of low-threshold health service centres 
targeting injecting drug users in Finland concluded that 
this combination of services had played a significant 
role in the prevention of infectious diseases. It was also 
considered as a cost-effective innovation, capable of 
operating within the country’s restrictive drug policy 
(Arponen et al., 2008). 
Treatment of injecting drug users with chronic 
hepatitis C
Up to 30 % of patients with untreated chronic hepatitis C 
will develop liver cirrhosis within 30 years, and the costs 
incurred in the management of end-stage liver disease are 
considerable (Jager et al., 2004). To reduce the burden of 
hepatitis C in Europe, it is essential to promote and expand 
access to treatment for the largest patient group — chronic 
carriers of the virus who are active drug injectors. 
Current treatments for chronic hepatitis C — a 6 to 
12 months course of combination therapy with long-
acting interferon and ribavirin — are effective with more 
than 50 % of patients achieving a sustained virological 
response. Although the number of long-term studies 
remains limited, available research has shown good 
compliance and success in antiviral treatment of injecting 
drug users (e.g. Moussalli et al., 2007). Cost-effectiveness 
of treating hepatitis C in prisons (Sutton et al., 2008) and 
the safety and effectiveness of the treatment for drug users 
with co-morbid psychiatric disorders have also been shown 
(Loftis et al., 2006).
Access of drug users to hepatitis C treatment, however, 
remains low. Reasons for this might include insufficient 
treatment capacity, lack of information about treatment 
options, or low prioritisation of drug users. Several EU 
countries, including Denmark, Germany, France, the 
Netherlands and the United Kingdom, have in recent years 
reviewed their policies in order to expand access to testing 
and treatment for chronic hepatitis C virus carriers who are 
active injecting drug users. 
Hepatitis C therapy in the context of drug addiction is 
sometimes challenging, but it can improve with carefully 
planned and organised clinical management and with 
the patients’ cooperation following informed consent. 
Multidisciplinary teams, which can manage drug 
dependence, liver treatment and co-morbid mental problems, 
improve treatment outcomes (Grebely et al., 2007).
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(143) See ‘Drug-related mortality: a complex concept’, in the 2008 annual report.
Needle and syringe schemes may also have a role in 
promoting good health. Training in health promotion, 
based on formal curricula or training handbooks, is 
offered to staff of needle and syringe programmes in 20 
countries and to pharmacists in nine countries. Guidelines 
for work in low-threshold settings, which cover topics such 
as infectious disease testing, syringe exchange, outreach 
work and peer training, are also reported in 11 EU 
Member States. 
Drug-related deaths and mortality
Drug use is one of the major causes of health problems 
and death among young people in Europe. This can be 
illustrated by an international study supported by the 
EMCDDA, which found that, in seven European urban 
areas, between 10 % and 23 % of mortality among those 
aged 15 to 49 could be attributed to opioid use (Bargagli 
et al., 2005). 
Drug-related mortality includes deaths that are directly 
caused by the pharmacological action of one or several 
substances (drug-induced deaths) and deaths that are 
indirectly caused by the use of drugs, often with other 
concurrent factors (e.g. accidents). Known causes of 
deaths include acute toxicity, traffic accidents in particular 
when combined with alcohol (EMCDDA, 2007c), violence, 
suicide among already vulnerable people, or chronic 
conditions due to repeated use (e.g. cardiovascular 
problems in cocaine users). While most drug-related 
deaths occur among problem drug users, some occur 
among other groups of users, including those using drugs 
only occasionally (143).
Drug-induced deaths
The EMCDDA definition of drug-induced deaths refers to 
those deaths that are directly caused (overdoses) by the 
consumption of one or more drugs, of which at least one 
is an illicit drug. The number of deaths can be influenced 
Figure 13: Mortality rates among all adults (15–64 years) due to drug-induced deaths
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NB: For the Czech Republic, EMCDDA Selection D was used instead of the national definition; for the United Kingdom, the drug strategy definition 
was used; for Romania, data refer only to Bucharest and several counties in the competence area of the Toxicology Laboratory of Bucharest; for 
Portugal, data include all cases in which illicit drugs were identified in post-mortem analyses, and are likely to produce an overestimate compared 
to Selection D. The calculations of population mortality rates are based on national populations for 2006 as reported by Eurostat. Comparisons 
of population rates should be made with caution, as there are some differences in case definitions and quality of reporting. For more information 
on the data see Figure DRD-7 (part i) in the 2009 statistical bulletin.
Sources: Reitox national reports (2008), taken from national mortality registries or special registries (forensic or police) and Eurostat.
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(144) For detailed methodological information see the 2009 statistical bulletin.
(145) See Figure DRD-7 (part i) and Tables DRD-5 (part ii) and DRD-107 (part i) in the 2009 statistical bulletin.
(146) As most cases reported to the EMCDDA are opioid overdoses (mainly heroin), general characteristics of reported drug-induced deaths are used for 
description of opioid cases.  
See Figure DRD-1 in the 2009 statistical bulletin.
(147) See Figures DRD-2 and DRD-3 and Table DRD-1 (part i) in the 2009 statistical bulletin.
by factors such as the prevalence and patterns of drug use 
(injection, polydrug use), the age and the co-morbidities 
of drug users, and the availability of treatment and 
emergency services. 
Improvements in the reliability of European data have 
allowed better descriptions of European and national 
trends, and most countries have now adopted a 
case definition in line with that of the EMCDDA (144). 
Nevertheless, differences between countries in the quality 
of case ascertainment, reporting to national mortality 
registries and reporting to the EMCDDA mean that 
comparisons should be made with caution. 
During the period 1990–2006, between 6 400 and 
8 500 drug-induced deaths were reported each year by 
EU Member States, Croatia, Norway and Turkey, adding 
up to more than 135 000 deaths. In 2006, the United 
Kingdom and Germany accounted for half of all reported 
deaths. Population mortality rates due to drug-induced 
death vary widely between countries, ranging from 3 
to over 85 deaths per million population aged 15–64 
years, with an average of 22 deaths per million in Europe. 
Rates of over 20 deaths per million are found in 17 out 
of 30 European countries, and rates of over 40 deaths 
per million in six countries (Figure 13). Among Europeans 
aged 15–39 years, drug overdose accounted for 4 % of 
all deaths (145). 
Deaths related to opioids
Heroin
Opioids, mainly heroin or its metabolites, are present in 
the majority of drug-induced deaths reported in Europe. 
In the 22 countries providing data, opioids accounted 
for 35 % to almost 100 % of all cases, with 11 of these 
countries reporting proportions of over 85 % (146). Other 
substances are also found in the toxicology reports in 
addition to heroin. The most frequently reported are 
alcohol, benzodiazepines, other opioids and, in some 
countries, cocaine. This suggests that a substantial 
proportion of all drug-induced fatalities may be related to 
polydrug use. 
Men account for most heroin overdose deaths occurring 
in Europe (82 %). In most countries the mean age of those 
dying from drug overdose is in the mid-thirties, and in 
many instances it is increasing, suggesting a possible 
stabilisation or decrease in the number of young heroin 
users. Overall, 14 % of overdose deaths reported in 
Europe occur among those aged under 25 years, though 
in Bulgaria, Austria and some countries reporting small 
numbers of drug-induced deaths (Malta, Cyprus, Slovakia, 
Romania), more than a third of overdose deaths occur in 
this age group. This may indicate a younger population of 
heroin or injecting drug users in these countries (147). 
Factors associated with heroin overdoses include injection 
and simultaneous use of other substances, in particular 
alcohol, benzodiazepines and some antidepressants, 
as well as co-morbidity, having experienced previous 
overdoses and being alone (Scottish Government, 
2008). The time immediately after release from prison 
or discharge from drug treatment was identified as a 
particularly high-risk period for overdoses. 
It is estimated that for each fatal overdose, there could 
be as many as 20 to 25 non-fatal overdoses, but their 
consequences are poorly recognised. The EMCDDA is 
conducting a critical review of associated risk factors and 
possible interventions in this field.
Methadone and buprenorphine
Research shows that opioid substitution treatment reduces 
the risk of fatal overdose. A number of deaths showing 
the presence of substances used in substitution treatment 
(methadone or buprenorphine) are nevertheless reported 
each year, mostly due to misuse or, in a small number of 
cases, to problems occurring during treatment. 
The presence of methadone in a substantial proportion 
of drug-induced deaths is reported by several countries, 
although in the absence of common reporting standards, 
the role played by the substance is often unclear, as other 
drugs may be present. In addition, other factors may be 
involved, including: loss of opioid tolerance, excessive 
dosage or inappropriate use, such as irregular and non-
therapeutic use. Deaths due to buprenorphine poisoning 
are infrequent, despite its increasing use in substitution 
treatment in Europe (see Chapter 6). In Finland, however, 
buprenorphine is now the most common substance 
detected in drug-induced deaths, usually in combination 
with sedative medicines or alcohol, or taken by injection. 
Fentanyl and other synthetic opioids
An epidemic of fentanyl poisonings in Estonia caused the 
death of 117 injecting drug users in 2005/06 (EMCDDA, 
2008b). No information on deaths related to fentanyl 
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(148) For data on deaths related to drugs other than heroin, see Table DRD-108 in the 2009 statistical bulletin.
(149) See Figures DRD-8 and DRD-11 in the 2009 statistical bulletin. For historical reasons, the EU trend refers to EU-15 and Norway. 
(150) See ‘Reducing overdose deaths after prison’, p. 89. 
(151) See ‘Estimating total mortality attributed to problem drug use: new developments’, p. 87.
in Estonia in 2007 is available, though recent studies 
confirm the increased use of the drug by injecting drug 
users. In 2007, two thirds of the injectors surveyed in 
Tallinn reported fentanyl as their primary drug, and one in 
10 injectors attending the syringe exchange programme 
reported injecting fentanyl in the last month. Another study 
carried out in Tallinn found that injectors reporting fentanyl 
as their main drug had higher HIV prevalence and higher 
odds for injecting risk behaviour and lifetime overdose 
compared to amphetamine injectors (Talu et al., 2009). In 
Finland, opioids such as oxycodone, tramadol or fentanyl 
were reported in 21 deaths, though the role of these drugs 
was not specified.
Deaths related to other drugs
Cocaine-induced deaths are more difficult to define and 
identify than those related to opioids. Deaths directly 
caused by overdose seem to be uncommon, and these are 
usually linked with very large cocaine doses. Otherwise, 
most cocaine deaths appear to be the result of chronic 
toxicity leading to cardiovascular and neurological 
complications. The role of the drug in these deaths may 
not always be identified, in which case they will not 
be reported as cocaine-related. Interpreting the data is 
further complicated by the frequent presence of other 
substances, making the drawing of causal links difficult. 
In 2007, around 500 deaths related to cocaine were 
reported in 12 Member States (compared to 450 in 
14 countries in 2006). Nevertheless, it is likely that the 
number of cocaine-induced deaths in the European Union 
is under-reported. 
Deaths in which ecstasy is present are infrequently 
reported and, in many of these cases, the drug has 
not been identified as the direct cause of death. While 
amphetamine deaths are also infrequently reported in 
Europe, in the Czech Republic a substantial proportion of 
fatal overdoses — excluding medicines — (11 out of 40) in 
2007 have been attributed to pervitin (methamphetamine), 
compared to 14 deaths attributed to opioids. In Finland, 
amphetamines were present in 40 % of the 229 reported 
deaths in 2007, although this does not necessarily imply 
that the drug was the direct cause of death (148). 
Trends in drug-induced deaths
Drug-induced deaths increased sharply in Europe during 
the 1980s and early 1990s, paralleling the increase in 
heroin use and drug injection, and thereafter remained 
at high levels. However, data from countries with long 
time series suggest differentiated trends: in some (e.g. 
Germany, Spain, France, Italy), deaths peaked in the early 
to mid-1990s; in other countries (e.g. Greece, Portugal, 
Finland), deaths peaked around the year 2000; and in 
some others (e.g. Denmark, Netherlands, Austria, United 
Kingdom), an upward trend was observed, but without a 
clear peak (149).
Between 2000 and 2003, most EU Member States 
reported a decrease, followed by a subsequent increase 
in deaths between 2003 and 2006. Preliminary data 
available for 2007 suggest a figure at least equal to that 
for the previous year, with increases reported by 14 out of 
18 countries.
The reasons for the sustained numbers of reported drug-
induced deaths are difficult to explain, especially given 
the indications of decreases in injecting drug use and 
increases in the numbers of opioid users in contact with 
treatment and harm reduction services. Against this 
possible reduction in the at-risk population, stable or rising 
numbers of drug-induced deaths have become a major 
cause of concern. 
A number of possible explanations may exist for this 
phenomenon, all of which require further investigation. 
These include: an ageing and more chronic population 
becoming more vulnerable; increased levels of polydrug 
use or high-risk behaviour; a failure of existing services to 
target or reach those most vulnerable; or even an increase 
in the numbers of relapsing opioid users leaving prison 
or treatment, who are known to be at particularly high 
risk (150). 
Overall mortality related to drug use
In addition to drug-induced deaths, the overall mortality 
related to drug use includes those deaths that are caused 
indirectly by drug use. These deaths are concentrated 
among problem drug users, although some could happen 
among occasional users (e.g. traffic accidents, some 
suicides). Although the number of deaths indirectly related 
to drug use is difficult to quantify, its impact on public 
health can be considerable.
Overall mortality can be estimated in different ways: one 
method consists of combining information from mortality 
cohort studies with estimates of drug use prevalence (151). 
Another approach is to use existing general mortality 
statistics and estimate the proportion related to drug use. 
Other specialised information sources can be used, for 
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(152) The year 2006 was taken as the more recent year for which information from almost all Member States regarding causes of death is available 
through Eurostat. For detailed information on sources, for the transmission groups, numbers and computations see Table DRD-5 (part iii) in the 2009 
statistical bulletin.
(153) See Figure DRD-7 (part ii) in the 2009 statistical bulletin.
instance, in the case of mortality related to HIV/AIDS, 
Eurostat and EuroHIV information is combined.
Mortality cohort studies 
Mortality cohort studies track the same groups of problem 
drug users over time and, through linkage with mortality 
registries, try to identify the causes of all deaths occurring 
in the group. This type of study can determine overall 
and cause-specific mortality rates for the cohort, and 
can estimate the group’s excess mortality compared to 
the general population. Large-scale longitudinal cohort 
studies can be used to test hypotheses about, for example, 
the reasons for changes in the numbers of drug-induced 
deaths, as well as to monitor the overall risk and detect 
changing patterns in the causes of death.
Depending on recruitment settings (e.g. studies carried 
out in drug treatment facilities) and inclusion criteria 
(e.g. injecting drug users, heroin users), most cohort 
studies show mortality rates in the range of 1–2 % per 
year among problem drug users. Although the relative 
importance of the causes of death varies between 
countries and over time, the main cause is generally 
drug overdose, accounting for up to 50–60 % of deaths 
among injectors in countries with low prevalence of HIV/
AIDS. Unfortunately, some countries show a low detection 
rate of overdoses in the general mortality registries and, 
therefore, a significant proportion of deaths recorded with 
an ‘unknown’ or an insufficiently specified cause (e.g. 
cardiac arrest) might be overdoses. To improve the validity 
of the description of causes of deaths other sources 
of information (i.e. special police or forensic mortality 
registries) can be consulted too.
The EMCDDA has developed a protocol to encourage 
Member States to undertake mortality cohort studies, 
with the aim of providing comparable information about 
mortality risks in problem drug users and to inform 
prevention and care policies. The most recent European 
studies were conducted in Germany, Spain, Italy, the 
Netherlands, the United Kingdom and Norway. A third 
of the EU Member States have yet to carry out a mortality 
cohort study, though several countries report studies that 
are on-going or planned for 2009 (e.g. Czech Republic, 
France, Latvia, Poland).
Deaths indirectly related to drug use 
It can be estimated that in 2006, over 2 100 people died 
of HIV/AIDS attributable to drug use in the European 
Union (152), with 89 % of these deaths occurring in Spain, 
France, Italy and Portugal. Following the introduction of 
highly active antiretroviral therapy in 1996, HIV/AIDS 
mortality decreased markedly in most EU countries, 
although the decrease was much less pronounced in 
Portugal. Increases observed in recent years in Estonia 
are consistent with the high estimates of HIV prevalence 
among injecting drug users in this country (5 to 6 out 
of 10) and the high proportion of them reportedly 
unaware of their infection. Recent increases have also 
been reported in Latvia. At present, estimated HIV/AIDS 
mortality rates among drug users are low in most 
countries, except in Spain and Portugal. In Italy, France 
and Latvia, HIV/AIDS mortality and overdose mortality are 
of similar levels (153).
Other diseases that also account for a proportion of 
deaths among drug users include chronic conditions 
such as liver diseases (due to hepatitis C infection and 
heavy alcohol use), cancer and cardiovascular problems. 
Other causes have received much less attention, despite 
indications that they have a considerable impact. 
For instance, trauma (accidents, homicides and other 
violence) and suicide could account for 25 % or more of 
the mortality of problem drug users. A literature review 
Estimating total mortality attributed to problem 
drug use: new developments 
Recent mortality cohort studies in the European Union 
indicate that drug-induced deaths (overdoses) represent 
typically between a fifth and a half of the overall number 
of fatalities among problem drug users. This suggests that 
the total mortality in this population could be around two 
to five times the number of registered drug-induced deaths. 
This multiplier varies across countries according to different 
factors, including risk behaviours, rate of fatal overdoses 
and prevalence of other possible causes of death.
The EMCDDA is promoting research into estimating the 
total mortality among problem drug users. In 2008, a 
project in collaboration with researchers from the Czech 
Republic reviewed the literature, data sources and possible 
methods in this field (1). An expert group recommended 
two methods for future studies: a multiplier method based 
on the number of registered fatal overdoses; and an 
extrapolation method based on mortality rates in cohorts 
of problem drug users and national estimates of the 
population of problem drug users. Both methods have been 
successfully pilot-tested in the Czech Republic, and the 
EMCDDA plans to set up a group of interested countries 
that could use this work in the near future.
(1) See http://www.emcdda.europa.eu/themes/key-indicators/drd
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(154) See Table HSR-8 in the 2009 statistical bulletin. Experts from 26 EU countries, Turkey and Norway rated the level of provision of selected 
interventions to prevent drug-related deaths.
(155) See Table HSR-8 (part ii) in the 2009 statistical bulletin.
(Darke and Ross, 2002) found that the suicide rate among 
heroin users was 14 times higher than among the general 
population. In recent cohort studies in Europe, suicide 
accounted for 6 % to 11 % of deaths among problem 
drug users. However, the overall impact of these causes is 
difficult to assess due to the limited availability of data.
Reducing drug-related deaths 
Twelve countries report that their national drug strategy 
includes a part dedicated to the reduction of drug-induced 
deaths. One country, the United Kingdom, has a specific 
action plan to reduce drug-related harm, which sets out 
specific actions for the prevention of drug-related deaths. 
Thirteen countries have neither a specific strategy or a 
section of the national drug strategy dedicated to the 
reduction of drug-induced deaths, and two countries 
reported no information.
Interventions
A prospective long-term study among problem drug 
users entering treatment in Italy showed that the risk of 
death among the cohort was, compared to the general 
population, increased by a factor of 10 (Davoli et al., 
2007). Being in treatment lowered the risk of death to 
four times that of the general population, confirming 
thereby that drug treatment reduces drug-related mortality. 
However, the study also showed that the highest mortality 
rate among drug users was observed in the 30 days after 
cessation of treatment. This finding highlights the need for 
careful after-care management, as well as the avoidance 
of very short treatment episodes, where risks could 
outweigh the benefits of treatment.
The provision of awareness raising and prevention 
materials is reported from most countries for which 
information is available. According to experts from 28 
countries (154), printed or multi-media overdose prevention 
materials for drug users have been provided during the 
last year to most or nearly all problem drug users in nine 
countries, and to a minority of them in 12 countries and in 
the French Community in Belgium. Such materials do not 
exist in Turkey, and few problem drug users have access 
to them in Estonia, Latvia, Hungary and Slovakia. No 
information is available from Bulgaria.
A large proportion of fatal and non-fatal drug overdoses 
are witnessed by others, including drug users’ peers or 
family members, health and social staff, police or prison 
guards, who would be in a position to intervene. Ten 
countries report specific materials that aim at helping 
families of drug users to recognise and manage drug 
overdoses; in eight countries, such materials are available 
for police officers; and in seven countries, they have 
been developed for prison staff (155). Other target groups 
include workers of drugs agencies, ambulance personnel, 
accident and emergency staff, as well as immigrants from 
Russian-speaking countries and the Roma population. The 
number of countries where materials for several target 
groups are available, however, is limited, and not all 
materials are accessible nationwide.
Education about overdose risk is reported by all countries, 
and in nine of them it exists in most relevant cities with a 
significant number of problem drug users. However, in four 
countries, such activities take place only in a minority of 
relevant cities, and in a further 12 countries in just a few 
cities. 
Specific training courses on overdose responses are 
provided either in individual or group sessions. Drug users 
are informed about overdose risks, including decreased 
tolerance after periods of abstinence, the effects and 
risks of polydrug use, in particular concomitant alcohol 
use, risks of using drugs when alone and skills in first 
aid. It is estimated by national experts that in seven 
countries a majority of problem drug users received some 
overdose response training in the last 12 months, while in 
10 countries only a minority received it, and in a further 
six countries (Belgium, Latvia, Austria, Poland, Romania, 
Slovakia) only a few problem drug users received this type 
of instruction. Overdose response training is not available 
in Estonia, Hungary and Turkey.
Drug users with previous experience of non-fatal overdose 
are at high risk of experiencing future overdoses (Coffin et 
al., 2007) and should be specifically targeted. Individual 
overdose risk assessments are conducted by trained staff, 
and aim at identifying those in need of additional support. 
According to experts, in nine countries most problem drug 
users received an overdose risk assessment at least once 
during the last year, while in 16 countries only a minority 
received this type of intervention. No information is 
available from Bulgaria, Germany and France. 
The provision of naloxone to users is not a standard 
approach in overdose prevention throughout Europe, 
though the distribution of take-home supplies is common in 
drugs services in Italy, where they may also be purchased 
in pharmacies without prescription. In the United Kingdom, 
the legal status of naloxone was changed in June 2005, 
permitting its administration by any member of the public 
in life-saving circumstances. In addition, the impact of 
overdose training integrated with naloxone take-home 
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(156) See EMCDDA (2004) for a review of this issue. 
supply was assessed in a cohort study with 239 opioid 
users recruited from treatment services (Strang et al., 
2008). Results show improved knowledge of signs of 
overdose and increased confidence of using naloxone. 
During the first 3 months, all 12 overdoses where naloxone 
was used had been reversed successfully, while one 
death had occurred in the six overdoses in which it was 
not used. The authors conclude that wider provision 
may reduce drug-related deaths further and recommend 
additional studies of the impact of overdose training and 
emergency naloxone-supply among opioid users.
Another controversial approach is the provision of 
supervised drug consumption facilities (156), which aim 
to reduce the risk of death for their clients by providing 
prompt and appropriate medical attention in the event 
of an on-site overdose. Operational data from such 
facilities in Europe, Canada and Australia indicate that 
drug overdoses that occur in the facility are successfully 
managed, with no reported fatal overdoses. Milloy and 
colleagues calculated the number of deaths potentially 
averted by the operation of the drug consumption facility 
in Vancouver. They estimated that between two and 
12 deaths a year may have been averted (Milloy et al., 
2008). This confirms earlier findings regarding the likely 
beneficial effect of these facilities on overdose deaths in 
neighbourhoods where coverage is sufficient.
Reducing overdose deaths after prison 
In England, it has been estimated that 15 % of the 1 506 
drug overdose deaths in 2005 occurred in people recently 
released from prison (Department of Health, 2007). 
International studies confirm this elevated risk of death 
due to unintentional drug overdose in the time immediately 
after release from prison (e.g. Farrell and Marsden, 2008). 
These studies also underline the need for better responses 
to mental health and drug problems for those who have 
been in prison. 
According to expert ratings from 24 countries, prison 
pre-release counselling on overdose risk and prevention 
is currently not provided in six European countries, 
only provided to a few problem drug users in prison in 
10 countries, and to less than half of them in a further six 
countries. Only Italy and Luxembourg provide this service 
to the majority of the target population. As the day of 
release may be difficult to predict, especially for remand 
prisoners, overdose risk awareness education should 
ideally be offered on a regular basis in prisons to reduce 
risk behaviours.
Opioid substitution treatment, which has shown a 
protective effect in the prison context (Dolan et al., 2005), 
appears to be becoming more available in prisons in the 
EU, and the legal option to initiate substitution treatment 
in prison exists in 21 countries (see Chapter 2). The 
opportunity to start this type of treatment in prison reduces 
the risk of overdose and death on leaving prison, and 
reduces reincarceration rates (WHO, 2009). It is, however, 
important that prison health services and community-based 
treatment providers are appropriately linked to avoid any 
gaps in the continuity of treatment.
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Introduction
The use of new psychoactive substances and new 
patterns of drug use can have important public health 
and policy implications. They are, however, difficult 
to detect because, typically, they first emerge at low 
levels and in specific localities or among restricted sub-
groups of the population. Few countries have monitoring 
systems that are sensitive to new phenomena in the drug 
field, and methodological difficulties to detect them are 
considerable. Nonetheless, the importance of identifying 
potential new threats is widely recognised. The European 
Union’s early-warning system provides a quick-response 
mechanism to the emergence of new psychoactive 
substances on the drug scene. Activities in support of the 
early-warning system form an important part of the work 
of the EMCDDA and fit within a broader perspective 
of using a wide variety of data sources to improve the 
timeliness and sensitivity of the European drug monitoring 
system.
Action on new drugs 
The Council decision on new psychoactive substances (157) 
establishes a mechanism for the rapid exchange of 
information on new psychoactive substances that may 
pose public health and social threats (the early-warning 
system) (158). It also provides the possibility to trigger a 
formal risk assessment process, the findings of which may 
lead to a political decision to place new substances under 
control across the European Union.
More than 90 substances have been reported through the 
early-warning system since its establishment in 1997. Until 
recently, phenethylamines and tryptamines accounted for 
a large proportion of notifications. However, in the past 
few years, a much more diverse range of substances has 
appeared. Included among these are numerous piperazine 
and cathinone derivatives, as well as a heterogeneous 
mix of other substances, including plant products, a few 
unusual stimulants and hallucinogens and some medicinal 
products.
During 2008, 13 new psychoactive substances were 
officially notified for the first time in the EU through the 
early-warning system. Besides new synthetic drugs, which 
accounted for 11 of the newly notified substances, the 
group included two plants, but no medicinal products. 
The chemical make-up of the two plants reported — 
kratom and kava — is relatively well known from the 
literature. They have been traditionally used in other parts 
of the world and their presence on the European drug 
scene seems to be limited. 
Most of the newly reported synthetic compounds are 
psychotropic substances similar to those listed in Schedules 
I and II of the 1971 United Nations Convention on 
Psychotropic Substances. Of the new substances reported 
in 2008, compared with previous years, fewer belong 
to the main chemical groups — phenethylamines (one), 
tryptamines (two) and piperazines (none). Notably, six of 
the newly notified substances are cathinone derivatives. 
Most of the new synthetic substances have stimulant 
properties, while only three produce hallucinogenic 
effects. 
For the first time ever, in 2008, a synthetic cannabinoid 
(JWH-018) was reported through the early-warning 
system. The appearance of synthetic cannabinoids 
marks the latest stage in the development of ‘designer 
drugs’: from those based on fentanyl in the 1980s; to 
ring-substituted phenethylamines in the late 1980s and 
tryptamines in 1990s; to piperazines and cathinone 
derivatives in the 2000s. There are over a hundred 
compounds with cannabinoid receptor activity, and it can 
be assumed that new substances from different chemical 
groups will continue to appear on the drug scene. All 
this presents a constant challenge to public health and 
law enforcement agencies, both for the forensic and 
toxicological identification of new substances, and for 
the prompt assessment of risk and, where necessary, 
implementation of control measures.
(157) Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk assessment and control of new psychoactive substances (OJ L 
127, 20.5.2005, p. 32)(http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2005:127:0032:0037:EN:PDF).
(158) http://www.emcdda.europa.eu/themes/new-drugs/early-warning
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(159) Naphthalen-1-yl-(1-pentylindol-3-yl)methanon.
(160) 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol.
‘Spice’ products and related synthetic 
cannabinoids
Products marketed on the Internet and in some specialised 
shops under the name ‘spice’ have been available since 
at least 2006. Although ‘spice’ may be advertised as 
incense, when smoked the effects are described by 
some users as similar to those of cannabis. Following a 
report from Sweden, the early-warning system has been 
monitoring ‘spice’ products since the beginning of 2008. 
Packaging information on ‘spice’ products indicates 
that they are composed of as many as 14 ingredients 
of plant origin. While at least two of the ingredients 
— Pedicularis densiflora and Leonotis leonurus — may 
have some psychoactive effect, little is known about the 
pharmacology and toxicology of the plant materials 
purportedly contained in ‘spice’ products. Thus, no definite 
statements can be made as to the potential health risks or 
possible psychoactive effects of these products. Synthetic 
ingredients are not mentioned in the product information. 
In 2008, ‘spice’ products, as well as various other ‘spice-
like’ herbal mixes, could be purchased from online shops, 
and were available in ‘head’ or ‘smart’ shops selling ‘legal 
highs’ in at least nine EU Member States (Czech Republic, 
Germany, Latvia, Lithuania, Luxembourg, Austria, Poland, 
Portugal, United Kingdom).
Extensive forensic science investigations have been 
undertaken by Member States in order to identify 
the psychoactive ingredients of ‘spice’ products. In 
December 2008, Germany and Austria detected the 
synthetic cannabinoid JWH-018 (159). The chemical 
structure of JWH-018 differs substantially from that of 
tetrahydrocannabinol (THC), the main active principle in 
all cannabis products. In experimental animals, JWH-018 
produces the same effects as THC, and has been reported 
to be more potent. Early in 2009, a second synthetic 
cannabinoid, CP 47,497 (160), and three of its homologues 
were detected in ‘spice’ samples in Europe. 
Synthetic cannabinoids have been identified only in a 
limited number of samples, and in varying amounts. It 
would appear that these synthetic substances have been 
added surreptitiously, as packaging information on ‘spice’ 
products only mentions herbal ingredients. 
The substances JWH-018 and CP 47,497 and its 
homologues are not known to have been widely used as 
psychoactive drugs, in their own rights. Therefore, it is still 
to be established if a specific demand for these particular 
substances exists, and if there is a need for further action 
as stipulated by Council Decision 2005/387/JHA. 
Responding to potential health concerns, five Member 
States have taken diverse legal actions to ban or 
Psychoactive plants reported through the  
early-warning system 
Products of five psychoactive plants have been reported 
in recent years. The species detected by the early-warning 
system are not under international control, but may be 
controlled by EU Member States.
Kava (Piper methysticum) is a shrub that has been used for 
centuries in the South Pacific Islands for ceremonial purposes. 
A tea brewed from the roots of the plant can be taken for its 
anti-anxiety and relaxant effects. Concern has been growing 
that long-term use of kava can cause liver damage. Neither 
the plant or its active principles (kavalactones) are reported to 
be controlled in any EU Member State. 
Khat is comprised of leaves and fresh shoots of Catha 
edulis, a shrub cultivated in East Africa and the Arabian 
Peninsula. It is used as a mild stimulant by chewing the fresh 
vegetable matter. The active components, cathinone and 
cathin, are close chemical relatives of synthetic drugs such 
as amphetamine and methcathinone, and are internationally 
controlled under the 1971 UN Convention. Catha edulis is 
controlled in 12 EU Member States. 
Kratom (Mitragyna speciosa) is a tree native to south-
east Asia. The leaves can be chewed, smoked or brewed 
into a tea. At low doses, it has stimulant effects. At higher 
doses, kratom has opioid-like effects, and has been used in 
traditional medicine to treat pain and opioid withdrawal. The 
main active principles of kratom are mitragynine, mitraphylline 
and 7-hydroxymitragynine; though mitragynine is probably 
responsible for kratom’s analgesic activity and for relieving 
the opioid withdrawal symptoms. The plant, mitragynine 
and 7-hydroxymitragynine are controlled in Denmark, while 
Lithuania controls the plant and mitragynine. 
Salvia divinorum is a perennial herb native to southern 
Mexico, where due to its hallucinogenic properties it is 
traditionally used for ceremonial purposes. The main active 
principle, salvinorin-A, is a potent kappa opioid receptor 
agonist. Recreational modes of use of Salvia include chewing 
the leaves, and smoking or sublingual administration of 
concentrated extracts, which appear to produce intense 
effects. Ingestion of the leaves or seeds of the plant produces 
a longer-lasting, but less intense effect. Salvia divinorum or 
its active principles are controlled in six Member States and 
Croatia. 
Hawaiian baby woodrose (Argyreia nervosa) is a perennial 
climbing vine. Its seeds contain the active principle d-lysergic 
acid amide (LSA, also known as d-lysergamide), a substance 
closely related to LSD, and can produce mild hallucinogenic 
effects. LSA is controlled as a drug in Ireland and the United 
Kingdom.
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(161) See ‘‘Spice’ products and related synthetic cannabinoids’ p. 92.
otherwise control ‘spice’ products and related compounds. 
Germany used emergency narcotics legislation to control 
five synthetic cannabinoids found in ‘spice’ for 1 year. 
France classified as narcotics six synthetic cannabinoids 
found in ‘spice’ products. Austria used its medicines 
act to prohibit smoking mixes containing six synthetic 
cannabinoids from being imported or marketed in the 
country. Luxembourg decided to control various synthetic 
cannabinoids as psychotropic substances. Poland 
amended the narcotic law, placing under control JWH-018 
and two of the claimed herbal ingredients of ‘spice’.
Internet: a marketplace for psychoactive 
substances 
The Internet has emerged as a new marketplace for 
psychoactive substances, providing retailers with the 
possibility of offering for sale alternatives to controlled 
drugs to a large public. The online marketplace has 
implications for the potential spread of new psychoactive 
substances, and monitoring it is an increasingly important 
element of identifying new drug trends. In particular, 
it is necessary to focus on the risks associated with the 
substances offered for sale. Information about new 
products is needed by both the users and professionals, 
including clinical toxicologists, poison control specialists 
and those working in the drugs field.
To identify current developments in the online drug market, 
the EMCDDA conducts an annual snapshot study. In 
2009, a total of 115 online shops were surveyed. Based 
on the country code domains and other information on 
the websites, these online shops appear to be located in 
17 European countries. The majority of online retailers 
identified were based in the United Kingdom (37 %), 
Germany (15 %), Netherlands (14 %) and Romania (7 %). 
Hallucinogenic mushrooms containing psilocin and 
psilocybin were not offered for sale in any of the online 
shops surveyed in 2009, unlike 2008. However, four 
online retailers based in France and the Netherlands 
offered scelerotia — the hardened mycelium of the 
hallucinogenic mushrooms Psilocybe mexicana and 
Psilocybe tampanensis.
New products offered for sale in 2009 include a range of 
herbal smoking products and ‘party pills’ containing new 
legal alternatives to benzylpiperazine (BZP). There has 
also been an increasing focus on snuff products or herbal 
powders.
‘Spice’ products (161) were offered for sale by 48 % of the 
retailers surveyed. While the online shops selling ‘spice’ 
were based in 14 different European countries, more 
than two fifths of these shops were located in the United 
Kingdom (42 %), with significant numbers also in Ireland, 
Latvia and Romania. 
Concern about ‘spice’ products has led to a number of 
countries taking legal action to ban or otherwise control 
these substances. By March 2009, ‘spice’ products had 
been withdrawn from online shops based in Germany, 
Austria and France.  
In 2009, alternative smoking blends to ‘spice’ started to 
appear on the online marketplace. The retailers surveyed 
offered for sale at least 27 different herbal smoking blends 
as alternatives to ‘spice’. These products are advertised 
as containing plant-based ingredients, though some also 
contain the hallucinogenic mushroom Amanita muscaria. 
The ‘spice’ alternatives offered for sale in Austria and 
Germany include several herbal smoking blends that are 
National risk assessment procedures 
In 2008, the EMCDDA conducted a study of the different 
national legal procedures involved in putting new 
substances under the control of the drugs legislation, the 
time taken for such a procedure, and whether any national 
risk assessment procedure would be involved. Across the 
26 countries studied, three distinct approaches to risk 
assessment are apparent. In six countries, national risk 
assessment is not carried out. Generally, these countries 
rely on risk assessments carried out at international or 
European level. In seven countries, national risk assessment 
may be carried out on an ad-hoc basis, when necessary. 
And, in 13 countries, a form of risk assessment will 
be undertaken when considering whether to control a 
substance, either mandated by the drug law or equivalent 
or as part of the required procedure for proposing any 
new legislation. 
The levels of harm detected will not affect the speed of 
the legislative procedure in 12 of the 20 countries that 
may carry out their own risk assessments. Four countries 
(Germany, Luxembourg, Slovakia, Sweden) may switch 
to a fast-track legislative procedure if the levels of risk 
are judged high. In France, Austria and Norway, cases 
of urgency will lead to a shortened duration for the risk 
assessment itself. In the Netherlands, both possibilities are 
available.
In 16 countries, national risk assessments are carried out 
by a group of experts within the public administration, 
either a competent ministry or a state or governmental 
agency. Six countries do or might provide for the 
possibility of consultation with independent scientists, if a 
need is perceived. And, in three countries (Netherlands, 
Austria, United Kingdom), risk assessment is performed by 
independent scientific bodies. 
See ELDD Legal reports for further information (http://eldd.
emcdda.europa.eu). 
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(162) Council Decision 2008/206/JHA of 3 March 2008 on defining 1-benzylpiperazine (BZP) as a new psychoactive substance which is to be made 
subject to control measures and criminal provisions (OJ L 63, 7.3.2008, p. 45)(http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2008:06
3:0045:0046:EN:PDF).
(163) Belgium, Denmark, Germany, Estonia, Ireland, Greece, France, Italy, Cyprus, Lithuania, Luxembourg, Malta, Hungary, Portugal, Slovakia, Sweden 
and Finland; as well as Croatia, Turkey and Norway.
being sold as ‘room odorisers’ or incense. The speedy 
appearance of substitute products for ‘spice’ underlines the 
ability of this marketplace to respond rapidly to changes 
in the legal status of psychoactive substances, often by 
bringing new substances on to the market.
Since BZP became subject to control measures in EU 
Member States, this substance may no longer be used 
in ‘party pills’ sold as legal alternatives to ecstasy. At 
the beginning of 2009, many online retailers were 
offering BZP-free ‘party pills’. For example, online shops 
based in Ireland, Poland and the United Kingdom were 
offering ‘retro pills’, which are purported to contain 
1-(4-fluorophenyl) piperazine (pFPP), a substance 
described as having mild hallucinogenic and strong 
euphoric effects. 
Snuff products are marketed as an alternative to controlled 
drugs such as cocaine or amphetamines. The products 
are purported to contain caffeine and a range of other 
plant-based ingredients such as Acorus calamus, Hydrastis 
canadensis and Tilia europea.
Follow-up on substances
Piperazines
In 2007, the EMCDDA–Europol active monitoring report 
on mCPP (1-(3-chlorophenyl)piperazine) concluded that it 
has no particular appeal to users and seems unlikely to 
establish itself as a recreational drug in its own right. In 
2008, however, mCPP continued to be the most widely 
available new synthetic drug on the illicit drug market, 
encountered alone or in combination with MDMA. This is 
evidenced both by the number of seizures and the amount 
of seized material reported to the EMCDDA and Europol. 
It is still unclear if the substance is used to enhance or 
mimic some of the effects of MDMA or simply as a ‘cutting 
agent’. However, as mCPP is not a controlled substance  
in most Member States, it is likely that seizures are  
under-reported. 
On 3 March 2008, the Council decided that Member 
States shall take the necessary measures, in accordance 
with their national law, to submit BZP to control measures 
proportionate to the risks of the substance, and criminal 
penalties, as provided for under their legislation 
complying with their obligations under the 1971 United 
Nations Convention on Psychotropic Substances (162). 
Member States shall endeavour to take this action, as 
soon as possible, but no later than 1 year from the date of 
the decision. At the time of the preparation of this report, 
17 Member States (163) have reported that they have 
controlled BZP. 
GHB/GBL and ketamine
In Europe, gamma-hydroxybutyric acid (GHB) and 
ketamine have been under surveillance since 2000, 
when a risk assessment of both of these substances was 
conducted under the terms of the 1997 joint action on new 
synthetic drugs (EMCDDA, 2002). 
Few countries report prevalence data on GHB and 
ketamine, and the prevalence estimates that are reported 
remain at much lower levels than for other illicit drugs. 
Changes in the situation are difficult to assess due to 
prevalence data being obtained from non-probabilistic 
samples with limited comparability over time and between 
samples. The Dutch ‘Trendwatch’ study reported a slight 
increase in the use of GHB in specific networks and 
regions in the Netherlands in 2007, but both GHB and 
ketamine are used less often than other party drugs and 
mostly in hidden populations, at home and at parties. 
In contrast to increases reported in previous years, the 
latest statistics on medical emergencies related to GHB in 
Amsterdam indicate a marked decline, from 444 cases 
in 2006 to 110 in 2007. A study carried out at a London 
hospital reported 58 emergencies related to ketamine use 
in 2006, and the same number in 2007. In most of the 
ketamine-related presentations, the drug was co-ingested 
with other drugs, with only 11 % involving ketamine on its 
own, and none of these required admission to critical care 
(Wood et al., 2008). 
The ESPAD school population surveys carried out in 2007 
provide the most recent data on GHB use among 15- to 
16-year-old school students across Europe. Among the 
school students surveyed in 26 EU countries plus Norway 
and Croatia, lifetime prevalence of GHB use ranges from 
zero to 3 %, though most countries report a level of 1 % 
or less. 
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